Abstracts
Skip to Late-Breaking Abstracts »
Poster Presentation Dates
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
| # | Title | Authors | Category | Keywords |
|---|---|---|---|---|
| O1 | Flexible Copper-64-nanoparticle-based cell labeling system allows for in vivo tracking of adoptively transferred T-cells by PET/CT | Hólmfridur R. Halldórsdóttir, MSc; Lars Ringgaard, PhD; Martin Bak, PhD; Ditte Jæhger, MSc; Esben Christensen, MSc; Fredrik Melander, PhD; Mie L. Hübbe, MSc; Rasmus Eliasen, PhD; Frederikke P. Fliedner, MSc; Andreas Kjaer, MD, PhD; Anders E. Hansen, DVM, PhD; Jonas R. Henriksen, PhD; Thomas L. Andresen, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; TLR |
| O5 | The road-map to Tumor-Infiltrating Lymphocyte (TIL) therapy: Understanding genetic alterations for improved patient treatment | Caitlin Creasy, MS; Yuzhong J. Meng, PhD; Tatiana Karpinets, MS; Cara Haymaker, PhD; Marie Andrée Forget, PhD; Chip Stewart, PhD; Carlos Antonio Torres Cabala, MD; Shari A. Pilon-Thomas, PhD; Amod A. Sarnaik, MD; Levi A. Garraway, MD, PhD; Patrick Hwu, MD; Rodabe N. Amaria, MD; Rameen Beroukhim, M.D, PhD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Clinical trial; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O7 | P-BCMA-ALLO1 — a Nonviral, Allogeneic Anti-BCMA CAR-T Therapy with Potent Antitumor Function for the Treatment of Multiple Myeloma | Maximilian Richter, PhD; Stacey Cranert, PhD; Yening Tan, MS; Min Tong, MS; Christine Domingo, BS; Elvira Argus, PhD; Samad A. Ibitokou, PhD; Jenessa B. Smith, PhD; Christopher E. Martin, PhD; Xinxin Wang, PhD; Burton E. Barnett, PhD; Eric M. Ostertag, MD, PhD; Julia Coronella, PhD; Devon J. Shedlock, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells |
| O9 | Enhancing affinity of CD22-directed CAR T cells increases activation signaling and in vivo response to CD22lo leukemia | Zachary H. Walsh, BA; Mark Kohler, MD, PhD; Terry J. Fry, MD; Zachary H. Walsh, BA; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Pediatric tumors; T cell; Targeted therapy; Tumor evasion |
| O10 | Licensing of CAR-T cell persistence and function by STING agonist in breast cancer | Nuo Xu, PHD candidate; Jonathan S. Serody, MD; Nuo Xu, PHD candidate; Nicholas P. Restifo, MD; Douglas C. Palmer; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| O12 | B-cells activated by checkpoint blockade immunotherapy and radiation improve overall survival in squamous cell carcinomas | Sangwoo S. Kim, B.A.; Sarek Shen; Sayuri Miyauchi; Philip D. Sanders; Loren K. Mell, MD; J. Silvio Gutkind; Ezra Cohen, MD; Joseph Califano; Andrew B. Sharabi, MD, PhD; | Checkpoint Blockade Therapy | Antibody; B cell; Checkpoint blockade; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O16 | Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) – Final Results of the phase II AVETUX trial (AIO-KRK-0216) | Alexander Stein, MD; Mascha Binder; Eray Goekkurt; Sylvie Lorenzen; Jorge Riera-Knorrenschild; Reinhard Depenbusch; Thomas Ettrich; Steffen Doerfel; Salah Al-Batran; Meinolf Karthaus; Uwe Pelzer; Donjete Simnica; Lisa Waberer; Axel Hinke; Carsten Bokemeyer; Susanna Hegewisch-Becker; Joseph Tintelnot, MD; | Clinical Trial Completed | Checkpoint blockade; Chemotherapy; Clinical trial; Immune monitoring; Solid tumors; Targeted therapy |
| O19 | Final results from a phase 2 study using off-the-shelf activated natural killer (aNK) cells in combination with N-803, an IL-15 superagonist, in patients with metastatic Merkel cell carcinoma (MCC) | Shailender Bhatia, MD; Candice Church, PhD; Kelly G. Paulson, MD, PhD; Robert H. Pierce, Jr., MD; Paul Nghiem, MD, PhD; John H. Lee, MD; Bridget M. Adcock, BS; Patrick Soon-Shiong, MD; Sunandana Chandra, MD; | Clinical Trial Completed | Adoptive immunotherapy; Checkpoint blockade; Clinical study; Cytokine; NK/NK T cell; Solid tumors; T cell |
| O24 | Phase II Trial of Concurrent Nivolumab and Radiation Therapy in Chemotherapy Ineligible Muscle Invasive Bladder Cancer [NUTRA trial NCT03421652] | Ulka N. Vaishampayan, MD; Saby George, MD, FACP; Lance Heilbrun; Jordan Maier, MD; Brenda Dickow; Michael Kuettel, MD; Arthur Frazier, MD; Stacey M. Suisham, RN BSN OCN CcRP; Prahlad Parajuli, PhD; Nitin Vaishampayan, MD; Ulka N. Vaishampayan, MD | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Tumor microenvironment |
| O27 | Clinical Response to Tumor Infiltrating Lymphocytes (TIL) in Stage 4 Non-small Cell Lung Cancer (NSCLC) Correlates with Neoantigen-Specificity: a Phase I Trial | Chao Wang, PhD; Jamie Teer; Jiqiang Yao, PhD; Anadon Galindo Carmen M; David Noyes; Eric Toloza; John E. Mullinax, MD; Ana Landin; Jhanelle Gray; Tawee Tanvetyanon; Andreas Saltos; Linda L. Kelley, PhD; Bin Fang, PhD; John Koomen, PhD; Amod A. Sarnaik, MD; Sungjune Kim, MD PhD; Shari A. Pilon-Thomas, PhD; Jose R. Conejo-Garcia, MD, PhD; Scott J. Antonia, MD. PhD; Eric Haura, MD; Ben C. Creelan, MD, MS; | Clinical Trial In Progress | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| O29 | Phase I study of multisite stereotactic body radiotherapy plus nivolumab and urelumab or nivolumab and cabiralizumab in patients with advanced solid tumors | Corey C. Foster, MD, MS; Jason J. Luke, MD, FACP; Robyn Hseu, CCRP, MLIS; Linda Janisch; Gini Fleming, MD; Steven J. Chmura, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Radiotherapy; Solid tumors |
| O31 | Intratumoral INT230-6 injection into solid tumors kills tumors and induces immune cell infiltration leading to abscopal responses and prolonged disease control in multiple refractory cancer types | Jacob Thomas, MD; Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Lewis H. Bender, M.S., M.A, M.B.A.; Ian B. Walters, MD; Giles F. Whalen, MD; Diana Hanna, MD; Vinay Duddalwar, MD; Phillip Cheng, MD; Kevin King, MD; Lilian L. Siu, MD; Anthony El-Khoueiry, MD; | Clinical Trial In Progress | Chemotherapy; Clinical trial; Dendritic cell; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| O37 | PD1 Blockade Augments Adoptive T Cell Therapy via Endogenous T cells Rather than Direct Enhancement of Transferred T Cells | John S. Davies, PhD; Farrah Karimipour, BS.; Ling Zhang, PhD; Carylinda Serna; Christian S. Hinrichs, MD; | Combination Immunotherapies | Adoptive immunotherapy; Checkpoint blockade; Coinhibition; Neoantigens; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| O38 | A Single-dose immunotherapy that remodels the tumor microenvironment for subsequent curative responses to checkpoint blockade | Chensu Wang, PhD; Chensu Wang, PhD; Ang Cui; Ayush Thomas; Simon Liang; Maurice Bukenya; Heikyun Suh; K. Dane Wittrup, PhD; Nir Hacohen, PhD; Darrell J. Irvine, PhD; | Combination Immunotherapies | Angiogenesis; Antibody; Checkpoint blockade; Cytokine; Dendritic cell; Monocyte/Macrophage; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O39 | Soluble TNFα induced mucin 4 is a mediator of trastuzumab resistance and of an immunosuppressive tumor microenvironment in HER2+ breast cancer | Sofia Bruni, MS; Mara De Martino, PhD; Florencia L. Mauro, MS; Lucia Santa maria de la Parra; Patricia V. Elizalde, PhD; Roxana Schillaci; Roxana Schillaci; | Combination Immunotherapies | Antibody; Immune suppression; Myeloid cells; MDSC; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| O40 | Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers | Jason J. Luke, MD, FACP; Jaime Merchan; Lauren Harshman, MD; Thomas U. Marron, MD PhD; John D. Powderly, II, MD, CPI; Minal Barve; Patricia LoRusso, DO; Melissa Johnson; Andrew Hotson, PhD; Rachel Gittelman, PhD; Brian Munneke; Joseph J. Buggy; Stephen Willingham, PhD; Emily C. Piccione, PhD; Mehrdad Mobasher; Richard A. Miller, MD; Richard A. Miller; | Combination Immunotherapies | Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Clinical trial; Targeted therapy |
| O41 | Vasoactive intestinal peptide: a novel checkpoint pathway in pancreatic ductal adenocarcinoma | Sruthi Ravindranathan, PhD; Shuhua Wang, MD; Brandon Ware; Mohammad Y. Zaidi, MD, MS; Jingru Zhu; Rohan K. Dhamsania, BS; Susan N. Thomas, PhD, BS; Yiwen Li, MS; Bassel El-rayes, MD; Gregory B. Lesinski, PhD, MPH; Edmund K. Waller, MD, PhD, FACP; | Combination Immunotherapies | Adoptive immunotherapy; Solid tumors; Targeted therapy |
| O62 | Targeting myeloid tumors by Off-the-Shelf NK cells using an NKG2C-IL15-CD33 Trispecific Killer Engager | Emily Chiu, BA; Martin Felices; Frank Cichocki, PhD; Zachary Davis, PhD; Hongbo Wang; Katie Tuininga; Daniel Vallera; Tom Lee, PhD; Ryan Bjordahl; Dan S. Kaufman, CAMD, PhD; Karl Johan Malmberg; Bahram Valamehr; Jeffrey S. Miller, MD; | Immuno-conjugates and chimeric molecules | Adoptive immunotherapy; NK/NK T cell; Targeted therapy |
| O63 | Gastric toxicity associated with PD-1 blockade therapy revealed by Multiplexed Ion Beam Imaging | Selena Ferrian, PhD; Theodore S. Nowicki, MD, PhD; David W. Dawson; Alex Baranski; John Glaspy, MD; Antoni Ribas, MD, PhD; Michael Angelo, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Inflammation; Systems biology |
| O64 | Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease | Hamzah Abu-Sbeih, MD; David Faleck; Biagio Ricciuti, MD; Robin Mendelsohn; Abdul Rafeh Naqash, MD; Justine V. Cohen, DO; MacLean C. Sellars; Aanika Balaji; Guy Ben-betzalel; Ibraheim Hajir; Jiajia Zhang, MD, MPH; Mark Awad, MD PhD; Giulia Leonardi; Douglas B. Johnson, MD, MSCI; David J. Pinato, MD, MRes, PhD; Dwight Owen; Sarah A. Weiss, MD; Giuseppe Lamberti, MD; Mark Lythgoe; Lisa Manuzzi; Christina Arnold; Wei Qiao, PhD; Jarushka Naidoo, MD; Gal Markel; Nick Powell; Sai-Ching J. Yeung, MD, PhD; Elad Sharon, MD, MPH; Michael Dougan, MD, PhD; Yinghong Wang, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune suppression; Immune toxicity; Inflammation |
| O66 | Patient-derived microbiota germ-free mouse model for identifying mechanisms of checkpoint blockade efficacy modulation | Vyara Matson, PhD; Jessica L. Fessler, BS; Yuanyuan Zha, PhD; Thomas F. Gajewski, MD, PhD; | Microbiome and other environmental factors | Checkpoint blockade; Microbiome |
| O67 | Variation in the commensal urinary microbiome is associated with response to Bacillus Calmette-Guérin (BCG) immunotherapy in early stage urothelial bladder cancer. | Randy F. Sweis, MD; Randy F. Sweis, MD; Ciro Andolfi; Jeffrey Bloodworth; Shay Golan, MD; Nimrod Barashi; Elle Hill; Ryan Werntz; Thomas F. Gajewski, MD, PhD; Gary D. Steinberg, MD; | Microbiome and other environmental factors | Biomarkers; Chemokine; Clinical study; Cytokine; Immune contexture; Microbiome; Solid tumors; Tumor microenvironment |
| O68 | Characteristics of the microbiome form and function of complete responders to Anti-PD1 and healthy individuals implicate donor selection for clinical trial design | Md Abdul Wadud Khan, PhD; Jennifer A. Wargo, MD, MMSc; Beth Helmink, MD PhD; Elizabeth Burton; Christine N. Spencer, PhD; Jennifer L. McQuade, MD; Miles Andrews, MD, PhD; Alexandria Cogdill; Lauren E. Haydu, MS, BChe, MIPH; Reetakshi Arora; Angela L. Harris; Vanessa B. Jensen, DVM; Adrienne F. Duran, B.A.S.; Linsey Martin; Elizabeth Sirmans; Sapna Patel, MD; Tim Heffernan; Robert Jenq, MD; Michael K. Wong, MD PhD FRCPC; Jeffrey E. Gershenwald, MD; Tawbi Hussein; Isabella C. Glitza, MD, PhD; Patrick Hwu, MD; Michael Davies, MD, PhD; David Cook; Jennifer Wortman; Theresa LaVallee, PhD; Adi Diab, MD; Vancheswaran Gopalakrishnan; Md Abdul Wadud Khan, PhD; | Microbiome and other environmental factors | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Microbiome |
| O69 | Helicobacter hepaticus remodels the tumor immune microenvironment and reduces colorectal tumor burden | Abigail E. Overacre-Delgoffe, PhD; Hannah Bumgarner; Ansen HP. Burr; Timothy W. Hand, PhD; | Microbiome and other environmental factors | Dendritic cell; Immune suppression; Microbiome; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O70 | CD122-selective IL-2 complexes treat ovarian carcinomas, possibly by dysregulating Treg differentiation and reducing suppression, and promoting T cell stem cells | Yilun Deng, MD, PhD; Justin M. Drerup; Xinyue Zhang; Ryan M. Reyes; Jenny A. Mendez; Myrna G. Garcia; Alvaro S. Padron; Harshita B. Gupta, PhD; Tyler Curiel, MD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Cytokine; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| O71 | AMV564, a novel bivalent, bispecific T-cell engager, targets myeloid-derived suppressor cells | Sterling C. Eckard, PhD; Leah N. Gehrs; Victoria Smith; Jeanmarie Guenot; John F. DiPersio; Sheng Wei, MD; Michael P. Rettig; | Novel Single-Agent Immunotherapies | Clinical trial; Immune suppression; Leukemia/Lymphoma; Myeloid cells; MDSC; Solid tumors; T cell; Targeted therapy |
| O72 | Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers | Fan Zhang, PhD; Neha Parayath, PhD; Michael Coon, MS; Sirkka Stephan, PhD; Matthias Stephan, MD, PhD; | Novel Single-Agent Immunotherapies | Dendritic cell; Immune adjuvant; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O73 | Designed improvement to T-cell immunotherapy by integrated single cell profiling. | Irfan N. Bandey, PhD; Jay RT. Adolacion, PhD; Gabrielle Romain, PhD; Melisa Martinez, PhD; An Xingyue, PhD; Arash Saeedi; Rasindu Rajanayke; Ivan Liadi, PhD; Harjeet Singh, PhD; Laurence JN. Cooper, MD, PhD; Navin Varadarajan, PhD; | Other | Antibody; Bioinformatics; Biomarkers; Chemokine; Costimulation; Gene expression; Immune suppression; Leukemia/Lymphoma; Metabolism; Proteomics |
| O78 | Identification of breast cancer neoantigens exposed by radiation therapy | Claire Lhuillier, PhD; Nils Rudqvist; Takahiro Yamazaki, PhD; Lorenzo Galluzzi; Sandra Demaria, MD; | Tumor and Stromal Cell Biology | Neoantigens; Radiotherapy; Solid tumors; Tumor antigens; Vaccine |
| O81 | IMpower110: Interim overall survival (OS) analysis of a Phase III study of atezolizumab (atezo) monotherapy vs platinum-based chemotherapy (chemo) as first-line (1L) treatment in PD-L1–selected NSCLC | Roy Herbst, MD, PhD, Filippo De Marinis, Giuseppe Giaccone, Niels Reinmuth, Alain Vergnenegre, Carlos Barrios, Masahiro Morise, Enriqueta Font, Zoran Andric, Sarayut Geater0, Mustafa Ozguroglu, Simonetta Mocci, Mark McCleland, Ida Enquist, Kim Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Jacek Jassem, David Spigel, MD | Clinical Trial Completed | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Solid tumors |
| O83 | Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors | Ronnie Shapira-Frommer, Marloes G. J. van Dongen, Konstantin Dobrenkov, Elliot Chartash, Fang Liu, PhD, Claire Li, Richard Wnek, Manish Patel, MD | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Solid tumors; Targeted therapy |
| P6 | Development of a peripheral blood mononuclear cells (PBMC) ImmunoGraft platform to evaluate the pharmacodynamics of Immuno-oncology therapeutics | Bhavana Verma, PhD; Bruce Ruggeri; Amy Wesa, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Antigen presenting cells; Checkpoint blockade; Immune monitoring; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma; Vaccine |
| P7 | Development of a Natural Killer (NK) ImmunoGraft Platform for the Evaluation of the Pharmacodynamics of Immuno-Oncology Therapeutics | Bhavana Verma, PhD; Bruce Ruggeri; Jon Weidanz, PhD; Amy Wesa, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Checkpoint blockade; Immune monitoring; NK/NK T cell; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P16 | Circulating immunological biomarkers for predicting response to neoadjuvant chemotherapy in TNBC patients | Charlotte K. Milton, PhD; Thanussuyah Alaguthurai; Atousa khiabany, Mres; Sheeba Irshad, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Chemokine; Chemotherapy; Clinical study; Cytokine; Immune contexture; Immune monitoring; Solid tumors |
| P17 | Role of plasma-derived exosome in monitoring immunotherapy response and toxicity | Arnav Mehta, MD PhD; Gyulnara Kasumova; Alvin Shi; Lina Hultin Rosenberg; Emmett Sprecher; Dennie Frederick; Ryan J. Sullivan, MD; Keith T. Flaherty; Nir Hacohen; Genevieve M. Boland; Marijana Rucevic, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; Proteomics; Solid tumors |
| P18 | Liquid biopsy protein biomarkers to predict responses and elucidate resistance to cancer immunotherapy | Arnav Mehta, MD PhD; Marijana Rucevic, PhD; Marijana Rucevic, PhD; Marijana Rucevic, PhD; Gyulnara Kasumova; Emmett Sprecher; Lina Hultin Rosenberg; Dennie Frederick; Ryan J. Sullivan, MD; Nir Hacohen; Keith T. Flaherty; Genevieve Boland; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Proteomics; Solid tumors |
| P23 | High dimensional immune monitoring of peripheral blood samples from breast cancer patients using mass cytometry (CyTOF) | Jose C. Villasboas, MD; Kaitlyn R. McGrath, M.S.; El-ad David Amir, PhD; Roberto A. Leon-Ferre, MD; Matthew P. Goetz, MD; Judy Boughey, MD; Jody Carter, MD, PhD; Krishna R. Kalari, PhD; Liewei Wang, MD, PhD; Vera J. Suman, PhD; Richard Weinshilboum, MD; Stephen M. Ansell, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemotherapy; Immune monitoring; Immune suppression; Immune tolerance; Myeloid cells; NK/NK T cell; Solid tumors |
| P38 | Sensitive methodologies for tracking T cell immunotherapy by MRI | Brooke M. Helfer, PhD; Deanne Lister; Charles F. O'Hanlon III; Eric Ahrens; Brooke M. Helfer, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; CAR T cells; Solid tumors; T cell; T cell lineages |
| P43 | A novel platform for highly multiplexed, single-cell imaging of cell suspensions | Anum Khan; Won-Mean Lee; Jon Mulholland; Anum Khan; Dhananjay Wagh; John Coller; Gabriel Mercado; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Antibody; Autoimmunity; B cell; Bioinformatics; Biomarkers; Immune monitoring; Inflammation; Proteomics; T cell |
| P65 | Mutation-Targeted T Cell Responses in Blood from Patients with Solid Tumors Prior to Treatment and which Evolve with Clinical Benefit from Anti-PD-1 Therapies | Benjamin T. Yuen, PhD; Fangfang Yin, PhD; Duo An, PhD; Boi Quach; Linlin Guo, PhD; Joanne BL. Tan, PhD; Songming Peng, PhD; Zheng Pan, PhD; Olivier Dalmas, PhD; Robert Bao, PhD; Kyle Jacoby, PhD; Barbara Sennino, PhD; Stefanie J. Mandl, PhD; Matt Walters, PhD; Juan C. Jaen, PhD; Alex Franzusoff, PhD; Benjamin T. Yuen, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P68 | Innate inflammatory pathways are associated with TIL growth and response to adoptive immunotherapy | Suhendan Ekmekcioglu, PhD; Dai Ogata, MD, PhD; Caitlin Creasy, MS; Marie A. Forget, PhD; Sun-Hee Kim, PhD; Jason Roszik, PhD; Mike Spencer; Patrick Hwu, MD; Elizabeth A. Grimm, PhD; Chantale Bernatchez, PhD; Suhendan Ekmekcioglu, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Biomarkers; Immune suppression; Inflammation; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P75 | targetSCAPE and ultraSCAPE: Simultaneous identification and deep profiling of human antigen-specific T cells and other immune cell subsets by mass cytometry | David Roumanes, PhD; Faris Kairi; Alessandra Nardin, DVM; Evan Newell, PHD; Michael Fehlings; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; Neoantigens; T cell |
| P86 | Predictive Immune Modeling enables biomarker discovery in NSCLC patients treated with second line immunotherapy | Natalie A. LaFranzo, PhD; Steve Daniel, PhD; Walt Carney, PhD; Milan Bhagat; Natalie A. LaFranzo, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Immune contexture; Immune monitoring; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P97 | TCRB repertoire convergence and clonal expansion define the NSCLC tumor microenvironment of responders to anti-PD-1 monotherapy | Timothy Looney, PhD; Katharina Leonards; Ilaria Alborelli; Luca Quagliatta; Philip Jermann; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P104 | Impact of chemotherapy (chemo) on peripheral T-cell diversity and implications for subsequent immunotherapy response in breast cancer | Joanna Pucilowska, PhD; Paul Fields, PhD; Valerie K. Conrad, BS; David B. Page, MD; Alison K. Conlin, MD; Joanna Pucilowska, PhD; Catherine Sanders, PhD; Raina A. Tamakawa, MS; Brie M. Chun, MD; Isaac K. Kim, MD; Mark Schmidt; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemotherapy; Clinical study; Immune monitoring; T cell |
| P106 | Tumor Mutational Burden profile (TMB) of Oncogenic Driver Mutations in Non Small Cell Lung Cancer | Nitika Sharma; Paul R. Walker, MD; Nitika Sharma; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Angiogenesis; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors; Targeted therapy |
| P112 | A new way of immunity exploration by linking highly multiplexed antigen recognition to immune repertoire and phenotype | Dagmar Walter, PhD; Stephane C. Boutet; Michael JT. Stubbington, PhD; Katherine A. Pfeiffer; Josephine Y. Lee; Luz Montesclaros; Julia K. Lau; Daniel P. Riordan; Alvaro Martinez Barrio; Liselotte Brix, phd; Kivin KJ. Jacobsen, PhD; Bertrand Yeung; Xinfang Zhao; Tarjei Mikkelsen; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Antibody; Biomarkers; Gene expression; Genetic polymorphism; T cell; T cell lineages |
| P114 | TISSUTAL IMMUNE PROFILE AND PATHOLOGICAL COMPLETE RESPONSE IN TRIPLE NEGATIVE BREAST CANCER. | Andrea Botticelli, MD; Bruna Cerbelli; Simone Scagnoli; Maria Ida Amabile; Alessandro De Luca; Lucio Fortunato; Leopoldo Costarelli; Marianna Nuti, PhD; Giulia D'Amati; Paolo Marchetti; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Chemotherapy; Immune adjuvant; Immune suppression; Immunoscore; Tumor microenvironment |
| P115 | Deep proteomic characterization of FFPE tumor samples from late-stage melanoma subjects treated with anti-PD-1 immunotherapy | Nicholas Dupuis, PhD; Jakob Vowinckel, PhD; Domenico Mallardo, MD; Mariaelena Capone, MD; Madonna Gabriele; Antonio Sorrentino; Vito Vanella; Daniel Heinzmann; Paolo Antonio A. Ascierto, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Proteomics; Solid tumors; Systems biology |
| P123 | Identification of mRNA signatures that predict response to immunotherapy in melanoma patients | Ioannis A. Vathiotis, MD; Amy Sullivan; Sarah Warren, PhD; Nicole Gianino; Sandra Martinez-Morilla, PhD; Pok Fai Wong, MD, MPhil; Harriet Kluger, MD; Konstantinos N. Syrigos; David L. Rimm, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Gene expression; Inflammation; NK/NK T cell; Tumor microenvironment |
| P124 | A Novel Cell-Mediated Immunotherapy for Treatment of Lung and Breast Cancer | Indu Venugopal, PhD; Kathlynn C. Brown; Michael J. McGuire; Claire Gormley; | Biomarkers, Immune Monitoring, and Novel Technologies | T cell; Targeted therapy |
| P129 | Correlation of circulating CD8 T cell activation with response to immunotherapy in advanced renal cell carcinoma | Jennifer Carlisle, MD; Caroline S. Jansen, BS; Adriana M. Reyes; Nataliya Prokhnevska, BS; Deborah Baumgarten, MD; Viraj A. Master, MD, PhD; R. Donald Harvey, PharmD; Bradley C. Carthon, MD, PhD; Omer Kucuk, MD; Mehmet A. Bilen; Haydn T. Kissick; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors; T cell |
| P134 | Prognostic value of tumor microenvironment based on PD-L1 expression and CD8+ TILs density in locally advanced NSCLC treated with concurrent chemoradiotherapy | Lukas Kaesmann, MD; Kathrin Gennen; Julian Taugner; Chukwuka Eze; Monika Karin; Olarn Roengvoraphoj; Jens Neumann; Amanda Tufman; Michael Orth; Simone Reu; Claus Belka; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemotherapy; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P138 | Review of evidence for predictive value of microsatellite instability/mismatch repair status in response to non-anti-PD-(L)1 therapies in patients with advanced or recurrent endometrial cancer | Cara Mathews, MD; Ellie Im; Liliana Alfaya; Cara Mathews, MD; Cara Mathews, MD; Karin Travers; Craig Gibson; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Chemotherapy; Targeted therapy |
| P140 | Myeloid cell contexture and IL-8 expression as a candidate immunotherapy target in Non-Small Cell Lung Cancer (NSCLC). | Venkata Vamsi Nagineni, MD; Kurt A. Schalper, MD, PhD; Shruti Desai, PhD; Ignacio Melero, MD; Miguel F. Sanmamed, MD, PhD; Richa Gupta; Roy S. Herbst, MD, PhD; Venkata Vamsi Nagineni, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Chemokine; Granulocyte; Targeted therapy; Tumor microenvironment; Tumor stroma |
| P145 | Expanding Iovance’s tumor infiltrating lymphocytes (TIL) from core biopsies for adoptive T cell therapy using a 22-day manufacturing process | Michelle R. Abelson, PhD; Kenneth D'Arigo; Florangel Hilton; Maria Fardis, PhD, MBA; Cecile Chartier; Cecile Chartier | Cellular Therapies | Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P146 | AUTO6NG: Next generation GD2-targeting CAR T-cell therapy with improved persistence and insensitivity to TGFb and checkpoint inhibition for relapsed/refractory neuroblastoma | Daniela Achkova, PhD; Adrian Zarzoso; Yusuf Demir; Fernando J. Gallardo; Maria Stavrou; Marco Della Peruta; Saket Srivastava; Mathew Robson; Shimobi Onuoha; Simon Thomas; Shaun Cordoba; Martin Pule; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Cytokine; Solid tumors |
| P147 | Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients. | Erik Marcelo Alcantar Orozco; Eytan Breman, MSc; Marie-Sophie Dheur, PhD; Fabian Borghese, PhD; Emilie Cerf, PhD; Nathalie Braun; Caroline Lonez, PhD; Anne Flament; Frederic Lehmann, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical trial; Immune monitoring; Solid tumors; T cell |
| P149 | Silencing PD-1 using self-delivering RNAi PH-762- to improve Iovance TIL effector function using Gen 2 manufacturing method | Inbar Azoulay-Alfaguter, PhD; Michelle R. Abelson, PhD; Krit Ritthipichai, DVM, PhD; Kenneth D’Arigo; Florangel Hilton; Marcus Machin, BS; Dingxue Yan; James Cardia; Maria Fardis, PhD, MBA; Cecile Chartier; | Cellular Therapies | Adoptive immunotherapy; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P150 | 1st-in-human CAR T clinical trial for metastatic breast cancers | Cynthia C. Bamdad, PhD; Andrew K. Stewart, PhD; Pengyu Huang, PhD; Benoit J. Smagghe, PhD; Scott T. Moe, PhD; Tyler E. Swanson; Thomas G. Jeon; Danica M. Page; Ketan M. Mathavan, PhD; Trevor J. Grant, PhD; Rachel M. Herrup; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P151 | Solid tumor cytotoxicity by natural killer cells expressing a HER2-directed chimeric antigen receptor enhanced by MyD88/CD40 (MC) | Xiaomei Wang, PhD; Daniel E. Jasinski, PhD; Jan L. Medina; David M. Spencer, PhD; Aaron E. Foster, PhD; Joseph H. Bayle, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy |
| P152 | Antigen delivery to PBMCs by microfluidic squeezing primes anti-tumor immunity | Matthew G. Booty, PhD; Kelan A. Hlavaty; Emrah I. Ozay, PhD; Carolyne Smith, PhD; Katherine Seidl, PhD; Howard Bernstein, MD, PhD; Armon Sharei; Scott M. Loughhead; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; T cell; Tumor antigens; Vaccine |
| P153 | Memory CD8+ T cells are more resistant to cancer stem cell (CSC) suppression than effector CD8+ T cells and are more effective at targeting CSC in a murine melanoma model | Brooke C. Bredbeck, MD; Shibin Qu; Alicia A. Kevelin; Ashley A. Pepple; amy E. Felsted; Anutosh Ganguly; Clifford S. Cho, MD, FACS; Brooke C. Bredbeck; | Cellular Therapies | Adoptive immunotherapy; Immune suppression; Stem cell/cancer-initiating cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P154 | Development of an Antigen-Presenting Bead Kit for Activation and Expansion of Human Antigen-Specific T Cells | Yelena Bronevetsky, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Cytokine; Immune monitoring; T cell; T cell lineages; Tumor antigens |
| P155 | Prospective Translational Study Evaluating Vaccine-Enhanced Adoptive T cell Therapy for Treatment of Osteosarcoma in Companion Dogs | Tammie A. Wahaus, BSBA; Noe Reyes, DVM; Jeffrey N. Bryan, DVM, MS, PhD, DACVIM-Oncology; Jeffrey N. Bryan, DVM, MS, PhD, DACVIM-Oncology; Gary W. Wood, PhD; Brian K. Flesner, DVM, MS, DACVIM-Oncology; Debbie Tate, RVT, VTS (Oncology); Lindsay L. Donnelly, DVM, MS, DACVIM-Oncology; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P157 | Optimized process for manufacturing Deep-Primed™ T cells creates product with improved functional characteristics and reactivity against multiple tumor-associated antigens | Shawn P. Carey, PhD; Christine M. McInnis, PhD; Alicia Worthylake; Angela Forte; Elisabeth Brown; Darren Smith; Kate Sackton, PhD; Rosemary Soucy; Tap Maniar, MD; Karsten Sauer, PhD; Thomas L. Andresen, PhD; Andy Rakestraw, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor antigens |
| P158 | Suboptimal ER stress Induced Autophagy Regulates Anti-Tumor T Cell Response | Shilpak Chatterjee; Danh T. Tran; Kim Dosung; Satish N. Nadig; Carl Atkinson; Hongjun Wang; J. Alan Dieh; Shikhar Mehrotra, PhD; Paramita Chakraborty, PhD; | Cellular Therapies | Adoptive immunotherapy; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs) |
| P160 | Engineered natural killer cells redirected against adenosinergic immunometabolic suppression for the immunotherapy of lung carcinoma | Andrea Chambers, MS; Kyle B. Lupo, BS; Jiao Wang, PhD; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Gene expression; Metabolism; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| P161 | High-efficiency CAR-T cell manufacturing by improved scalable electroporation | Jian Chen, PhD; George Sun; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Gene expression; NK/NK T cell; T cell |
| P162 | Development of CD4+ and CD8+ TCRαβ-deficient bioluminescent reporter T cells for screening and characterization of neoantigen-specific TCRs | Zhijie J. cheng, PhD; Jamison J. Grailer, PhD; Michael Slater; Pete Stecha; Jim Hartnett; Frank Fan, PhD; Mei Cong, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Neoantigens; T cell; Targeted therapy |
| P163 | Effect of common gamma-chain cytokines on myeloid-derived suppressor cell and M2 macrophage suppressive function: Implications for cellular immunotherapy | Anna Cole, BA; Charlotte Rivas; Josue Pineda; Corrine Baumgartner; Stephanie Fetzko; Robin Parihar; | Cellular Therapies | CAR T cells; Cytokine; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor microenvironment |
| P164 | Effect of NK cell treatment on PD-L1 expression and anti-PD-L1 response | Alicja Copik, PhD; Jeremiah L. Oyer; Sarah B. Gitto; Deborah A. Altomare, PhD; | Cellular Therapies | Adoptive immunotherapy; Checkpoint blockade; NK/NK T cell; Solid tumors |
| P165 | Robust, reproducible and highly scalable manufacturing of P-BCMA-ALLO1, an allogeneic CAR-T stem cell memory product for Multiple Myeloma, from numerous healthy donors | Stacey Cranert, PhD; Maximilian Richter, PhD; Min Tong, MS; Leslie Weiss, M.S.; Yening Tan, MS; Eric Ostertag, MD/PhD; Julia Coronella, PhD; Devon Shedlock, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; Targeted therapy |
| P167 | Improved efficacy leveraging CAR-T therapeutics that produce tightly controlled, tumor proximal, immunomodulatory outputs | Michon Pinnix; Krista McNally; Jay Danao, BS; Melissa Fardy; Rachel Hovde, MS; Charlotte Davis; Nicole Grant; Dianna Lester-Zeiner; David Mai; Ben Wang, PhD; Gus Zeiner, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| P169 | Enriching non-genetically modified antigen specific marrow infiltrating lymphocytes (MILs) to target HPV+ oropharyngeal squamous cell carcinoma | Danielle W. Dillard, PhD Candidate; Vanessa Chan; LAKSHMI RUDRARAJU, MS; Elizabeth DeOliveira; Amy Thomas; Ervin Griffin; Megan K. Heimann, PhD candidate; Luca Biavati, MD; Elizabeth Zawidzka; Marguerrita El Asmar; Drew M. Pardoll, MD, PhD; Kellie N. Smith, PhD; Carole Fakhry, MD; Ivan M. Borrello, MD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P171 | T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers | Smita S. Chandran, PhD; Jiaqi Ma; Martin Klatt, PhD; Friederike Dundar, PhD; Paul Zumbo; Matthew R. Femia; Doron Betel, PhD; David Scheinberg; Brian M. Baker, PhD; Christopher A. Klebanoff, MD; Smita S. Chandran, PhD; | Cellular Therapies | Adoptive immunotherapy; Gene expression; Neoantigens; Proteomics; T cell |
| P172 | Shape and Material Properties Increase Artificial Antigen Presenting Cell Effectiveness | Savannah Est Witte, BS; Kaitlyn G. Calebrisi; Jordan J. Green, PhD; Savannah Est Witte, BS; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; T cell; Targeted therapy |
| P173 | Case reports: Correlates of response following adoptive transfer of ADP-A2M4, affinity-enhanced T-cells targeting MAGE-A4, in synovial sarcoma | Svetlana Fayngerts, PhD; Zohar Wolchinsky; Shravani Shitole; Joana Senra; Rebecca Dryer-Minnerly, PhD; Ruoxi Wang; Jean-Marc Navenot, PhD; Olga Ochkur; Gareth Betts, PhD; Natalie Bath, MSc; Erin Van Winkle; Tom Holdich; Malini Iyengar, PhD; Rafael Amado, MD; Marcus O. Butler, MD; David S. Hong, MD; Alex J. Tipping, PhD; Samik Basu, MD; Indu Ramachandran, PhD | Cellular Therapies | Adoptive immunotherapy; Clinical study; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P174 | Combinatorial tumor targeting using a novel switchable RevCAR system | Anja Feldmann, PhD; Anja Hoffmann; Ralf Bergmann; Liliana Loureiro, PhD; Enrico Kittel-Boselli; Nicola Mitwasi; Stefanie Koristka; Justyna Jureczek; Nicole Berndt; Claudia Arndt; Michael Bachmann; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Targeted therapy |
| P175 | PD-L1: A side-effect of T cell engagement or a main player in MDS tumor immune evasion? | Valentina Ferrari, BA; Alison Tarke; Hannah Fields; Tiffany Tanaka; Rafael Bejar; Thomas A. Lane, MD; Antonella Vitiello, PhD; Maurizio Zanetti, MD; | Cellular Therapies | Adoptive immunotherapy; Myeloid cells; Neoantigens; T cell; Tumor evasion; Tumor microenvironment |
| P176 | Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for metastatic uveal melanoma: feasibility of treatment using a product generated from the primary tumor | Marie-Andree Forget, PhD; Cara Haymaker, PhD; Orenthial J. Fulbright, BS; Shawne Thorsen, BS; Esteban Flores, BS; Arely Wahl, MSc; Rene J. Tavera, BS; Benjamin Tintera, BS; Timothy L. Woody; Michelle Williams; Yun Shin Chun; Patrick Hwu, MD; Dan S. Gombos; Sapna Patel, MD; Rodabe N. Amaria, MD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P177 | NF-kB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma | Rahul Suresh, PhD; David Barakat, PhD; Theresa Barberi, PhD; Lei Zheng, PhD MD; Elizabeth M. Jaffee, MD; Kenneth J. Pienta, MD; Alan D. Friedman, MD; | Cellular Therapies | Adoptive immunotherapy; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| P178 | Dual inhibition of PI3Kdelta and PI3Kgamma to enhance mitochondrial mass and ex vivo expansion of central and stem cell memory T cells from CLL patients | Christopher R. Funk, BS; Shuhua Wang, MD; Alexandra Waller, BS; Lauren C. Fleischer, BS; Aditi Sharma; Harold T. Spencer, PhD; Vikas Gupta, MD, PhD; Sruthi Ravindranathan, PhD; Mala Shanmugam, PhD; Christopher Flowers, MD, MS; Edmund K. Waller, MD, PhD, FACP; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Leukemia/Lymphoma; T cell |
| P179 | Checkpoint Cbl-b siRNA-based APN401 adoptive cell therapy: Superior efficacy & immune memory induction in murine hepatocellular carcinoma following APN401 monotherapy and synergism with anti-PD1. | Anderson Gaweco, MD, PhD; Anderson Gaweco, MD, PhD; Kathrin Thell; Maria Urban; Julia Harrauer; Isabella Haslinger; Josef Penninger; Vincent Chung; Anthony El-Khoueiry, MD; Carlos Becerra, MD; | Cellular Therapies | Adoptive immunotherapy; Checkpoint blockade; Coinhibition; NK/NK T cell; Solid tumors; T cell; Targeted therapy |
| P180 | SENTI-101, an allogeneic cell product, induces potent and durable anti-tumor immunity in pre-clinical models of peritoneal carcinomatosis | Alba Gonzalez Junca, PhD; Gary Lee, PhD; Alba Gonzalez Junca, PhD; Archana Nagaraja, PhD; Alyssa Mullenix; Russell M. Gordley, PhD; Daniel O. Frimannson, PhD; Anissa Benabbas; Chen-Ting Lee, PhD; Tiffany A. Truong; Mengxi Tian; Allison Bi. Quach; Rishi Savur; Rowena Martinez; Alyssa Perry-McNamara; Don-Hong Wang, PhD; Ori Maller, PhD; Dharini Iyer, PhD; Ashita Magal; Christina J. Huynh; Carmina C. Blanco; Jack T. Lin, PhD; Brian S. Garrison, PhD; Philip Lee, PhD; Sravani Mangalampalli; Timothy K. Lu, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Solid tumors; Tumor microenvironment |
| P181 | Multi-phenotype CRISPR-Cas9 screens identify p38 kinase as a target for adoptive immunotherapies | Devikala Gurusamy, PhD; Suman Vodnala; Amanda Henning; Rigel Kishton; Tori N. Yamamoto; Arash Eidizadeh; Li Jia; Christine M. Kariya; Mary Black; Robert L. Eil; Douglas Palmer; Zhiya Yu; Jenny Pan, MD; Madhusudhanan Sukumar; Shashank J. Patel; Nicholas P. Restifo, MD; | Cellular Therapies | Adoptive immunotherapy; Bioinformatics; CAR T cells; Leukemia/Lymphoma; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P182 | GAIA-102: a new class NK cell-like phenotype manufactured in accordance with GMP/GCTP that can eliminate solid tumors | Yui Harada, PhD; Yoshikazu Yonemitsu, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; MDSC; NK/NK T cell; Solid tumors |
| P183 | Development of novel chimeric antigen receptor T cells for immunotherapy of hepatocellular carcinoma | Yukai He, PhD; Leidy Caraballo Galva; Xiaotao Jiang; | Cellular Therapies | Adoptive immunotherapy; Antibody |
| P184 | Activating marrow infiltrating lymphocytes in hypoxia enhances their efficacy in adoptive T-cell therapy | Megan K. Heimann, PhD candidate; Ervin Griffin; Luca Biavati, MD; Amy Thomas; Danielle Dillard; Elizabeth Zawidzka; Brianna Richardson; Robert D. Leone; Gregory Szeto; Kimberly A. Noonan, PhD; Ivan M. Borrello, MD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Gene expression; Metabolism; T cell; Tumor antigens; Tumor microenvironment |
| P185 | T cell antigen presenting cell (tAPC) is a strategy to induce CAR T expansion in vivo in the absence of a tumor for on-target toxicity studies | Yen Ho, BS; Jon Jones, BA; Jon Jones, BA; Patrick Carlson, BS; Patrick Carlson, BS; Cyr de Imus; Rebekah Turk; Dina Alcorn; Kyle Kolaja; Ruth Salmon, PhD; Thomas Long; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Immune toxicity; T cell |
| P186 | Evaluation of antigen-specific T-cell immunity at the single cell level using large panels of DNA barcoded MHC multimers | Kivin KJ. Jacobsen, PhD; Dagmar Walter; Michael Stubbington; Katherine Pfeiffer; Charlotte Halgreen; Liselotte Brix, phd; Stephane Boutet; Kivin KJ. Jacobsen, PhD; | Cellular Therapies | Adoptive immunotherapy; Biomarkers; Gene expression; Immune monitoring; Neoantigens; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P187 | Single-cell RNA sequencing and functional assessment of healthy donor- and cancer patient-derived T and CAR-T cells | Zinkal Padalia, MS; Konstantinos Karagiannis, PhD; Brigid Mcewan, MA; Vahan Simonyan, PhD; Jonathan Terrett, PhD; Demetrios Kalaitzidis, PhD; Demetrios Kalaitzidis, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Systems biology; T cell; Targeted therapy; Tumor antigens |
| P188 | Enhanced anti-tumor activity of human placental CD34+ derived natural killer cells in combination with ACY-241 for multiple myeloma immunotherapy | Lin Kang, PhD; Xiaokui Zhang; Shuyang He; Vanessa Voskinarian-Berse; Bhavani Stout; Valentina Rousseva; William van der Touw; James Edinger; Robert Hariri; | Cellular Therapies | Adoptive immunotherapy; Chemotherapy; NK/NK T cell |
| P193 | CoStAR (Costimulatory Antigen Receptor) Enhancement of Tumour Infiltrating Lymphocyte Therapy | Gray Kueberuwa, PhD; John S. Bridgeman, PhD; Martina Sykorova; milena Kalaitsidou; Michelle L. Le Brocq; Martina Sykorova; Robert Hawkins; | Cellular Therapies | Adoptive immunotherapy; Costimulation; Immune contexture; T cell; Tumor infiltrating lymphocytes (TILs) |
| P195 | Loss of function of the TSC1-TSC2 complex renders tumors eligible for GD3 CART therapy | Ancy Thomas; Saurav Sumughan; Zhussipbek Mukhatayev; Emilia Dellacecca; Nicola Lancki; Levi Barse; Jesus Zamora-Pineda; Suhail Akhtar; Maria Picken; Denise Scholtens; Daniel Dilling; Richard P. Junghans, PhD, MD; Caroline Le Poole; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; NK/NK T cell; Solid tumors; T cell; Tumor antigens |
| P196 | The first step toward the universal cell therapy: Simultaneous removal of HLAs (Human leukocyte antigens) using CRISPR-mediated quadruple genome editing in allogeneic T cells | Jeewon Lee, Ph D; Munkyung Kim; Joong Hyuk Sheen; Jihye Ryu; Yu Young Kim; Okjae Lim; | Cellular Therapies | Adoptive immunotherapy; Gene expression; T cell |
| P197 | The development of an autologous neoantigen specific T cell product from peripheral blood, NEO-PTC-01, through the ex-vivo induction protocol, NEO-STIM™ | Divya R. Lenkala; Marit M. Van Buuren, PhD; Brian McCarthy; Jessica Kohler, PhD; Michael Nelson; Flavian Brown; Yvonne Ware, Masters; Yuting Huang, Master of Science; Janani Sridar; Yusuf S. Nasrullah, Master's in Biological Research, United Kingdom; Dewi Harjanto; Joost H. Van Den Berg, PharmD; Matthew Goldstein, MD, PhD; Richard B. Gaynor, MD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Immune monitoring; Neoantigens; T cell |
| P198 | Short-lived and extended half-life target modules for redirecting UniCAR T-cells against sialyl-Tn expressing cancer cells | Liliana Loureiro, PhD; Liliana Loureiro, PhD; Anja Feldmann, PhD; Ralf Bergmann; Stefanie Koristka; Nicole Berndt; Nikolett Hegedüs; Domokos Máthé; Paula Videira; Michael Bachmann; Claudia Arndt; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Targeted therapy |
| P199 | Generation of functionally and phenotypically mature, allogeneic natural killer cells from human induced pluripotent stem cells under chemically-defined, feeder- and serum- free culture conditions | Kyle B. Lupo, BS; Andrea Chambers, MS; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Stem cell/cancer-initiating cell; Solid tumors |
| P200 | CART-engineered Marrow-infiltrating Lymphocytes (MILsTM) are more polyfunctional than their matched peripheral blood counterparts | Eric R. Lutz, PhD; LAKSHMI RUDRARAJU, MS; Elizabeth DeOliveira; Srikanta Jana; Jing Zhou, MD, PhD; Sean G. Mackay, MBA; Ivan M. Borrello, MD; Kimberly A. Noonan, PhD; Eric R. Lutz, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
| P201 | Comparison of phenotype and anti-tumor profile of CD19-CAR-T cells generated from either umbilical cord blood- or peripheral blood-derived T lymphocytes | Cristina Maccalli, PhD; Dhanya Kizhakayil, PhD; Shilpa Ravindran, BSc.; Saad Rasool; Rebecca Mathew; Valentina Mattei; Monica Casucci, PhD; Sara Deola, MD, PhD; Chiara Cugno, MD; Damien Chaussabel; Sara Tomei, PhD; Christof von Kalle; Cristina Maccalli, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Immune monitoring; Leukemia/Lymphoma; Systems biology; T cell; Tumor antigens |
| P202 | Mechanisms underlying human placental CD34+-derived natural killer cell cytotoxicity against glioblastoma | Tanel Mahlakoiv, PhD; Bhavani Stout; Valentina Rousseva; Irene Raitman; Lin Kang, PhD; Robert Hariri; Xiaokui Zhang; William van der Touw; Tanel Mahlakõiv; | Cellular Therapies | Adoptive immunotherapy; Gene expression; NK/NK T cell; Solid tumors |
| P203 | Discovery and characterization of the first fully human Phosphopeptide Tumor Target-specific T cell receptor | Xavier Michelet, PhD; Eleni Chantzoura, PhD; Ekaterina Breous-Nystrom, PhD; Alessandra Franchino; Rachel Smith; Daniel Pollacksmith; Jan Bergmann; Alvaro Sebastian Yague; Paisley T. Myers, PhD; Erin Jeffrey; Benjamin Wolf; Dennis Underwood, PhD; Marc A. Van Dijk, PhD; Arthur A. Hurwitz, PhD; | Cellular Therapies | Adoptive immunotherapy; Leukemia/Lymphoma; Neoantigens; T cell; Targeted therapy; Tumor antigens |
| P204 | Ex vivo-activated allogeneic CD4+ T-cells disrupt immunosuppressive tumor microenvironment, and induce host tumor-specific cytotoxic T-cells in mice | Kazuhiro Mochizuki, MD, PhD; Shogo Kobayashi; Nobuhisa Takahashi; Hideki Sano; Yoshihiro Ohara; Shin Mineishi, MD; Yi Zhang; Atsushi Kikuta; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Dendritic cell; Inflammation; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P206 | Transmembrane and linker domain amino acid composition alters chimeric antigen receptor (CAR) membrane residence and may conceal detection of novel functional CAR formats | Dina Schneider, PhD; Virginia Hoglund, MS; Ying Xiong, PhD; Darong Wu, MS; Boro Dropulic, PhD, MBA; Rimas J. Orentas, PhD; Rimas J. Orentas, PhD; Rimas J. Orentas, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
| P207 | A patient-driven ex vivo 3D tumor organoid model to assess efficacy of tumor infiltrating T-cell adoptive cell therapy | Jenny Kreahling, PhD; Mibel Pabon, PhD; Mibel Pabon, PhD; Melba Page, PhD; Vijayendra Agrawal, PhD; Soner Altiok, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Biomarkers; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P208 | Impact of combined blockade of PD1 and activation of CD137 on tumor infiltration and tumor cell killing efficacy of TILs in an ex vivo autologous 3D tumoroid model of NSCLC patient samples. | Jenny Kreahling, PhD; Melba Page, PhD; Melba Page, PhD; Mibel Pabon, PhD; Vijayendra Agrawal, PhD; Soner Altiok, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Checkpoint blockade; Cytokine; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P209 | Hijacking CAR-CD19 T cells to potently control Her2-positive solid tumors in vitro and in vivo through the use of unique and selective bridging proteins | Paul Rennert, PhD; Christine Ambrose, PhD; Fay Dufort, PhD; Lihe Dufort; Alyssa Birt; Thomas Sanford; Lan Wu; Roy Lobb, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Tumor antigens; Tumor evasion |
| P210 | Deep phenotypic and functional analysis of transduced anti-CD19 CAR T cells and untransduced T cells in patients treated with axi-cel by single cell mass cytometry | Yohei Arihara, MD, PhD; Caron Jacobson, MD; Philippe Armand, MD; John M. Rossi, MS; Nathalie Scholler, MD, PhD; Stuart Sievers, PhD; Edmund Chang, PhD; Mauro Avanzi, MD, PhD; Adrian Bot, MD, PhD; Jerome Ritz, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Clinical study; Immune monitoring; Leukemia/Lymphoma |
| P211 | Combining Deep™ IL-12 Primed and Deep™ IL-15 Primed T cells leverages complementary mechanisms to enhance anti-tumor activity | Katharine Sackton, PhD; Elena Geretti, PhD; Pengpeng Cao, PhD; Shawn P. Carey, PhD; Xiaoyan Liang; Jonathan Nardozzi, PhD; Zishu Gui; Alicia Worthylake; Glenn Leary; Becker Hewes, MD; Tap Maniar, MD; Jonathan B. Fitzgerald, PhD; Andy Rakestraw, PhD; Karsten Sauer, PhD; Douglas Jones, PhD; Thomas L. Andresen, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Solid tumors; T cell |
| P212 | Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy | Donastas Sakellariou-Thompson, BS; Marie-Andree Forget, PhD; Emily Hinchcliff, MD; Joseph Celestino; Patrick Hwu, MD; Amir A. Jazaeri, MD; Cara Haymaker, PhD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P213 | Conversion of peripheral blood mononuclear cells into tumor-specific cytolytic cell populations using tumor cells engineered with multiple immunomodulatory factors | Joshua Keegan; James Lederer; Frank Borriello, MD, PhD; Nathan Schomer, MS; James Lederer; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Costimulation; Cytokine; Immune adjuvant; NK/NK T cell; T cell; T cell lineages; Targeted therapy; Vaccine |
| P214 | T cells precision engineered to express neoepitope-specific TCRs cloned from a patient with colorectal cancer specifically target and kill relevant neoantigen-expressing tumor cells | Barbara Sennino, PhD; Adam Litterman; John Gagnon; Andrew Conroy; Bhamini Purandare; Zheng Pan, PhD; Dalmas Olivier; Kyle Jacoby, PhD; Songming Peng, PhD; Alex Franzusoff, PhD; Stefanie J. Mandl, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens |
| P215 | Depletion of CD45RA-positive cells potentiates the reactivation of EBV-specific T-cells from EBV positive lymphoma patients | Sandhya Sharma, BSc.; Sandhya Sharma, BSc.; Naren Mehta; Kathan Parikh, RA; Cliona M. Rooney, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; T cell; Tumor antigens |
| P218 | A novel, bioluminescent assay for the selective detection of target cell killing in mixed cultures | Richard Somberg, PhD; Brock Binkowski; Aileen Paguio; Peter Stecha; Chris Eggers; Braeden Butler; Michael Beck; Julia Gilden, PhD; Jey Cheng; Mei Cong, PhD; Frank Fan, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; CAR T cells; Chemokine; Costimulation; Cytokine; NK/NK T cell; T cell; Targeted therapy |
| P220 | Targeting neoantigens with immunotherapy: Are we limited to pre-existing autologous neoantigen-specific T-cells? | Aline Bracher; Slavoljub Milosevic; Daniel Sommermeyer; Daniel Sommermeyer; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Tumor antigens |
| P221 | Superior anti-tumor activity of metabolically enhanced bispecific antibody armed CAR-less Bionic T cells | Archana Thakur, PhD; John Scholler; Edwin T. Bliemeister; Carl H. June, MD; Lawrence G. Lum, MD, DSc; | Cellular Therapies | Adoptive immunotherapy; Antibody; Chemokine; Cytokine; Solid tumors; T cell; Targeted therapy |
| P222 | Modulating BRD4 in T cells using self-delivery RNAi to improve adoptive cell therapy of cancer | Jeroen Melief, PhD; Laura L. Van Leeuwe Kirsch, BSc; Esmeralda Hemme; John A. Barrett, PhD; Simon P. Fricker, PhD; Gerrit Dispersyn, PhD; Rolf Kiessling, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; Tumor infiltrating lymphocytes (TILs) |
| P224 | Case studies of sarcoma and MRCLS following treatment with NY-ESO-1 TCR T Cells (GSK3377794): correlates of predictable response characteristics | Brian Van Tine, MD, PhD; Sandra P. D'Angelo, MD; Alexandra Gyurdieva; Laura Johnson; David C. Turner; Jenna Tress; M. Phillip DeYoung; Yuehui Wu; Aisha N. Hasan, MBBS MD; Dejka Araujo, MD; | Cellular Therapies | Adoptive immunotherapy; Clinical study; Cytokine; T cell |
| P225 | Generating iPSC-derived CAR T cells with an endogenous T cell phenotype and conventional CAR T functionality | Zhiqiang (Daniel) Wang, Ph.D; Zhiqiang (Daniel) Wang, Ph.D; Hellen McWilliams-Koeppen, MS; Christian Huynh, BS; Hernan Reza; Vibhuti Vyas; Xiuli Wang, PhD; Wen-Chung Chang, MS; Julie R. Ostberg, PhD; Renate Starr, MS; Jamie Wagner; Brenda Aguilar, BS; Xiwei Wu; Jinhui Wang; Wei Chen; Chris Seet; Gay Crooks; Christine Brown, PhD; Stephen J. Forman, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Stem cell/cancer-initiating cell; T cell; T cell lineages |
| P226 | Iovance Gen2 TIL manufacturing process produces drug products that exhibit favorable quality attributes for adoptive cell transfer across 5 solid tumor indications | Seth Wardell; Seth Wardell; Maritza Lienlaf-Moreno; Lavakumar Karyampudi; Anand Veerapathran, PhD; Ian Frank; Michelle A. Blaskovich, BS; Kenneth Onimus; Arvind Natarajan; Maria Fardis, PhD, MBA; Joe Wypych | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P227 | Co-expression of the metabolic enzyme GOT2 with a GPC3-targeted CAR-T overcomes challenges of the solid tumor microenvironment, substantially improving therapeutic efficacy in solid tumor xenografts | Kathleen R. Whiteman, MS; Kathleen R. Whiteman, MS; Tapasya Pai; Eugene Choi; Taylor Hickman; Tyler Johnson; Luke Barron, PhD; Taylor Friedman; Madaline Gilbert; Binzhang Shen; Seth Ettenberg; Kathleen McGinness; Greg Motz; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Metabolism; Solid tumors; T cell; Tumor microenvironment |
| P228 | Tumor infiltrating lymphocyte recognition of shared neoantigens from mutated DNA repair/remodeling proteins in a patient with metastatic pancreatic adenocarcinoma | Ghanshyam Singh S. Yadav, PhD; Chetana Bhaskarla, PhD; Smriti Chaurasia, PhD; Joshua Tobin; Xinming Zhuo; Yinghong Pan; Annerose Berndt; Udai S. Kammula, MD, FACS; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P229 | The Next Generation “off-the-shelf” Universal CAR for Adoptive Immunotherapy | Weichih Yang, PhD; Yun Ji; Xiaobing Luo; Huijuan Cui; Michael Patrick; Yutian Wei; Shigui Zhu; Jiaqi Huang; Xin Yao; Yihong Yao; Aibing Liang; Ping Li; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; T cell lineages |
| P230 | Activating Antigen Carriers for Cancer Therapy: Preclinical Immune Responses Drive Tumor Regression | Defne Yarar, PhD; Amritha Ramakrishnan; Katarina Blagovic, PhD; Katherine Seidl; Howard Bernstein, MD, PhD; Armon Sharei; | Cellular Therapies | Adoptive immunotherapy; Immune adjuvant; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P231 | Invariant natural killer T cells as an allogeneic cell therapy platform | Burcu Yigit, PhD; Xavier Michelet, PhD; Simon Yue; Darrian Moskowitz; Mark Exley; Burcu Yigit, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell |
| P235 | A dense, proliferative myeloid and T cell-rich, immune infiltrate characterizes Immunotherapy-induced skin rash | Cormac Cosgrove, PhD; Cory Kosche; Suyeon Hong; Caroline Le Poole; Jennifer Choi; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Dendritic cell; Immune toxicity; Inflammation; Monocyte/Macrophage; Myeloid cells; T cell |
| P240 | Quantitative cell-based bioassays to advance immunotherapy programs targeting immune checkpoint receptors | Vanessa Ott, PhD; Jamison J. Grailer, PhD; Jun Wang; Julia Gilden, PhD; Pete Stecha; Denise Garvin; Michael Beck; Jim Hartnett; Frank Fan, PhD; Mei Cong, PhD; Zhi-jie Jey Cheng; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; Costimulation; T cell; Targeted therapy |
| P243 | Modulating the immunogenicity of low-mutation soft tissues sarcomas with epigenetic targeted therapy | himavanth R. gatla, PhD; Maggie Phillips; Brian Ladle; himavanth R. gatla, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Cytokine; Gene expression; Pediatric tumors; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P244 | The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies. | Sonia Iyer, PhD; Shuang Zhang; Anniina Farkkila; Sean G. Smith, PhD; David Pepin; Raghav Mohan; Tian Xia; Ferenc Reinhardt; Tony Chavarria; Esmee Hoefsmit; Shailja Pathania; Yunlan Zhou; Kevin Elias; Benjamin Neel; Robert Weinberg, PhD; | Checkpoint Blockade Therapy | Carcinogenesis; Checkpoint blockade; Chemokine; Dendritic cell; Immune contexture; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell |
| P245 | Durvalumab after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) – a German radiation oncology survey | Lukas Kaesmann, MD; Chukwuka Eze; Julian Taugner; Olarn Roengvoraphoj; Claus Belka; Farkhad Manapov; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Radiotherapy |
| P246 | Prospective evaluation of outcome and toxicity of durvalumab treatment after chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) patients | Lukas Kaesmann, MD; Julian Taugner; Lukas Kaesmann, MD; Chukwuka Eze; Olarn Roengvoraphoj; Claus Belka; Farkhad Manapov; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Immune toxicity; Radiotherapy |
| P248 | Pembrolizumab plus axitinib (P+A) versus other first-line (1L) systemic therapies for advanced/metastatic clear-cell renal cell carcinoma (ccmRCC) by IMDC Risk Status – a network meta-analysis (NMA) | Ian McGovern, MPH; Rohan Shirali, MS; Andrew Simon, ScM; Yichen Zhong, PhD; Rodolfo Perini, MD; Maria Lorenzi, MSc; Oluwakayode Adejoro, MD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade |
| P253 | Distinct clinical and immunological responses to αPD-1, ⍺PD-L1 and ⍺PD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences | Myrna G. Garcia, BS; Alvaro Padron; Yilun Deng, MD, PhD; Harshita B. Gupta, PhD; Aravind Kancharla; Tyler Curiel, MD; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Costimulation; Cytokine; Dendritic cell; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs) |
| P254 | Requirement of Fc gamma receptor-mediated myeloid-cell activation for effective cancer immunotherapy with an anti-TIGIT antibody | Jin-hwan Han, PhD; Mingmei Cai; Jeffery Grein; Samanthi Perera, PhD; Hongmei Wang; Mike Bigler; Roenna Ueda; Thomas W. Rosahl; Elaine Pinheiro, PhD; Drake LaFace; Wolfgang Seghezzi; Sybil M. Williams, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Chemokine; Cytokine; Gene expression; Myeloid cells; T cell |
| P257 | Obesity is associated with diminished anti-PD-1-based immunotherapy response rates in renal cancer | Rachael M. Orlandella, BS; Shannon Boi; Justin T. Gibson, BS; William J. Turbitt; Gal Wald; Lewis Thomas; Katlyn E. Norris; Lakshminarayanan Nandagopal, MD; Peng Li, PhD; Eddy Yang, MD, PhD; Tatiana T. Marquez-Lago, PhD; Lyse A. Norian, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Myeloid cells; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P261 | Recruitment of CD103+ DCs via tumor stroma-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy | John-Michael Williford, PhD; Jun Ishihara, PhD; Ako Ishihara; Aslan Mansurov, BChen; Tiffany Marchell; Melody Swartz, PhD; Jeffrey Hubbell; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Chemokine; Dendritic cell; T cell; Targeted therapy; Tumor microenvironment; Tumor stroma |
| P270 | Expression and clinical significance of the CD47/SIRPα pathway as a candidate immunotherapy target in non-small cell lung cancer (NSCLC) | Shruti Desai, PhD; Franz Villarroel-Espindola; Patricia Gaule, PhD; Adam Ducler; Marisa Peluso, MS; Benjamin Lee, MD PhD; Pamela Holland, PhD; Kurt A. Schalper, MD, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P276 | Efficacy of PD-1/PDL-1 Immune Checkpoint Inhibitors in Elderly Patients with Non-Small-Cell Lung Cancer; A Subgroup Meta-analysis of Randomized Controlled Trials | Faisal S. Ali; Maryam R. Hussain; Arafat Farooqui; Syed H. Jafri, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Clinical trial; Immune monitoring; Tumor microenvironment |
| P278 | PD-1/PDL-1 Immune Checkpoint Inhibitors in Smokers with Non-Small-Cell Lung Cancer; A Subgroup Meta-Analysis of Randomized Controlled Trials | Faisal S. Ali; Bibek Pannu; Maryam R. Hussain; Arafat Farooqui; Taha Alrifai; Phyo T. Myint; Syed H. Jafri, MD; | Checkpoint Blockade Therapy | Carcinogenesis; Checkpoint blockade; Chemotherapy; Tumor microenvironment |
| P280 | Impact of tumor mutational burden on overall survival in patients with non-small cell lung cancer treated with immunotherapy | Mark Awad, MD PhD; Navin R. Mahadevan; Andrew Polio; Natalie Vokes; Elizabeth J. Aguilar; Biagio Ricciuti, MD; Giuseppe Lamberti, MD; Gonzalo Recondo, MD; Giulia C. Leonardi; Anika Adeni; Pasi A. Janne, MD PhD; Eliezer Van Allen, MD; Adem Albayrak, M.S.; Renato Umeton; Lynette M. Sholl; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| P281 | Durable response after immunotherapy discontinuation: a multicenter real-life experience | Maria Bassanelli, MD, PhD; Diana Giannarelli, MD; Marco Russano; Fabiana Letizia Cecere; Maria Rita Migliorino; Silvana Giacinti; Viola Barucca; Emilio Bria; Enzo Maria Ruggeri; Fabio Calabrò; Alain Gelibter; Daniele Santini; Anna Ceribelli; | Checkpoint Blockade Therapy | Immune toxicity; Solid tumors |
| P284 | Pitfalls in preclinical development of immunotherapies for ER+ breast cancer: estrogen as an immunomodulator potentially influencing pembrolizumab efficacy in a breast cancer model in humanized mice | Tiina E. Kähkönen; Mari I. Suominen; Jenni HE. Mäki-Jouppila; Emrah Yatkin; Philip Dube; Azusa Tanaka; Jussi M. Halleen; Jenni Bernoulli, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P290 | Interferon Gamma Production by Regulatory T cells is Necessary for Response to Cancer Immunotherapy | Angela M. Gocher, PhD; Dario A. Vignali, PhD; Creg Workman, PhD; Sanah Handu; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Cytokine; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P291 | Driving T cell dysfunction in vitro for rational immunotherapy design | Matthew Hancock; Cailin CJ. Joyce, PhD; Thomas Horn; Simarjot Pabla; Benjamin Duckless; Andrew Basinski; Dhan Chand, PhD; Jeremy D. Waight, PhD; Mariana Manrique, PhD; Nicholas S. Wilson; Alex Duncan, PhD; Jennifer S. Buell, PhD; David Savitsky, PhD; Lukasz Swiech; John C. Castle, PhD | Checkpoint Blockade Therapy | Bioinformatics; Checkpoint blockade; Gene expression; Systems biology; T cell; Tumor evasion; Tumor microenvironment |
| P298 | PBRM1 loss defines distinct tumor phenotype associated with immunotherapy resistance in renal cell carcinoma | Xiande Liu, Ph.D; Wen Kong; Christine B. Peterson; Daniel J. McGrail; Anh Hoang; Xuesong Zhang; Truong Lam; Patrick G. Pilie, MD; Haifeng Zhu, PhD; Kathryn E. Beckermann; Scott M. Haake; Sevinj Isgandrova; Margarita Martinez-Moczygemba; Nidhi Sahni; W. Kimryn Rathmell; Eric Jonasch, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P300 | Real World data analysis related to metastatic melanoma patients treated with immunotherapy from 2012 to 2018 at Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale” of Napoli, Italy | Gabriele Madonna; Mariaelena Capone, MD; Marilena Tuffanelli; Marcello Curvietto, PhD; Miriam Paone, PhD; Assunta Esposito, PhD; Antonio Sorrentino; Marco Palla; Luigi Scarpato; Domenico Mallardo, MD; Ester Simeone, MD; Antonio M. Grimaldi, MD; Kristina Viktorsson; Lisa Villabona; Rolf Lewensohn; Giuseppe V. Masucci, MD, PhD; Paolo Antonio A. Ascierto, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Solid tumors; Targeted therapy |
| P308 | The impact of obesity on the response rates of checkpoint Inhibitor (CPI) cancer immunotherapy | Philip A. Haddad, MD, MPH; David Sommerhalder, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Solid tumors; Tumor microenvironment |
| P314 | Alterations of DNA damage response signaling in the development of antibody-dependent cellular cytotoxicity (ADCC) resistance | Yongwei Zhang; Louis M. Weiner, MD; Yongwei ZHANG; Dalal Aldeghaither; David Zahavi, MS, BS; | Checkpoint Blockade Therapy | Adoptive immunotherapy; Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Gene expression; Neoantigens; NK/NK T cell; Solid tumors; Targeted therapy |
| P315 | The expression of programmed death ligand 2 (PD-L2) in immunosuppressive tumor microenvironment of non-small cell lung cancer (NSCLC) and its potential association with immunotherapy | Qu Zhang, PhD; Stefan Bentink; Vinay Pawar; Farzad Sekhavati, PhD; Keith E. Steele, DVM, PhD; Jason Hipp; Song Wu, PhD; | Checkpoint Blockade Therapy | Biomarkers; Clinical trial; Gene expression; Immune suppression; T cell; Tumor microenvironment |
| P317 | Utilization of Second-Line Immuno-Oncology Agents and Associated Health Outcomes Among United States Veterans with Advanced Non-Small Cell Lung Cancer | Mina A. Allo, PharmD, MPH; Lin Gu, MS; Vishal Vashistha, MD; Ashlyn Press, MPH; Michael J. Kelley, MD; Christina Williams, PHD, MPH; Mina A. Allo, PharmD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Epidemiology |
| P321 | Real-world clinical outcomes among patients with advanced non-small cell lung cancer who initiated first-line regimens | Eric Nadler, MD; Eric Nadler, MD; Bhakti Arondekar, PhD; Kathleen M. Aguilar; Jie Zhou; Jane Chang; Xinke Zhang; Vivek Pawar; | Checkpoint blockade therapy | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Targeted therapy |
| P323 | IPH5301, a CD73 blocking antibody targeting the adenosine immunosuppressive pathway for cancer immunotherapy. | Ivan Perrot; Caroline Denis, PhD; Marc Giraudon-Paoli; Severine Augier; Rachel Courtois; Diana Jecko; Violette Breso; Thomas Arnoux; Nicolas Gourdin, PhD; Romain Remark, PhD; Cecile Bonnafous; Ariane Morel, PhD; Eric Vivier; Yannis Morel, PhD; Pascale Andre; Carine Paturel, PhD; | Checkpoint Blockade Therapy | Antibody; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| P324 | Pan-tumor analysis of the association of cancer and immune biology-related gene expression signatures with response to pembrolizumab monotherapy | Razvan Cristescu, PhD; Michael Nebozhyn, PhD; Chunsheng Zhang, PhD; Andrew Albright, PhD; Julie Kobie, PhD; Lingkang Huang; Qing Zhao, MD PhD; Anran Wang; Hua Ma; Andrea Webber; Petar Jelinic; Mohini Rajasagi; Sandra C. Souza; Raluca Predoiu; Z. Alexander Cao; Junshui Ma; Michael Morrissey; Clemens Krepler, MD; Stephen Keefe; Jonathan Cheng, MD; Vassiliki Karantza; Sukrut Shah; Rodolfo Perini, MD; Antoni Ribas, MD, PhD; Petros Grivas, MD, PhD; David Cescon; Terrill K. McClanahan, PhD; Alexandra Snyder, MD; Mark Ayers, PhD; Jared Lunceford, PhD; Andrey Loboda, PhD; | Clinical Trial Completed | Angiogenesis; Biomarkers; Checkpoint blockade; Clinical study; Gene expression; Immune suppression; Solid tumors; Tumor microenvironment; Tumor stroma |
| P325 | Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy. | Bernardo L. Rapoport, MD; Simon Nayler; Jerome Galon, Dr; T Mlecnik; Teresa Smit; Jacqui Barnard-Tidy; Aurelie Fugon; Marine Martel; Ronald Anderson, Professor; Carol Benn; | Clinical Trial Completed | Chemotherapy; Clinical study; Immunoscore; T cell; Tumor infiltrating lymphocytes (TILs) |
| P327 | Evaluation of PD-L1 and cutoff selection to define a predictive biomarker for pembrolizumab monotherapy in esophageal cancer using KEYNOTE-180 | Mary Savage; Serafino Pantano; Qi Liu; Jared Lunceford, PhD; Peter Kang; Pooja Bhagia, MBBS, MD; Kenneth Emancipator, MD; | Clinical Trial Completed | Biomarkers; Checkpoint blockade; Solid tumors |
| P330 | Results from the completed dose-escalation of the alloSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients | Hans Prenen, MD; Marika Rasschaert, MD; Alain Hendlisz, MD; Leila Shaza, MD; Erik Alcantar-Orozco, MD, PhD; Emilie Cerf, PhD; Florence Renard; Caroline Lonez, PhD; Anne Flament; Jeroen Dekervel, MD; Eric Van Cutsem, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical study; Solid tumors |
| P331 | Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients | Leila Shaza, MD; Alain Hendlisz, MD; Ahmad Awada, MD, PhD; Jean-Luc Canon, MD; Javier Carrasco; Eric Van Cutsem, MD, PhD; Jeroen Dekervel, MD; Erik Alcantar-Orozco, MD, PhD; Florence Renard; Emilie Cerf, PhD; Caroline Lonez, PhD; Anne Flament; Marc Van den Eynde, MD; Jean-Pascal Machiels, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical study; Solid tumors |
| P333 | Timed anti-tumor vaccination during chemotherapy induces strong T-cell immunity and prolonged survival of late stage cervical cancer patients. | Marij J. Schoenmaekers-Welters, PhD; Marij JP. Welters, PhD; Cornelis J. Melief, MD, PhD; Ignace Vergrote; Judith Kroep, MD, PhD; Gemma G. Kenter, MD,PhD; Nelleke Ottevanger; Wiebren AA. Tjalma; Hannelore Denys; Mariette van Poelgeest, MD, PhD; Hans Nijman; Anna KL. Reyners; Thierry Velu; Frederic Goffin; Roy I. Lalisang; Nikki M. Loof; Sanne Boekestijn; Willem Jan Krebber; Leon Hooftman; Sonja Visscher; Brent A. Blumenstein, PhD; Richard B. Stead; Winald R. Gerritsen; Sjoerd H. van der Burg, PhD; | Clinical Trial Completed | Biomarkers; Clinical study; Clinical trial; Cytokine; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P336 | Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with acute lymphoblastic leukemia | Amita Kulshrestha; Haneen Shalabi, Do; Vandana Sachdev; Douglas R. Rosing; Stanislav Sidenko; Crystal L. Mackall, MD; Brandon Wiley; Daniel W. Lee; Nirali N. Shah; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Immune monitoring; Pediatric tumors; T cell |
| P344 | A randomized multi-center phase 2 study of combined PD-L1/CTLA-4 inhibition with or without radiation in non-small cell lung cancer patients who progressed on PD-(L)1 directed therapy: ETCTN 10021 | Arta M. Monjazeb, MD, PhD; Anita Giobbie-Hurder, MS; Ana Lako; Mark Awad, MD PhD; Ryan D. Gentzler, MD; Carrie Lee; Joleen Hubbard; James L. Abbruzzese, MD; Salma K. Jabbour, MD; Nataliya Uboha; Kevin Stephans; Jennifer Johnson, MD; Haeseong Park; Liza C. Villaruz, MD; Katrina Kao; Elad Sharon, MD, MPH; David Raben, MD; Raymond Mak; Howard Streicher, MD; Helen Chen, MD; Mansoor M. Ahmed, PhD; Scott J. Rodig, MD, PhD; F. Stephen Hodi, Jr., MD; Jonathan Schoenfeld, MD, MPH; | Clinical Trial Completed | Checkpoint blockade; Clinical study; Clinical trial; Radiotherapy |
| P348 | A Phase 1 Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies | Aparna Hegde, MD; Priyamvada Jayaprakash, PhD; Elizabeth Sumner; Di Nguyen; Hira Zain; Sarina A. Piha-Paul, MD; Daniel Karp; Jordi Rodon; Shubham Pant, MBBS; Siqing Fu, MD, PhD; Ecaterina I. Dumbrava, MD; Timothy A. Yap, MD PhD; Vivek Subbiah, MD; Priya Bhosale, MD; Jack P. Higgins, PhD; Eric T. Williams; Thomas F. Wilson; Funda Meric-Bernstam, MD; Michael A. Curran, PhD; David S. Hong, MD; | Clinical Trial Completed | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; MDSC; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| P349 | Effects of bintrafusp alfa (M7824) and radiation combination therapy on antitumor activity, immune response, and radiation-induced fibrosis in multiple cancer models | Yan Lan, MD; Chunxiao Xu, PhD; Huakui Yu; Guozhong Qin; Bo Marelli; Jin Qi; Rachel E. Fontana; Amit Deshpande; George Locke; Alex Rolfe; Molly H. Jenkins; Joern-Peter Halle; Kin-Ming Lo; | Clinical Trial Completed | Antibody; Checkpoint blockade; Gene expression; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P350 | Clinical Signal/Profile in a Phase I Study of T-Cell Receptor (TCR) Affinity-Enhanced Specific T-Cells (TAEST) in Advanced Cancer Patients | Zhaosheng Han, MD, PhD; Xing Zhang, MD; Jian Zhang; Chengzhi Zhou; Haiping Gong; Desheng Weng, MD; Jianchuan Xia, PhD MD; Johnson YN. Lau; Shiyue Li; Weiliang Zhu; Zhaosheng Han, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; Clinical study; Clinical trial; T cell; Tumor antigens |
| P351 | Association between response assessment using RECIST and irRECIST in 1765 patients with advanced solid tumors treated with avelumab monotherapy | Juliane Manitz, PhD; Julian Manitz; Peter Eggleton; Marcis Bajars; Oliver Bohnsack, MD, PhD, MBA; James L. Gulley, MD, PhD, FACP; | Clinical Trial Completed | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P354 | Exploring correlates of clinical and immune response to cancer immunotherapy using FAUST, a novel unbiased cell population discovery method, in whole blood flow cytometry | Steven P. Fling, PhD; Nirasha Ramchurren, PhD; Leonard D'Amico; Martin A. Cheever, MD; Evan Greene; Greg Finak; Raphael Gottardo, PhD; | Clinical Trial Completed | Biomarkers; Clinical study; Immune monitoring; Myeloid cells; T cell; Tumor antigens; Vaccine |
| P357 | Phase I/II clinical and immune responses for locally advanced or metastatic pancreatic cancer using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) | Lawrence G. Lum, MD, DSc; Tri Le; Minsig Choi; Archana Thakur, PhD; Matthew Reilly; Paul R. Kunk, MD; Abhinav Deol, MD; Karen Ballen, MD; Tamila Kindwall-Keller, DO; Dana L. Schalk; Ewa Kubicka; Manley Huang, PhD; Philip A. Philip, MD; Hussein Aoun; Gregory Dyson, PhD; Qin Liu; Anthony F. Shields, MD PhD; | Clinical Trial Completed | Adoptive immunotherapy; Antibody; Chemotherapy; Clinical study; Clinical trial; Immune monitoring; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P358 | Phase 1 trial of NY-ESO-1-specific adoptive T-cell therapy with GSK3377794 in patients with advanced synovial sarcoma | Sandra P. D'Angelo, MD; George Demetri; Brian Van Tine, MD, PhD; Mihaela Druta; John Glod, MD; Warren Chow; Jenna Tress; M. Phillip DeYoung; Aisha N. Hasan, MBBS MD; Yuehui Wu; David C. Turner; Ran Ji; Alexandra Gyurdieva; Dejka Araujo, MD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Clinical trial; Gene expression; T cell |
| P359 | Tracking and profiling of NY-ESO-1 TCR-transgenic T cells upon adoptive transfer in patients with NY-ESO-1-expressing solid tumors: in vivo differentiation associated with response | Michael Fehlings; Alessandra Nardin, DVM; Faris Kairi; Evan Newell, PHD; Yoshihiro Mihayara; Shinichi Kageyama; Hiroshi Shiku, MD; | Clinical Trial Completed | Adoptive immunotherapy; Clinical trial; Immune monitoring; Solid tumors; T cell; Tumor antigens |
| P368 | ZI-H04 - A novel MHC class II restricted TCR based cellular therapy targeting hTERT to treat solid tumours | Jens-Peter Marschner, MD; Mona Welschof, PhD; Miguel Forte; Eva Kristine Klemsdal; Sylvie Pollmann; Namir Hassan; Inês Cardoso, PhD | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P369 | Feasibility of a phase I personalized adoptive T-cell therapy in patients with relapsed/refractory solid tumors | Apostolia M. Tsimberidou, MD, PhD; Ali Mohamed; Stephen L. Eck, MD, PhD; Harpreet Singh; Patrick Hwu, MD; Cassian Yee, MD; Borje Andersson, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Biomarkers; Clinical trial; Solid tumors; T cell |
| P370 | The positive correlation between baseline absolute eosinophil count (AEC) in blood and clinical benefit to PD-(L)1 inhibition monotherapy | Danni Yu, PhD; Anna M. Szpurka, PhD; Michelle Carlsen; Danni Yu, PhD; Antoine Hollebecque, MD; Hyun Cheol Chung, MD, PhD; Amita Patnaik; Johanna Bendell, MD; Antoine Italiano, MD; Yung-Jue Bang, MD PhD; Chia-Chi Lin, MD, PhD; Marcus O. Butler, MD; Timothy A. Yap, MD PhD; María José de Miguel, MD; María José de Miguel, MD; Jean-Pascal Machiels, MD, PhD; Marc Peeters, MD, PhD; Wu-Chou Su, MD; Victor Moreno, MD; Yumin Zhao, PhD; Erik Rasmussen, PhD; Xiaojian Xu, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Solid tumors |
| P374 | TCR repertoires from peripheral blood correlate with prognostic response in TNBC cancer vaccine immunotherapy | Sadanand Vodala, PhD; Andrew Nguyen, PhD; Noe Rodriguez; Peter Sieling; Charles J. Vaske; Jon Van Lew; kayvan Niazi; John H. Lee, MD; Patrick Soon-Shiong, MD, FRCS, FACS; Shahrooz Rabizadeh; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Immune suppression; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P375 | Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC) | Daniel V. Catenacci, MD; Minori Rosales; Jon M. Wigginton, MD; Hyun Cheol Chung, MD, PhD; Harry Yoon; Lin Shen; Yoon-Koo Kang; Markus Moehler; | Clinical Trial In Progress | Adoptive immunotherapy; Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell; Tumor antigens |
| P377 | Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with pembrolizumab in patients with metastatic colorectal or gastric cancer. | Keun-Wook Lee, MD; Young Suk Park, MD, PhD; Joong Bae Ahn; Sun Young Rha; Hark Kyun Kim; Park Young Lee; Min-Hee Ryu; Jeeyun Lee, MD, PhD; Jin Kyung Lee; Sunjin Hwang; Seong-Jin Kiim; Tae Won Kim, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Tumor microenvironment; Tumor stroma |
| P387 | A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer (PORTER) | Leo Nissola, MD; Karen Autio, MS, MD; Nina Bhardwaj, MD, PhD; Matthew D. Galsky, MD; Kristopher Wentzel, MD; Vanessa M. Lucey; Cheryl Selinsky, PhD; Christopher Perry; Christopher Cabanski, PhD; Ari J. Bitton; Justin Fairchild; Christine E. Horak, PhD; Jeffrey M. Skolnik, MD; Michael Yellin, MD; Ute Dugan, MD, PhD; Ramy Ibrahim, MD; Lawrence Fong, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Immune tolerance; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P390 | Pembrolizumab plus olaparib vs enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer who experienced progression on chemotherapy: phase 3 KEYLYNK-010 study | Evan Y. Yu; Se Hoon Park; Yi-Hsiu Huang; Mostefa Bennamoun; Lu Xu; Jeri Kim; Emmanuel S. Antonarakis, MD; | Clinical Trial In Progress | Clinical trial |
| P392 | Phase 1 combination study of the CHK1 inhibitor prexasertib (LY2606368) and anti-PD-L1 antibody LY3300054, in patients with high-grade serous ovarian cancer and other advanced solid tumors | Khanh T. Do; Claire Manuszak; Sarah E. Kelland; Allison P. Powers; Adrienne Anderson; Alona Muzikansky; Andrew Wolanski; Mariano Severgnini, MSc; Geoffrey Shapiro, MD, PhD; Khanh T. Do, MD; | Clinical Trial In Progress | Biomarkers; Clinical trial; Solid tumors; Targeted therapy; Tumor antigens |
| P395 | Phase 2/3 open-label trial of enoblituzumab in combination with MGA012, with and without chemotherapy, in the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma | Fernanda I. Arnaldez; Charu Aggarwal, MD MPH; Scott Currence; Jan Baughman, MPH; Paul Moore, PhD; George R. Blumenschein, Jr., MD; Jon M. Wigginton, MD; Robert L. Ferris, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P401 | Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC): the phase 3 KEYNOTE-689 study | Ravindra Uppaluri, MD, PhD; Nancy Y. Lee, MD; William Westra; Ezra Cohen, MD; Robert I. Haddad; Stephane Temam; Christophe Le Tourneau; Rebecca Chernock; Sufia Safina; Arkadiy Klochikhin; Amichay Meirovitz; Irene Brana, MD; Joy Yang Ge; Ramona F. Swaby, MD; Cecilia Pinheiro; Douglas Adkins, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Immune adjuvant; Radiotherapy |
| P404 | Developing canine CART-19 to fully leverage comparative oncology and inform human clinical trials | Kumudhini P. Haran, M.S; Ailian Xiong; Enrico Radaelli; Patrick J. Savickas; Avery Posey; Donald Siegel; Nicola Mason, B.Vet Med PhD; | Clinical Trial In Progress | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma |
| P410 | Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with durvalumab in patients with advanced non-small cell lung cancer (NSCLC) | Ji-Youn Han, MD, PhD; Kyoung-Ho Pyo; Jea Hwan Kim; Chun-Feng Xin; Jin Kyung Lee; Sunjin Hwang; Seong-Jin Kim; Byoung Chul Cho, MD.phD; Byoung Chul Cho, MD.phD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical study; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P412 | Validation of a Single-Blinded (Patients Only) Study Design for the Prevention of Premature Patient Consent Withdrawal in the Immuno-Oncology Trial DUBLIN-3 | Ramon Mohanlal, MD, PhD, MBA; Huang Lan, PhD; Ramon Mohanlal, MD, PhD, MBA; | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Dendritic cell |
| P417 | ATLAS™ identifies relevant neoantigens for therapeutic anti-tumor vaccination and may serve as a biomarker for efficacy of immunotherapy of solid tumors | Parul Agnihotri; Tulin Dadali; Parul Agnihotri, PhD; | Clinical Trial In Progress | Antigen presenting cells; Biomarkers; Clinical study; Clinical trial; Dendritic cell; Neoantigens; Solid tumors; T cell; Targeted therapy; Vaccine |
| P419 | A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC) | Johanna Bendell, MD; Drew Rasco, MD; Wungki Park, MD; Lei Zhou, MD, MS; Anna Galkin, PhD; Debbie Slee, PhD; Laura L. Carter, PhD; David Nickle, PhD; Rebecca Tran, MS; Jack Li, PhD; Beatrice Ferguson, MS; Jakob Dupont, MD; Vineet Gupta, PhD; Eileen O'Reilly; | Clinical Trial In Progress | Antibody; Immune suppression; MDSC; Solid tumors |
| P421 | Phase 1 study of the safety, tolerability and preliminary anti-tumor activity of COM701 monotherapy in patients with advanced solid tumors. | Ecaterina I. Dumbrava, MD; Gini F. Fleming, MD; Erika P. Hamilton, MD; Ryan J. Sullivan, MD; Amita Patnaik, MD FRCP(C); Kyriakos P. Papadopoulos, MD; Adam ElNaggar, MD; John Hunter, PhD; Judy Olweny; Adeboye H. Adewoye, MD; Bartosz Chmielowski, MD, PhD; Dale Shepard, MD PhD; Manish R. Sharma, MD; Emerson Lim, MD; Daniel Vaena, MD; Drew Rasco, MD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P422 | Phase 1 study of COM701 monotherapy and in combination with nivolumab in patients with advanced solid tumors. | Ecaterina Dumbrava, MD; Gini Fleming, MD; Erika P. Hamilton, MD; Ryan J. Sullivan, MD; Amita Patnaik, MD FRCP(C); Kyriakos P. Papadopoulos, MD; Adam ElNaggar, MD; John Hunter, PhD; Judy Olweny; Adewoye H. Adewoye, MD; Adeboye H. Adewoye, MD; Bartosz Chmielowski, MD, PhD; Dale Shepard, MD PhD; Manish R. Sharma, MD; Emerson Lim, MD; Daniel Vaena, MD; Drew Rasco, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Checkpoint blockade; Clinical trial; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P423 | SURPASS trial design: A phase 1 dose escalation trial to assess safety and efficacy of ADP-A2M4CD8 in HLA-A2+ patients with MAGE-A4+ tumors | Paula M. Fracasso, MD, PhD; David S. Hong, MD; Marcus Butler; Melissa L. Johnson, MD; Tanner Johanns; Francine Brophy; Rebecca Dryer-Minnerly, PhD; Trupti Trivedi, MS; Rafael Amado, MD; Paula M. Fracasso, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor antigens |
| P426 | A first-in-human phase 1, multicenter trial of toll-like receptor (TLR) 7 agonist DSP-0509 as monotherapy and in combination with pembrolizumab in adult patients with advanced solid tumors | Shadia Jalal, MD; Jared Weiss, MD; Anthony J. Olszanski, MD, RPh; Jordan Berlin, MD; Makoto Origuchi; Zhonggai Li; Bella Ertik; Hongliang Cai; Daniel Clancy; Jose Iglesias; Vivek Subbiah, MD; Shadia Jalal, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; TLR |
| P427 | A Phase 1 Study of IMC-001, Novel Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors | Bhumsuk Keam, MD, PhD; Tae Min Kim, MD, PhD; Do-Youn Oh, MD, PhD; Chan-Young Ock, MD, PhD; Won Ki Kang, MD, PhD; Yeon Hee Park, MD, PhD; Jeeyun Lee, MD, PhD; Ji Hye Lee, MD; Yun Jeong Song, MD; Young Suk Park, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Antibody; Clinical study; Clinical trial; Solid tumors; T cell |
| P432 | A phase 1 dose-escalation study of safety, tolerability, and pharmacokinetics (PK) of ABBV-368 monotherapy and combination in patients (pts) with locally advanced or metastatic solid tumors | Christophe Le Tourneau; Wu-Chou Su, MD; Ki Y. Chung, MD; Patricia LoRusso, DO; Chia-Chi Lin, MD, PhD; Fabrice Barlesi, MD, PhD; Her-Shyong Shiah; Eric Angevin, MD; Alexander I. Spira, MD, PhD, FACP; Amita Patnaik, MD FRCP(C); John D. Powderly, II, MD, CPI; Dimitrios Colevas; Helen Chew, MD; Maulik Patel, PharmD, PhD; Stacie L. Lambert; Yan Li; Daniel Da Costa; Martha E. Blaney, PharmD; Michael A. McDevitt, MD, PhD; Philippe Cassier; | Clinical Trial In Progress | Antibody; Clinical trial; Regulatory T cell (Treg cell); Solid tumors |
| P441 | ARTISTRY-2: a phase 1/2 study of subcutaneously administrated ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors | John D. Powderly, II, MD, CPI; Bradley C. Carthon, MD, PhD; Marc S. Ernstoff, MD; Anthony J. Olszanski, MD, RPh; Stephen V. Liu, MD; Kelly K. Curtis, MD; Yangchun Du, PhD; Lei Sun, PhD; Emily L. Putiri, PhD; Yan Wang, PhD; Heather C. Losey, PhD; Bruce J. Dezube, MD; Ulka N. Vaishampayan, MD; | Clinical Trial In Progress | Checkpoint blockade; Cytokine; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors |
| P444 | The Quest for Highly Potent Human Papillomavirus-Specific T Lymphocytes for Adoptive Immunotherapy of HPV-Associated Malignancies | Pei Yun Teo, PhD; Sandhya Sharma, BSc.; Alex Salyer; Dimitrios L. Wagner; Benjamin Shin; Sachin Thakar; Li-Chun Huang; Shian Jiun Shih; Carlos Ramos; Cliona M. Rooney, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P446 | A Novel Regulatory T Cell-Targeted Immunotherapy by targeting their Crucial Signal by HSP90 Inhibitors | Ayaka Tsuge, MD; Yosuke Togashi, MD, PhD; Kohei Shitara, MD; Hiroyoshi Nishikawa, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical trial; Regulatory T cell (Treg cell); Solid tumors; Tumor microenvironment |
| P447 | ALKS 4230, an engineered IL-2 fusion protein, in monotherapy dose-escalation and combination therapy with pembrolizumab in patients with solid tumors: ARTISTRY-1 trial | Ulka N. Vaishampayan, MD; Jameel Muzaffar, MD; Vamsidhar Velcheti, MD, FACP; Christopher J. Hoimes, DO; Lucy Gilbert, MD; David F. McDermott, MD; Anna Spreafico, MD PhD; Quincy Chu, MD; Kelly K. Curtis, MD; Yangchun Du, PhD; Harald Mackenzie, MB; Lei Sun, PhD; Emily L. Putiri, PhD; Heather C. Losey, PhD; Bruce J. Dezube, MD; Marc S. Ernstoff, MD; | Clinical Trial In Progress | Checkpoint blockade; Cytokine; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors |
| P452 | SPEARHEAD-1 trial design: A phase 2, single arm, open-label clinical trial of ADP-A2M4 SPEAR T-cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma | Dejka Araujo, MD; Jean-Yves Blay; Sandra Strauss; Claudia Valverde; Erin Van Winkle; Malini Iyengar, PhD; Rafael Amado, MD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P453 | Autologous T cells with NY-ESO-1-specific T-cell receptor (GSK3377794) in HLA-A*02+ previously-treated and -untreated advanced metastatic/unresectable synovial sarcoma: A master protocol study design | Sandra P. D'Angelo, MD; Jean-Yves Blay; Warren Chow; George D. Demetri; Fiona Thistlethwaite, MD, PhD; Michael Wagner; David Loeb; Steven Attia; Albiruni R. Razak; John Haanen, MD PhD; Aisha N. Hasan, MBBS MD; Julia Billiard; Laura Pearce; Yuehui Wu; Ran Ji; Laura Johnson; Chandra Srinath; Aiman Shalabi; Sandra Strauss; Katherine Thornton; Crystal L. Mackall, MD; William Tap; Brian Van Tine, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; CAR T cells; Clinical trial; T cell; Targeted therapy |
| P461 | Phase 1b study of INCMGA00012, a programmed cell death-1 (PD-1) inhibitor, in combination with chemotherapy in patients with advanced solid tumors (POD1UM-105) | David Planchard, MD, PhD; Jill Bowman; Nawel Bourayou, MD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical trial; Solid tumors |
| P462 | ImmTAC®-chemotherapy combination: A preclinical evaluation shows potential benefits | Adel Benlahrech, BSc PhD; Filipa Bravo-Lopes; Nora Rippaus; Kristina Petrovic; Francesca Amicarella; Adam Taylor; Laure Humbert; Rupert Kenefeck; Adel Benlahrech, BSc PhD; | Combination Immunotherapies | Chemotherapy; T cell; Targeted therapy |
| P463 | Immunotherapy combinations for betel-nuts related HNSCC: one institutional experiences in Taiwan | Jo-Pai Chen, MD; Ruey-Long Hong, MD, PhD; Wei-Chen Lu, MD; | Combination Immunotherapies | Checkpoint blockade |
| P464 | IFN-α and 5-Aza-2’-deoxycytidine enhance the anti-tumor efficacy of a dendritic-cell targeting MIP3α-Gp100-Trp2 DNA vaccine by affecting T-cell and Dendritic Cell recruitment into tumor | James Gordy, PhD; Richard Markham, BS MD; | Combination Immunotherapies | Antigen presenting cells; Chemokine; Chemotherapy; Dendritic cell; Immune adjuvant; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P465 | Immune-mediated mechanisms involved in the synergistic anti-tumor efficacy of NHS-IL12 combined with the class I HDAC inhibitor entinostat. | Kristin C. Hicks, PhD; Yohei Ozawa, MD, PhD; Karin M. Knudson, PhD; Jeffrey Schlom; Sofia Gameiro, PharmD, PhD; | Combination Immunotherapies | Cytokine; Immune adjuvant; Immune suppression; Monocyte/Macrophage; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P466 | Carboplatin and paclitaxel after anti-PD1 or anti-PDL1 therapy: A retrospective study in patients with squamous cell carcinoma of the head and neck | Audrey Humphries, BS; Madeleine Welsh, BA; Alain Algazi, MD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy |
| P467 | ALPN-202, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, Enhances the Activity of Multiple Standard of Care Modalities | Katherine E. Lewis, PhD; Mark F. Maurer, BS; Sherri Mudri, BS; Kayla N. Susmilch, MS; Fariha Ahmed-Qadri, MS; Chelsea J. Gudgeon, BS; Steven D. Levin, PhD; Martin Wolfson, BS; Stacey R. Dillon, PhD; Kristine M. Swiderek, PhD; Stanford L. Peng, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Costimulation; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P468 | Targeting the ICOS pathway in combination with chemotherapy to enhance T-cell mediated anti-tumor immune responses | Tamer Mahmoud, PhD; Jeffrey M. Riggs; Madhu Ramaswamy, PhD; Leigh Hostetler; Brian Naiman; Ilyssa Ramos; Sean Turman; Fernanda Pilataxi; Christopher A. Morehouse, MD; Alex Alfaro; Norman Peterson; Ryan Fleming; Nazzareno Dimasi; Kyle Kuszpit; Ronald Herbst; Gianluca Carlesso, PhD; | Combination Immunotherapies | Antibody; Chemotherapy; Costimulation; Metabolism; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P469 | Chemotherapy enhances effector T cell responses to tumor associated antigens in human and mouse pancreatic cancer | Francesco Novelli, PhD; Giorgia Mandili, PhD; Claudia Curcio, PhD; Sara Bulfamante, MS; Laura Follia, MS; Daniele Giordano, MD; Rossella Spadi, MD; Maria Antonietta Satolli, MD; Paola Cappello, PhD MS; Francesco Novelli, PhD; | Combination Immunotherapies | Antibody; Chemotherapy; Proteomics; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P470 | Impact of treatment-induced necrosis in the anti-tumor efficacy of Entinostat combined with the immunocytokine NHS-IL12 | Yohei Ozawa, MD, PhD; Kristin C. Hicks, PhD; Karin M. Knudson, PhD; Jeffrey Schlom; Sofia Gameiro, PharmD, PhD; | Combination Immunotherapies | Cytokine; Monocyte/Macrophage; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P471 | Combination of BL-8040, anti PD-1 and chemotherapy significantly reduced pancreatic tumor growth and changed the balance between CD4+/FOXP3+ cells and CD8+ cells in the tumor | Amnon Peled, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemokine; Chemotherapy; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P472 | STAT3 ASO and Cisplatin combination sensitizes protected tumor microenvironments to checkpoint-mediated therapy | Theresa Proia, PhD; Maneesh Singh, PhD; Nanhua Deng; Minwei Ye; Frank McGrath; Douglas Ferguson; Simon Barry; | Combination Immunotherapies | Antigen presenting cells; Checkpoint blockade; Chemotherapy; Myeloid cells; Tumor microenvironment |
| P473 | Adoptive transfer of Deep IL-12 Primed T cells increases sensitivity to PD-L1 blockade for superior efficacy in checkpoint refractory tumors | Gulzar Ahmad, PhD; Jonathan Nardozzi, PhD; Lars R. Petersen, PhD; Esben Christensen, MSc; Ditte Jaegher; James Suchy, PhD; Karsten Sauer, PhD; Douglas S. Jones, PhD; Thomas L. Andresen, PhD; | Combination Immunotherapies | Adoptive immunotherapy; Cytokine; MDSC; Solid tumors; T cell; Tumor microenvironment |
| P474 | Efficacy and toxicity evaluation of anti-human CD47 and SIRPa antibodies in genetically humanized B-hSIRPa/hCD47 mice | Frank An; Yanan Guo; Jie Xiang; Chaoshe Guo; | Combination Immunotherapies | Antibody; Immune toxicity; T cell |
| P475 | PD1 and LAG3 converge to limit polyfunctionality and systemic immunity. | Lawrence P. Andrews, PhD; Sasikanth Manne; E. John Wherry, PhD; Creg Workman, PhD; Dario A. Vignali, PhD; | Combination Immunotherapies | Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P476 | The combination of a STING agonist with cytokines results in robust anti-tumor effects in autochthonous tumor models | Cristina Blaj, PhD; Yingjoy Li; Allen Chen; Anthony L. Desbien, PhD; Brian Francica, PhD; Sarah McWhirter; Lora Picton; K. Christopher Garcia; David Raulet, PhD; | Combination Immunotherapies | Cytokine; NK/NK T cell; Solid tumors; T cell; Tumor microenvironment |
| P477 | Isoform-specific blockade of active TGFb1 with mAb 13A1 enhances the efficacy of PD-L1 checkpoint therapy in a EMT6 mouse tumor model | Matteo Brioschi; Jacques Van Snick, PhD; Catherine Uyttenhove; Pamela Cheou; George Coukos, MD, PhD; Gerd Ritter; Steven M. Dunn, PhD; Steven M. Dunn, PhD | Combination Immunotherapies | Antibody; Checkpoint blockade; Coinhibition; Cytokine; Immune contexture; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P478 | SEMA4D antibody blockade overcomes mechanisms of immune suppression and combination immunotherapy including TGFβ blockade promotes efficient tumor regression | Elizabeth E. Evans, PhD; Terrence L. Fisher, Jr., PhD; Crystal Mallow, BS; Holm Bussler, PhD; Sebold Torno, BS; Desa Rae Pastore; Alan Howell, MS; Luis I. Ruffolo, MD; Nicholas Ullman; Brian A. Belt, JD; Joe Bucukovski; Christine Reilly, BS; Benjamin Dale; Ernest S. Smith, PhD; David C. Linehan, MD; Maurice Zauderer, PhD; Elizabeth E. Evans, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Clinical trial; Immune suppression; Myeloid cells; MDSC; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P479 | Evaluation of a TNFR2 antibody with and without anti-PD-1 therapy in two murine colon cancer models | Katie L. Case; Lisa Tran; Hui Zheng; Michael Yang; Denise L. Faustman, MD, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Regulatory T cell (Treg cell); Solid tumors; Tumor microenvironment |
| P480 | Heterologous Prime-Boost Vaccination Safely Enhances Antitumor Immunity to the Colorectal Antigen GUCY2C | John C. Flickinger, Jr., BS; Robert carlson; Jagmohan Singh; Trevor Baybutt, BS; Elinor Leong; Alicja Zalewski; Amanda Pattison; Jeffrey Rappaport; Joshua Barton; Scott A. Waldman; Adam E. Snook, PhD; John C. Flickinger, Jr., BS; | Combination Immunotherapies | Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| P481 | Obesity impairs immunotherapeutic efficacy in pre-clinical breast cancer | Justin T. Gibson, BS; Rachael M. Orlandella, BS; William J. Turbitt; Robert E. Sorge, PhD; Lyse A. Norian, PhD; | Combination Immunotherapies | Immune suppression; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P482 | STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to Tumor-Resident Myeloid Cells After IV Dosing and Demonstrates Potent Anti-Tumor Efficacy in Preclinical Studies | Laura H. Glickman, PhD; Christopher Rae, PhD; Alexandre Iannello, PhD; Anastasia M. Makarova, PhD; Haixing Kehoe, MS; John Faulhaber; Bill Hanson; Christopher Thanos, PhD; | Combination Immunotherapies | Chemokine; Cytokine; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P483 | TLR enhanced GVAX elicits tumor-specific tissue resident memory T cells independent of T cell priming | Michael J. Korrer; David Taylor; Young J. Kim, MD, PhD; Michael J. Korrer, PhD; | Combination Immunotherapies | Antigen presenting cells; Immune adjuvant; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Vaccine |
| P484 | CB-708, an orally bioavailable small molecule inhibitor of CD73 with immunostimulatory and anti-tumor activity | Clarissa Lee, PhD; Deepthi Bhupathi; Roland Billedeau; Jason Chen; Lijing Chen; Rosalyn Dang; Matthew Gross; Tony Huang; Weiqun Li, PhD; Yong Ma; Andrew MacKinnon; Gisele Marguier, MS; Silinda Neou, MS; Francesco Parlati, PhD; Natalija Sotirovska, MS; Sandra Spurlock; Timothy Stanton; Susanne Steggerda, PhD; Jing Zhang; Winter Zhang; Jim Li; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| P485 | Synergistic efficacy of anti-PD-L1/IL-15 fusion protein in combination with anti-CTLA-4 antibody in a murine orthotopic 4T1 breast carcinoma model | Stella Martomo, PhD; Dan Lu, MA; Jeegar Patel; Zhanna Polonskaya; Xenia Luna; Kevin McCracken; | Combination Immunotherapies | Antibody; Checkpoint blockade; Cytokine; Gene expression; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P486 | Releasing the break on T cell activation through novel small molecule inhibition of HPK1 | Minhui Shen; Gayathri Bommakanti, PhD; Deanna A. Mele, PhD; Deanna A. Mele, PhD; Neil Grimster, PhD; | Combination Immunotherapies | T cell; Tumor evasion |
| P487 | Combining an engineered costimulatory vaccine with NK cells induces an anti-tumor effect against murine neuroblastoma in vitro and after bone marrow transplant in vivo | Nicholas R. Mohrdieck, BS.; Paul Bates; Sean P. Rinella; Katharine E. Tippins; Christian M. Capitini, MD; | Combination Immunotherapies | Adoptive immunotherapy; Costimulation; Cytokine; Immune adjuvant; NK/NK T cell; Pediatric tumors; Solid tumors; Vaccine |
| P488 | IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, unleashes immune responses in combination with cancer therapies. | Pascale Andre; Ivan Perrot; Caroline Denis, PhD; Marc Giraudon-Paoli; Severine Augier; Rachel Courtois; Diana Jecko; Thomas Arnoux; Violette Breso; Nicolas Gourdin, PhD; Nadia Luheshi, PhD; Ariane Morel, PhD; Yannis Morel, PhD; Eric Vivier; Carine Paturel, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Coinhibition; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| P489 | Identification and characterization of MCLA-145 (CD137 x PD-L1): A bispecific antibody that requires PD-L1 binding to activate CD137. | Simon E. Plyte; Cecile Geuijen; John de Kruif; Pieter Fokko van Loo, PhD; Paul Tacken; vanessa Zondag-vander Zande; Rinse klooster; hans van Maaden; Erik Rovers; steef engels; floris franzen; abdul basmeleh; willem bartelink; Mark Throsby; Patrick Mayes; Horacio Nastri; shaun stewart; jing zhou; steve wang; Chen-yen Huang; thomas codamine; ashwini kularni; yao bin lui; arpita mondal; leslie hall; soeon kim; marina martinez; shaun o'brien; edmund moon; steven albelda; | Combination Immunotherapies | Antibody; Checkpoint blockade; Costimulation; T cell; Targeted therapy |
| P490 | Antibody derived from an elite responder to checkpoint inhibitor therapy relieves immunosuppression by tumor associated macrophages | Randi Simmons; Siddarth Chandrasekaran; Melissa Conerly; Tyrel Smith; Sam Lam; Jacqueline Pham; Ray Fox; Darbie Whitman; Meghan Zuck; Sara Carbonetti; Kamal D. Puri, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P491 | Preclinical Development of a Novel TNFRSF25 Agonist Antibody, PTX-35, for Cancer Immunotherapy Combinations | Matthew M. Seavey, PhD; Jayalakshmi Miriyala, MS; Jason Rose, MS; Vikas Tahiliani, PhD; Patrick Dillon, PhD; Elena Gorovits, PhD; Jeff Hutchins, PhD; Rahul R. Jasuja, PhD; | Combination Immunotherapies | Antibody; Immune adjuvant; Inflammation; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P492 | A new generation anti-TGFβ antibody, SAR439459, relieves immunosuppression and improves anti-tumor efficacy of PD1 blockade | Rita M. Greco; Hongjing Qu; Joachim Theilhaber; Gary Shapiro; Richard Gregory, PhD; Christopher Winter; Natalia Malkova; Lily Pao; Mikhail Levit; Alexei Protopopov; Jack Pollard, PhD; Tun Tun Lin, MD; Dmitri Wiederschain; Sharad Sharma, PhD; | Combination Immunotherapies | Coinhibition; Immune suppression; T cell; Tumor microenvironment |
| P493 | High-Dimensional Analysis Delineates Modulation of Myeloid and Lymphoid Compartments with STAT3 ASO and PDL-1 combination Therapy | Theresa Proia, PhD; Maneesh Singh, PhD; Larissa S. Carnevalli, PhD; Gayathri Bommakanti, PhD; Nanhua Deng; Matthew Griffin; Lukasz Magiera; Adina Hughes; Laura Prickett; Patricia McCoon, PhD; Corinne Reimer; Simon Barry, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P494 | A Novel TNFRSF25 Agonist, PTX35, Synergizes with Gp96-Ig/OX40L-Ig to Enhance Effector and Memory Anti-Tumor CD8+ T Cell Responses and Delay Tumor Growth | Vikas Tahiliani; Patrick Dillon, PhD; Jayalakshmi Miriyala, MS; Jason Rose, MS; Anh Trinh; Rahul R. Jasuja, PhD; Jeff Hutchins, PhD; Matthew M. Seavey, PhD; | Combination Immunotherapies | Antibody; Immune adjuvant; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
| P495 | Secondary immune resistance mechanisms induced by therapeutic cancer vaccines which prevent tumor regression and foster recurrences. | Sjoerd H. Van der Burg, PhD; Elham Beyranvand Nejad; Camilla Labrie; Suzanne van Duikeren, Ing; Ramon Arens, PhD; Thorbald van Hall, PhD; Sjoerd H. van der Burg, PhD; | Combination Immunotherapies | Checkpoint blockade; Cytokine; Immune contexture; Inflammation; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma; Vaccine |
| P496 | Inhibition of Autophagy Enhances Multifunctional Genetically-Engineered NK cell-Based Immunotherapy of Glioblastoma | Jiao Wang, PhD; Sandro Matosevic, PhD; Jiao Wang, PhD; | Combination Immunotherapies | Adoptive immunotherapy; Antibody; Checkpoint blockade; Chemokine; Immune suppression; NK/NK T cell; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P497 | DRP-104, A Novel Broad Acting Glutamine Antagonist, Induces Distinctive Immune Modulation Mechanisms and Synergistic Efficacy in Combination with Immune Checkpoint Blockade | Yumi Yokoyama, PhD; Michael Nedelcovych, PhD; Robert Wild, PhD; | Combination Immunotherapies | Checkpoint blockade; Monocyte/Macrophage; Metabolism; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P498 | Blockade of PD-1 and LAG-3 on CD8+ T cells, induced by vaccination, elicits superior anti-tumor efficacy | Christopher W. Zahm, PhD; Douglas G. McNeel, MD, PhD; Laurne E. Delmastro; | Combination Immunotherapies | Antigen presenting cells; Checkpoint blockade; Dendritic cell; Solid tumors; T cell; Tumor evasion; Tumor microenvironment; Vaccine |
| P499 | Nano-Pulse Stimulation in combination with the TLR 7/8 agonist, resiquimod, synergizes to eliminate murine melanoma through innate and adaptive immune responses | Joel Benjamin, PhD; Amanda McDaniel, BA; Kristin von Rothstein; Sasha Farina; Bruce Freimark, PhD; Richard Nuccitelli, MS, PhD; | Combination Immunotherapies | Antigen presenting cells; Biomarkers; Dendritic cell; Immune adjuvant; TLR; Tumor antigens; Tumor microenvironment; Vaccine |
| P500 | Targeting PARP-1 with metronomic therapy as a new approach to modulate MDSC function and enhance anti-PD1 immunotherapy in colon cancer | Salome Valentina Ibba, PhD; Mohamed Ghonim; Abdelmetalab Tarhuni; Matthew Dean; Hamid Boulares, PhD; Augusto C. Ochoa, MD; Youssef Errami; Ali Elbahraway; Ilyes Benslimane; Dorota Wyczechowska; Luis Del Valle, MD; Amir Al-Khami; Hanh Luu; | Combination Immunotherapies | Checkpoint blockade; Cytokine; Gene expression; Immune suppression; Inflammation; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P501 | Dietary deprivation of non-essential amino acids improves anti-PD-1 immunotherapy in murine colon cancer | Xiyan Li, PhD; Zehui Li, PhD; Grace X. Yang, PhD; Shuang Zhou, PhD; Xin Wang, MD, PhD; Xiyan Li, PhD; | Combination Immunotherapies | Metabolism; Solid tumors |
| P502 | In Vitro and In Vivo RRx-001 Synergy with Regorafenib and In Vivo Attenuation of Regorafenib-Induced Toxicity | Bryan Oronsky, MD PhD; Tony Reid, MD PhD; Corey A. Carter, MD; Christopher Larson, MD PhD; Pedro Cabrales, PhD; | Combination Immunotherapies | Costimulation; Immune adjuvant; Immune tolerance; Immune toxicity; Solid tumors |
| P503 | Local treatment with adenovirus expressing TNF-α and IL-2 proteins promotes abscopal effect in mice receiving anti-PD-1 immunotherapy | Dafne C. Quixabeira; Victor Cervera-Carrascon, MS; Joao M. Santos, MS; Riikka Havunen; Akseli Hemminki, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Cytokine; Solid tumors; T cell; Tumor microenvironment |
| P504 | ¬Arginase therapy combines effectively with checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth | William L. Redmond, PhD; Annah S. Rolig, Ph. D; Scott Rowlinson, PhD; Melissa J. Kasiewicz, BS; Mark D. Badeaux, PhD; William L. Redmond, PhD; Giulia Agnello, PhD; Leslie Priddy, BS; Danlee Enzler, BS; Jason F. Wiggins, BS; Christopher Daige; Jessica Van Cleef; | Combination Immunotherapies | Antigen presenting cells; Checkpoint blockade; Costimulation; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P505 | Abscopal immunity achieved via in situ vaccination using a novel combination of cryoablation and Interleukin-12 | Maura R. Vrabel; Francis B. Gillam, PhD; Jared J. Hopkins; Khue G. Nguyen, PhD; David A. Zaharoff, PhD; David A. Zaharoff, PhD; | Combination Immunotherapies | Immune adjuvant; Inflammation; Neoantigens; Solid tumors; Tumor antigens; Tumor microenvironment; Vaccine |
| P506 | Targeting inflammation in the tumor micro-environment to improve radiation and immunotherapy | Debashree Basudhar, PhD; Veena Somasundaram, PhD; Robert Cheng; David A. Scheiblin; Erika Palmieri; William F. Heinz; Noemi Kedei; Jinqiu Chen; Daniel W. McVicar, PhD; Stephen J. Lockett; David A. Wink; Lisa Ridnour, PhD; Debashree Basudhar, PhD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Immune suppression; Inflammation; Monocyte/Macrophage; Radiotherapy; T cell; Targeted therapy; Tumor microenvironment |
| P508 | Combination of a radiation-enhancing nanoparticle, radiotherapy,and immune checkpoint inhibitors for treating metastasized lung cancer in mice | Yun Hu; James Welsh; Sébastien PARIS; Angelica M. Cortez; | Combination Immunotherapies | Checkpoint blockade; Radiotherapy; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs) |
| P509 | Myeloid Cell-Selective STAT3 Inhibition Sensitizes Head and Neck Cancers to Radiation Therapy and Stimulates T-cell-Dependent Tumor Regression | Marcin Kortylewski, PhD; Dayson F. Moreira, PhD; Marcin Kortylewski, PhD; Sagus Sampath; Haejung Won; Chongkai Wang; Peter P. Lee, MD; Ellie Maghami; Erminia Massarelli, MD, PhD, MS; William C. Spanos, MD; Seok White; | Combination Immunotherapies | Clinical study; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Radiotherapy; Solid tumors; TLR; Tumor microenvironment |
| P510 | Treatment of murine mammary carcinoma with focal radiation and immune checkpoint inhibition results in reduced immune suppression and enhanced cytotoxic immune cell activity | Philip E. Lapinski, PhD; Maryland Franklin, PhD; David Draper, PhD; Scott Wise, BS; | Combination Immunotherapies | B cell; Checkpoint blockade; Immune suppression; NK/NK T cell; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P511 | Mechanistic insights into combination low dose targeted radionuclide and checkpoint blockade treatment to turn a “cold” tumor “hot” | Ravi Patel, MD, PhD; Reinier Hernandez, PhD; Peter M. Carlson, BS; Ryan Brown; Luke Zangl; Amber Bates; Ian Arthur; Justin C. Jagodinsky; Joseph Grudinski; Amy K. Erbe, PhD; Jamey Weichert; Paul M. Sondel, MD, PhD; Zachary S. Morris, MD, PhD; Ravi Patel, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Radiotherapy; Solid tumors; Targeted therapy; Tumor microenvironment |
| P512 | Efficacy of combined radio- and immuno-therapies vs. radiotherapy alone in the treatment of brain metastases: a systematic review and meta-analysis | Kirill Peskov; Veronika Voronova; Svetlana Lebedeva; Marina Sekacheva; Gabriel Helmlinger, PhD; | Combination Immunotherapies | Immune tolerance; Radiotherapy; Solid tumors |
| P513 | Radiation therapy as a tool to optimize immunomodulation by cell cycle inhibitors in HR+ breast cancer | Giulia Petroni; Aitziber Buqué Martinez; Maurizio Di Liberto; Takahiro Yamazaki, PhD; Norma Bloy; Ai Sato; Selina Chen-Kiang; Silvia Formenti, MD; Lorenzo Galluzzi; | Combination Immunotherapies | Cytokine; Radiotherapy; Solid tumors; Targeted therapy |
| P514 | Molecularly targeted radionuclide therapy modulates the composition of the murine prostate cancer microenvironment | Hemanth K. Potluri, BA; Reinier Hernandez, PhD; Christopher W. Zahm, PhD; Joseph Grudzinski, PhD; Christopher Massey; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD; | Combination Immunotherapies | MDSC; Radiotherapy; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P515 | Defining the TCR repertoire and functional differentiation of tumor-infiltrating T cells in mice responding to radiotherapy and CTLA-4 blockade | Nils-Petter Rudqvist, PhD; Claire Lhullier, PhD; Erik Wennerberg, PhD; Jennifer Sims, PhD; Sandra Demaria, MD; | Combination Immunotherapies | Checkpoint blockade; Immune monitoring; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P516 | Radiation-driven changes in immunomodulatory DNA cargo of exosomes produced by cancer cells | Sheila Spada, PhD; Sandra Demaria, MD; Sheila Spada, PhD; Nils-Petter Rudqvist, PhD; Tuo Zhang, PhD; | Combination Immunotherapies | Dendritic cell; Immune contexture; Radiotherapy; Solid tumors |
| P517 | Potent anti-tumor effect of systemically administered nanoparticles containing a TLR7 agonist in combination with radiotherapy | Camilla Stavnsbjerg, MSc; Esben Christensen, MSc; Rasmus Münter, MSc; Andreas Kjær, MD, PhD; Svetlana Panina, MD, PhD; Martin Bak, PhD; Jonas R. Henriksen, PhD; Simon Jensen, PhD; Anders E. Hansen, DVM, PhD; Thomas L. Andresen, PhD; | Combination Immunotherapies | Antigen presenting cells; Immune adjuvant; Myeloid cells; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment |
| P518 | Testing a new platform for precision use of radiation therapy to induce in situ vaccination in breast cancer | Samantha J. Van Nest, PhD; Tasnim Anika; Adriana Irizarry; Laura Martin; Giorgio Inghirami; Silvia Formenti, MD; Sandra Demaria, MD; Samantha J. Van Nest, PhD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Radiotherapy; Vaccine |
| P519 | Immunogel - an intratumoral multi-drug sustained release technology that polarizes the tumor microenvironment towards a proinflammatory and immunosupportive state | Trine B. Engel, PhD; Jennifer S. Jørgensen, PhD; Lars Ringgaard, PhD; Fredrik Melander, PhD; Sophie B. Jensen, MSc; Linda M. Bruun, PhD; Camilla Stavnsbjerg, MSc; Andreas Tue I. Jensen, PhD; Julianna Thuróczy, DVM, PhD, Dipl. ECAR; Lajos Balogh, DVM, PhD; Frederikke P. Fliedner, MSc; Martin Bak, PhD; Andreas Kjær, MD, PhD; Jonas R. Henriksen, PhD; Anders E. Hansen, DVM, PhD; Thomas L. Andresen, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P520 | Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/ metastatic renal cell carcinoma | Yufei Wang; Yichen Zhong, PhD; Shahrul Mt-Isa; Rodolfo Perini, MD; Oluwakayode Adejoro, MD, MPH; Oluwakayode Adejoro, MD, MPH; Oluwakayode Adejoro, MD, MPH; | Combination Immunotherapies | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy |
| P521 | MEK inhibition enhances oncolytic herpes virus immunotherapy | Praveen K. Bommareddy, MS, PhD; Andrew Zloza, MD, PhD; Samuel Rabkin, PhD; Howard L. Kaufman, MD, FACS; | Combination Immunotherapies | Checkpoint blockade; Dendritic cell; Gene expression; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P522 | Preclinical development of M4112, an IDO1/TDO2 dual selective and orally bioavailable small molecule inhibitor, and combination with avelumab, for treatment of solid tumors | Jieqing Chen, MD; Chia Lin Chu, PhD; Feng Jiang, PhD; Chunxiao Xu, PhD; Yanping Zhang; Sireesha Yalavarthi; Molly Coop; Hong Wang; Yanyan Wang; Bettina Hanschke; Anindya Siddharta; Sen Zhang; Amit Deshpande; Bartholomew Naughton, PhD; Filippos Porichis; Tai-An Lin, PhD; Joern-Peter Halle; Tilo Senger; Brian Sherer; Jacques Moisan; | Combination Immunotherapies | Checkpoint blockade; Coinhibition; Immune suppression; Metabolism; Solid tumors; Tumor evasion; Tumor microenvironment |
| P523 | Immunotherapy plus gene therapy: A tumor-targeting nanomedicine carrying the TP53 gene crosses the blood–brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma | Joe B. Harford, PhD; Sang-Soo Kim, PhD; Manish Moghe; Caroline Doherty; Esther H. Chang, PhD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Dendritic cell; Gene expression; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P524 | CRISPR CAS9 mediated BRCA1 knockout modulates the tumor infiltrating lymphocytes landscape and cytokine profile in a murine breast cancer model | Julia Schuler; Anya Avrutskaya; Kanstantsin Lashuk; Mariette Heins, PharmD; Cordula Tschuch; Astrid Jensen; Gerhard Kelter; Anne-Lise Peille; Maycee Robinson; William Durham; Armin Mayer; Anne-Marie Zuurmond; | Combination Immunotherapies | Checkpoint blockade; Monocyte/Macrophage; MDSC; NK/NK T cell; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P525 | Dose-dependent sensitization of combined anti-angiogenic and PD-1 blockade in breast cancer | Wen Jiang, MD, PhD; Yifan Wang, PhD; Betty Y. Kim; Jieqiong Liu, MD, PhD; | Combination Immunotherapies | Angiogenesis; T cell; Targeted therapy; Tumor microenvironment |
| P526 | Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC) | Emily N. Kinsey, MD; Landon C. Brown, MD; Chester Kao, MD; Patrick Healy; Michael R. Harrison, MD; Megan A. McNamara, MD; Andrew J. Armstrong, MD; Sundhar Ramalingham, MD; Daniel J. George, MD; Tian Zhang, MD; | Combination Immunotherapies | Checkpoint blockade; Immune toxicity; Solid tumors; Targeted therapy |
| P527 | IgE-based therapeutic strategy against pancreatic cancer | Kamiya Mehla, PhD; Ragupathy Madiyalakan, PhD; Christopher Nicodemus, MD; Thomas Caffrey; Michael A. Hollingsworth, PhD; kelly A. O' connell; | Combination Immunotherapies | Antibody; Dendritic cell; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; Targeted therapy; TLR; Tumor antigens; Tumor microenvironment |
| P528 | Combination antibody treatment targeting PD-L1 and 4-1BB leads to reduced anti-tumor immunity against CT26 tumors in B-cell deficient JH-/- mice | Zhengming Yan; Heather Llewellyn; Kerry Kelleher; Bernadette Pascual; Angela Stauffer; Ying Ding; Xiaorong Li; Mark Ozeck; Jeffrey Toste; Han Yang; Haikuo Zhang; Sripad Ram, PhD; Sripad Ram, PhD; Sripad Ram, PhD; Cathy Zhang; | Combination Immunotherapies | Antibody; B cell; Checkpoint blockade; Immune contexture; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P529 | A tumor microenvironment-recognizable polymeric conjugate for antigen delivery and cancer immunotherapy | Jung Min Shin; Seok Ho Song; Jae Ah Lee; Jae Hyung Park, PhD; | Combination Immunotherapies | T cell; Targeted therapy; Tumor microenvironment; Vaccine |
| P530 | Blockade of IDO/TDO downstream effectors restricts a Treg-macrophage suppressive axis and resistance to anti-PD-1 therapy | Luis F. Campesato, PhD; Sadna Budhu, PhD; Jeremy H. Tchaicha, PhD; Mathieu Gigoux, PhD; Ivan Cohen; Levi M. Mangarin, BS; David Redmond; Stephane Pourpe; Cailian Liu, MD; Roberta Zappasodi, PhD; Dmitriy Zamarin, MD, PhD; Mark Manfredi, PhD; Karen McGovern, PhD; Taha Merghoub, PhD; Jedd D. Wolchok, MD, PhD; Luis F. Campesato, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; Metabolism; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P531 | A Tumor PD-L1-NLRP3 Inflammasome Signaling Axis Drives Adaptive Resistance to Anti-PD-1 Immunotherapy | Balamayooran Theivanthiran, PhD; Kathy Evans, BS; Nicholas DeVito, MD; Michael Plebanek, PhD; Michael Sturdivant, BS.; Alisha H. Holtzhausen, PhD; Luke P. Wachsmuth, BS.; April Salama, MD; Yubin Kang, MD; David Hsu, MD, PhD; Justin M. Balko, PhD, PharmD; Douglas B. Johnson, MD, MSCI; Mark Starr, BS.; Andrew Nixon, PhD; Brent A. Hanks, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemokine; Gene expression; Immune suppression; MDSC; Proteomics; Solid tumors; TLR; Tumor evasion; Tumor microenvironment |
| P532 | Increased adiposity reduces the response rate to a combinatorial CTLA-4 based therapy in diet-matched, renal tumor-bearing mice without substantially altering intra-tumoral T cell profiles | William J. Turbitt, Jr., PhD; Shannon Boi; Rachael M. Orlandella, BS; Justin T. Gibson, BS; Lyse A. Norian, PhD; | Combination Immunotherapies | Checkpoint blockade; Gene expression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P533 | The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies. | Sonia Iyer, PhD; Shuang Zhang; Anniina Farkkila; David Pepin; Raghav Mohan; Sean G. Smith, PhD; Tian Xia; Ferenc Reinhardt; Tony Chavarria; Esmee Hoefsmit; Shailja Pathania; Yunlan Zhou; Kevin Elias; Benjamin Neel; Robert Weinberg, PhD; | Combination Treatments | Checkpoint blockade; Chemotherapy; Immune contexture; Immune suppression; Myeloid cells; MDSC; Regulatory T cell (Treg cell); Targeted therapy; Tumor evasion; Tumor microenvironment |
| P536 | Orbital tumor board: life saver or time waster ? | Ayesha Butt, Medical Student; Irfan Jeeva, MBBS, MRCOphth (UK), FRCOphth (UK), FEBO (EU), CCT; Ayesha Butt, Medical Student; | Education and Treatment Management | Chemotherapy; Pediatric tumors; Radiotherapy; Solid tumors; Surgery |
| P538 | Outcomes of a Newly Formed Multidisciplinary Retinoblastoma Service | Ayesha Butt, Medical Student; Irfan Jeeva, MBBS, MRCOphth (UK), FRCOphth (UK), FEBO (EU), CCT; | Education and Treatment Management | Pediatric tumors; Radiotherapy; Solid tumors; Surgery |
| P539 | Management of Melanoma: Education Improving Clinical Decisions of Oncologists | Kinjal Parikh, PharmD; Haleh Kadkhoda, MS; Jeffrey S. Weber, MD, PhD; Charlotte Warren; Ann Carothers, MEd; | Education and Treatment Management | Checkpoint blockade; Solid tumors |
| P540 | Understanding oncologist preferences for chemotherapy and immunotherapy monotherapy and combinations for first-line treatment of metastatic non-small cell lung cancer: a discrete choice experiment | Candice Yong, PhD; Brian Seal, RPh, MBA, PhD; Kathleen Beusterien, MS; M. Janelle Cambron-Mellott, PhD; Martine C. Maculaitis, PhD; Kelly Clapp; Emily Mulvihill, MBA; Ion Cotarla, MD, PhD; Ranee Mehra, MD; | Education and Treatment Management | Adoptive immunotherapy; Chemotherapy; Targeted therapy |
| P541 | Informing and Empowering Cancer Caregivers about Immunotherapy: Results from a Psychoeducational Workshop on Immunotherapy | Maria B. Gonzalo; Claire Saxton, MBA; Claire Saxton, MBA; Alexandra Zaleta, PhD; Kirstin Fearnley; | Education and Treatment Management | Targeted therapy |
| P542 | Case of an outstanding anti-cancer immune response in a microsatellite stable metastatic colon cancer | Thomas Duhen, PhD; Carmen Ballesteros Merino, PhD; Venkatesh Rajamanickam; Brady M. Bernard, PhD; Bernard A. Fox, PhD; Eric C. Anderson, MD, PhD; Philippa H. Newell, MD; | Immune Cell Biology | Chemotherapy; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P548 | Beyond a cell metabolite: Glutamate receptor signaling improves antitumor T cell immunity | Anil Shanker, PhD; Maria Teresa P. De Aquino, PhD; Thomas Hodo, MS; Roman V. Uzhachenko, PhD MD; Anil Shanker, PhD; | Immune Cell Biology | Adoptive immunotherapy; Costimulation; Immune adjuvant; Immune suppression; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P551 | Bone marrow infiltrating lymphocytes possess a resident memory, stem-like phenotype that may account for enhanced anti-tumor efficacy in multiple myeloma–implications for adoptive T cell therapy | Luca Biavati, MD; Megan K. Heimann, PhD candidate; Elizabeth Zawidzka; Amy Thomas; Ervin Griffin; Danielle Dillard; Bruno Paiva; Ivan M. Borrello, MD; | Immune Cell Biology | Adoptive immunotherapy; Immune monitoring; Immune tolerance; T cell; T cell lineages; Tumor evasion; Tumor microenvironment |
| P570 | Assay the interaction of 1000s of individual T cells and antigen-presenting cells for CAR-T or TCR screening in 24hrs. | Mark White, PhD; | Immune Cell Biology | Adoptive immunotherapy; CAR T cells; Cytokine; Immune monitoring; T cell |
| P574 | Remodeling Translation Primes CD8+ T Cell Anti-Tumor Immunity | Jessica E. Thaxton, PhD, MSCR; Kiley A. Lawrence; Katie E. Hurst; Lauren Ball, PhD; Lee Leddy, MD, MsCR; Dongjun Chung, PhD; | Immune Cell Biology | Adoptive immunotherapy; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P578 | In Vitro Assessment of the Impact of Chemotherapy Agents on Immune Cell Function | Dana Banas; Dawn Stetsko; Miye Jacques; Sium Habte; Matthew Loya; Xiaodong Wang; Krishna M. Vasudevan, DVM, PhD; Laurence Menard, PhD; Julie Carman, PhD; | Immune Cell Biology | Antigen presenting cells; Chemotherapy; Dendritic cell; Immune toxicity; T cell |
| P579 | Predictive and prognostic relevance of CD8+ tumor-infiltrating lymphocyte density combined with PD-L1 expression in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy | Changhoon Song, MD; Yoonjin Kwak; Hye Seung Lee; Sung-Bum Kang; Jae-Sung Kim; | Immune Cell Biology | Biomarkers; Chemotherapy; Clinical study; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P584 | Functional cytomic targeting of PD-L1 at the surface of living cells to investigate resistance to immunotherapy in multiple myeloma | Jolene A. Bradford, MLS, SCYM(ASCP); Laura G. Rico; Jordi Juncà; Jorge Bardina; Àngel Bistué-Rovira; Michael D. Ward; Jordi Petriz; | Immune Cell Biology | Checkpoint blockade; Immune suppression; MDSC; T cell; Targeted therapy; Tumor microenvironment |
| P588 | Development of in vitro immune effector function assays to better approximate the in vivo behavior of biotherapeutics and cell therapies | Chris Langsdorf, BS; | Immune Cell Biology | Antibody; Leukemia/Lymphoma; Monocyte/Macrophage; NK/NK T cell; Solid tumors; T cell |
| P590 | The use of in vitro T cell assays to accelerate cancer development of immunotherapy and immune checkpoint inhibitors | Amin Osmani; Thibault Jonckheere; Juliette Lamy; Thibaut Janss; Mayuko Oh; Sofie Pattijn; Thibaut Janss; | Immune Cell Biology | Antigen presenting cells; Dendritic cell; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; MDSC; Neoantigens; Regulatory T cell (Treg cell); T cell |
| P592 | TGFβR1 antagonism improves radiation efficacy by enhancing CXCR3 dependent tumor recruitment of CD8+ T cells | Andrew J. Gunderson, PhD; Tomoko Yamazaki, PhD; Kayla McCarty, BS; Nathaniel Fox; Michaela Phillips, BA; Alejandro Alice, PhD; Tiffany Blair; Mary McCormick, RN; Andrea Burt, RN; Iliana L. Gonzalez, BS; Mark Whiteford, MD; David O'Brien; Rehan Ahmad; Maria X. Kiely, MD; Amanda V. Hayman, MD, MPH; Rui Li, MD, PhD; Todd Crocenzi, MD; Michael J. Gough, PhD; Marka R. Crittenden, MD, PhD; Kristina H. Young, MD, PhD; | Immune Cell Biology | Chemokine; Chemotherapy; Clinical trial; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P596 | Targeted IRAK-M degradation as a novel approach in cancer immunotherapy overcoming innate-driven immunosuppression | Kanae Gamo, MS; Naomi Kitamoto; Tomoaki Hayashi; Yoshihide Tomata; Yusuke Tominari; | Immune Cell Biology | Cytokine; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; MDSC; Targeted therapy; TLR; Tumor evasion; Tumor microenvironment |
| P605 | Severity of Cytokine Release Syndrome as a Predictor of Infections after T-cell replete Haploidentical Hematopoietic Cell Transplantation (haploHCT) | Muhammad Bilal Abid, MD, MRCP (UK); Parameswaran Hari, MBBS, MD, MRCP; Aniko Szabo; Mehdi Hamadani; Mary Beth Graham; Saurabh Chhabra; | Immune Cell Biology | Chemotherapy; Clinical study; Cytokine; Immune toxicity; Inflammation; Leukemia/Lymphoma; T cell |
| P608 | ATOR-1017, a 4-1BB antibody developed for tumor-directed immunotherapy of cancer | Doreen Werchau, BS; Anna Rosen, MSc; Mia Eriksson; Sofia Järnum, PhD; Christina Furebring, PhD; Karin Enell Smith, PhD; | Immune-stimulants and immune modulators | Antibody; Costimulation; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P610 | Claudin18.2 bispecific T-cell engager for gastric cancer immunotherapy | Sribalaji Lakshmikanthan, PhD; Swarna Pandian, PhD; Zusheng Li; Eugene Chan, MD; Robert Markelewicz, MD; Timothy L. Wyant, PhD; Sribalaji Lakshmikanthan, PhD; | Immune-stimulants and immune modulators | Antibody; Solid tumors; T cell; Targeted therapy |
| P613 | Discovery of pharmacologically differentiated Interleukin 15 (IL-15) agonists employing a synthetic biology platform | Carolina E. Caffaro, PhD; Jerod L. Ptacin, PhD; Robert W. Herman; Lina Ma, PhD; David B. Chen; Ingrid B. Joseph, PhD; Marcos E. Milla, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Cytokine; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor microenvironment |
| P617 | Delivery of Interleukin-2 to the Acidic Tumor Microenvironment by Ultra-pH Sensitive Nanoparticles for Immunotherapy | Xinliang Ding, PhD; Jason B. Miller, PhD; Ashley Campbell; Jonathan Almazan; Tian Zhao; | Immune-stimulants and immune modulators | Cytokine; Solid tumors; Targeted therapy; Tumor microenvironment |
| P623 | Bempegaldesleukin in combination with local radiation and systemic checkpoint blockade induces a robust systemic anti-tumor immunity. | Alexander Pieper, BS.; Alexander L. Rakhmilevich, MD, PhD; Dan Spiegelman; Ravi Patel, MD, PhD; Claire Baniel; Amy K. Erbe, PhD; Jacquelyn A. Hank, PhD; Deborah Charych, PhD; Willem W. Overwijk, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Radiotherapy; Solid tumors; T cell; Vaccine |
| P626 | Substantial improvement of cancer immunotherapy by an RNA encoded extended half-life Interleukin-2 variant. | Mathias Vormehr, PhD; Lena M. Kranz; Alexander Muik, PhD; Sina Fellermeier-Kopf; Nadja Salomon; Jan Diekmann; Claudia Lindemann; Sonja Witzel; Marlen Lepper; Friederike Gieseke; Veronika Jahndel; Özlem Türeci; Ugur Sahin; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Immune adjuvant; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens; Vaccine |
| P627 | Comparing the functionality of Proleukin® and Akron Interleukin-2 through an analysis of key T cell subsets | Claudia Zylberberg, PhD; John Koreth, MBBS, DPhil; Jerome Ritz, MD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Autoimmunity; Biomarkers; CAR T cells; Cytokine; Immune adjuvant; Immune toxicity; Regulatory T cell (Treg cell); T cell; Targeted therapy |
| P631 | Immunotherapy plus gene therapy: A novel nanomedicine carrying the RB94 gene that suppresses tumor growth in non-small-cell lung cancer by inducing immunogenic cell death & modulating host immunity | Joe B. Harford, PhD; Caroline Doherty; Manish Moghe; Antonina Rait, PhD; Steven Metallo, PhD; Kathleen F. Pirollo, PhD; Esther H. Chang, PhD; Sang-Soo Kim, PhD; | Immune-stimulants and immune modulators | Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; NK/NK T cell; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P634 | Predicting radiation-induced immune trafficking and activation in localized prostate cancer | Simon P. Keam; Heloise Halse; ThuNgoc Nguyen; Catherine Mitchell; Franco Caramia; David J. Byrne; Sue Haupt; Georgina Ryland; Phillip K. Darcy; Shahneen Sandhu, MBBS FRACP; Piers Blombery; Ygal Haupt; Scott G. Williams; Paul J. Neeson, PhD; | Immune-stimulants and immune modulators | B cell; Immune contexture; Immune suppression; Monocyte/Macrophage; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P637 | Immunomodulation of solid tumors by carbon-ion therapy versus conventional photon therapy | Catherine S. Spina, MD, PhD; Chizuru Tsuruoka; Wendy Mao; Masaaki Sunaoski; Mathew Chaimowitz; Yi Shang; Shizuko Kakinuma; Charles G. Drake, MD, PhD; Catherine S. Spina, MD, PhD; | Immune-stimulants and immune modulators | Radiotherapy; Tumor infiltrating lymphocytes (TILs) |
| P638 | Integrin-mediated augmentation of antigenic immunity | Upendra K. Marathi, Ph.D; Yared Hailemichael, PhD; Nandadeva Lokugamage; Michael Schotsaert; Angela Choi; Imran Chwdhury; Nisha Garg; Adolfo Garcia-Sastre; Lionel Lewis; Siddhartha De; Peter Vanderslice, PhD; Jeffrey Actor; Darren G. Woodside, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Costimulation; Immune adjuvant; T cell; Vaccine |
| P639 | Depth of tumor implantation predicts response to in situ vaccination in a syngeneic melanoma model - an important variable influencing response to immunotherapy | Peter M. Carlson, BS; Manasi Mohan; Mat Rodriguez; Vladimir Subbotin; Amy K. Erbe, PhD; Zachary S. Morris, MD, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Radiotherapy; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Vaccine |
| P646 | Reprogramming CD8 cells into metabolically fit stem cell memory with superior therapeutic activity by MEK1/2 manipulation. | Vivek Verma, PhD; Pankaj Gaur, PhD; Jose Lopez; Fatmah Alolaqi; Seema Gupta, PhD; Samir N. Khleif, MD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Stem cell/cancer-initiating cell; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P647 | Is intracellular STING expression a biomarker for oncolytic herpes virus immunotherapy? | Praveen K. Bommareddy, MS, PhD; Samuel Rabkin, PhD; Andrew Zloza, MD, PhD; Howard L. Kaufman, MD, FACS; | Immune-stimulants and immune modulators | Biomarkers; T cell; Tumor microenvironment |
| P653 | Labeling method for flow cytometric analysis of radioactive tumors following immunotherapy and molecular targeted radionuclide therapy (mTRT): demonstration of augmented immune infiltrate | Peter M. Carlson, BS; Manasi Mohan; Ravi Patel, MD, PhD; Lauren Nettenstrom; Dagna Sheerar; Kathryn Fox; Mat Rodriguez; Anna Hoefges, MS; Reinier Hernandez, PhD; Chris Zahm, PhD; Douglas G. McNeel, MD, PhD; Jamey Weichert, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Immune monitoring; Radiotherapy; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Vaccine |
| P654 | CD137 agonists as an adjunct to immune checkpoint inhibitors to overcome resistance in melanoma | Sreedevi Danturti, PhD; Lena Sophie Mayer, MD; Sreedevi Danturti, PhD; Vesselin Tomov; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Checkpoint blockade; Chemokine; Costimulation; Cytokine; Monocyte/Macrophage; Myeloid cells; T cell; T cell lineages; Targeted therapy |
| P655 | EOS100850, an A2A receptor antagonist demonstrates efficacy in murine syngeneic tumor models regardless of adenosine concentrations | Romain Pirson, MSc; Anne Catherine Michaux; Diane Jamart; Julie Preillon, MSc.; Lucas Chaible; Chiara Martinoli, PhD; Gregory Driessens, PhD; Erica Houthuys, PhD; Stefano Crosignani, PhD; Reece Marillier, PhD; | Immune-stimulants and immune modulators | Chemotherapy; Immune suppression; Immune tolerance; Metabolism; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P656 | PEGylated cationic liposomal-oxaliplatin display impressive anti-cancer efficacy by dual-targeting of immunosuppressive populations and cancer-cells | Lars R. Petersen, PhD; Lars Ringgaard, PhD; Fredrik Melander, PhD; Ragnhild G. Østrem, PhD; Kasper Kristensen, PhD; Jonas R. Henriksen, PhD; Dennis R. Elema, PhD; Andreas Kjær, MD, PhD; Thomas L. Andresen, PhD; | Immune-stimulants and immune modulators | Chemotherapy; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor antigens; Tumor microenvironment |
| P659 | ENPP1 antagonists in combination with radiation or checkpoint inhibitors demonstrate antitumor activity in syngeneic mice models of pancreatic adenocarcinoma, neuroblastoma, TNBC, and colon cancer | Lingyin Li, PhD; Mark Smith, PhD; Betty Chang, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P662 | Inhibiting DNA methylation can reverse epigenetic silencing of STING in melanoma and enhance antitumor T-cell activity | Rana Falahat, PhD; James Mulé, PhD; Anders E. Berglund, PhD; Patricio Perez-Villarroel; Shota Aoyama, MD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Bioinformatics; Chemokine; Cytokine; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P667 | Neoadjuvant STING agonists combined with systemic immunotherapy block metastatic recurrence in orthotopic breast tumors | Lauren Milling, BS; Darrell J. Irvine, PhD; | Immune-stimulants and immune modulators | Cytokine; Dendritic cell; Surgery; T cell; Tumor microenvironment |
| P668 | TTI-10001, a next generation small molecule STING agonist, demonstrates potent anti-tumor activity in mice following oral or intravenous administration | Natasja Viller; Peter Dove; David Rosa; Bolette Bossen, BSc; Tran Truong; Tapfuma Mutukura; Debbie Jin; Marilyse Charbonneau; Laura Brinen; Karen Dodge; Gloria HY. Lin; Jeff Winston; Robert A. Uger; Malik Slassi; Zezhou Wang, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antigen presenting cells; Cytokine; Dendritic cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P669 | Pharmacological evaluation of the ubiquitin ligase CBL-B as a small molecule, tumor immunotherapy target | Jennifa Gosling, MS; Christoph W. Zapf; Ryan Rountree; Chenbo Wang; Thomas Cummins; Frederick Cohen; Hiroko Tanaka; Dahlia Weiss; Mario Cardozo; Christopher Karim; May Tan; Austin Tenn-McClellan; Szerenke Kiss von Soly; Julie Sheung; Ketki Dhamnaskar; Katherine Kurylo; Neil Bence; Arthur Sands; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; T cell |
| P670 | Pharmacodynamic response in vitro and in vivo of novel orally administered Toll-like Receptor 7 agonists for systemic immunotherapy of cancer | James R. Appleman, PhD; Stephen E. Webber; | Immune-stimulants and immune modulators | Chemokine; Cytokine; Dendritic cell; TLR |
| P671 | Delivery of TLR7 agonists by Deep-Primed™ T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity | Austin W. Boesch, PhD; Vasily Rybakin; Nathan Westcott; Ji Young Hwang; Kira Jørgensen; Rasmus Lassen; Martin Kraemer; Martin Bak, PhD; Gael Veiga; Jonas Bruun, PhD; Carlos Tassa; Harrison Rodts; Manny Sequeira; Glenn Leary; Santina Caruso; Becker Hewes, MD; Jonathan B. Fitzgerald, PhD; Karsten Sauer, PhD; Thomas L. Andresen, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antigen presenting cells; Cytokine; Dendritic cell; Immune toxicity; MDSC; T cell; TLR; Tumor antigens; Tumor microenvironment |
| P675 | Multimodal intratumoral immunotherapy potentiates complete immunologic tumor elimination of breast cancer origin diffuse liver metastases | Erik R. Soule; Jason R. Williams, MD; | Immune-stimulants and immune modulators | Antibody; Biomarkers; Checkpoint blockade; Immune adjuvant; Neoantigens; Regulatory T cell (Treg cell); Stem cell/cancer-initiating cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Vaccine |
| P676 | Intratumoral delivery of TransCon™ TLR7/8 Agonist provides potent anti-tumor activity as a monotherapy and in combination with IL-2 while minimizing systemic cytokine induction | Luis A. Zuniga, PhD; Torben Leßmann; Lars Holten-Andersen; Nicola Bisek; Joachim Zettler; Sebastian Stark; Frank Faltinger; Oliver Kracker; Samuel Weisbrod; Robin Müller; Tobias Voigt; Kornelia Bigott; Mohammad A. Tabrizifard; Vibeke Breinholt; Kennett Sprogøe; Juha Punnonen; | Immune-stimulants and immune modulators | Antigen presenting cells; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P680 | Discovery of immunogenic ERV-derived antigens as targets for melanoma immunotherapy | Ray Jupp, PhD; George Kassiotis; Nicola Ternette; George Young; Duncan Howie; Fabio Marino; Matthew Davies; Hayden Selvadurai; Alvaro Sanchez; Jonathan Dodd; Laura Lozza; Elizabeth Soilleux; Peter W. Mason; Kevin Pojasek; | Immune-stimulants and immune modulators | T cell; Tumor antigens; Vaccine |
| P682 | AI-augmented design of effective therapeutic cancer vaccines and adoptive cell therapies | Piotr Stepniak; Giovanni Mazzocco, M.Sc.; Alexander Myronov, M.Sc.; Iga Niemiec, M.Sc.; Katarzyna Gruba, M.Sc.; Piotr Skoczylas, M.Sc.; Anna Sanecka-Duin, PhD; Michal Drwal, M.Sc.; Jan Kaczmarczyk, PhD; Giovanni Mazzocco, M.Sc.; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Bioinformatics; Immune adjuvant; Neoantigens; T cell; Vaccine |
| P693 | Cooperative targeting of immunotherapy-resistant melanoma and lung cancer models by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade | Julia Boshuizen, MD; Nora Pencheva; Oscar Krijgsman, PhD; Maarten Janmaat; Patricia Garrido Castro; Elke Gresnigt-Van den Heuvel; Andreas Lingnau; Maria Jure-Kunkel; Daniel Peeper, PhD; | Immuno-conjugates and chimeric molecules | Adoptive immunotherapy; Antibody; Checkpoint blockade; T cell; Tumor evasion |
| P697 | Pre-clinical characterization of the mechanism of action of a CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting regulatory T cells in solid cancers | Francesca Zammarchi, PhD; Simon Chivers; Patrick H. van Berkel, Ph.D; Francesca Zammarchi, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Checkpoint blockade; Chemotherapy; Clinical trial; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P702 | Informing rational immunotherapy combinations for enhancing therapeutic activity of Bi-Specific T cell Engager (BiTE®) antibody constructs in solid tumors | Deepali V. Sawant, PhD; Brian Belmontes; Famke Aeffner; Olivier Nolan-Stevaux; Jackson Egen; Jason DeVoss, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Solid tumors; T cell; Tumor antigens; Tumor microenvironment |
| P708 | Real world evidence of patient clinical profiles with advanced solid tumor malignancies receiving immune checkpoint inhibitors to investigate potential predictors for immune-related adverse events. | Stephanie Berg, DO; Joseph I. Clark, MD; Jose Guevara; Elizabeth Elliott, DO; Stephanie Berg, DO; Stephanie Berg, DO; Michael Wesolowski; Blaine Knox, MD; Daniel Linden, DO; Courtney Wagner, MD; | Immunotherapy Toxicities | Biomarkers; Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors |
| P709 | Immunotherapy Adverse Events Predict Treatment Response | Diana V. Maslov; Katherine Thomas, MD, MS; Victoria Simenson, MD; Caitlin Sullivan, MD; Alaa Mohammed, MPH; Jessica Boyce; Jonathan Lu, MD; John Kucharczyk, MD; Marc R. Matrana; | Immunotherapy Toxicities | Checkpoint blockade; Immune tolerance; Immune toxicity; Solid tumors; Targeted therapy |
| P710 | Immune Checkpoint Inhibitors increase the risk of Hypothyroidism in Patients with Primary Head and Neck Cancer Compared to Other Cancers | Omar A. Alaber, MD; Apoorva K. Chandar; Prateek Mendiratta, MD; Monaliben Patel, MD; Chris J. Hoimes, MD; Pierre Lavertu, MD; Ankit Mangla, MD | Immunotherapy Toxicities | Checkpoint blockade; Epidemiology; Immune toxicity; Radiotherapy; Solid tumors; Targeted therapy |
| P711 | Single-Center Analysis of Safety and Efficacy of Immune Checkpoint Inhibitors (ICI) in Non-Hematologic Malignancies: Effects of Age and Eosinophilia | Justin T. Moyers, MD; Dhanu Desai; Jasmine Mitchell; Jeffrey Ahn; Steven Hardin; Mie Mie Thinn; | Immunotherapy Toxicities | Checkpoint blockade; Immune monitoring; Immune toxicity |
| P712 | Conditional immune toxicity rate with immune checkpoint inhibitors | Pier Vitale Nuzzo, MD, PhD; Gregory Russell Pond, M.Sc, PhD; Amin Nassar, MD; Sarah Abou Alaiwi, MD; Ronan Flippot, MD; Catherine Curran; Kerry Kilbridge, MD; Xiao Wei, MD; Bradley Mcgregor, MD; Lauren Harshman, MD; Toni K. Choueiri; Guru Sonpavde, MD; | Immunotherapy Toxicities | Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; Targeted therapy |
| P714 | Immunological features of immune-related adverse events during anti-PD-1/PD-L1 immune checkpoint inhibition | Meghali Goswami, MPhil; Gege Gui; Katherine E. Lindblad; Jaydira Del Rivero, MD; Jennifer Marte, BS MD; Pradeep K. Dagur, PhD; Christin B. Destefano, MD; Julie Thompson, RN; Bogdan Popescu, MD; Laura Dillon, PhD; Cheryl D. Johnson; Steven J. Soldin, PhD; Catherine Lai, MD, MPH; James L. Gulley, MD, PhD, FACP; Christopher S. Hourigan, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune toxicity; Leukemia/Lymphoma; T cell |
| P715 | Strategies to mitigate immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer | Célia Jacoberger-Foissac, PhD; Stephen J. Blake; Célia Jacoberger-Foissac, PhD; Jing Liu; Stacey Allen; Juming Yan; Heidi Harjunpaa; Mark J. Smyth; Michele W. Teng, PhD; | Immunotherapy Toxicities | Antibody; Autoimmunity; Cytokine; Immune suppression; Immune toxicity; Regulatory T cell (Treg cell); Solid tumors |
| P716 | An In Vivo PBMC Humanized Mouse Model for Determining Checkpoint and Bispecific Antibody Treatment Related Cytokine Release Syndrome | Chunting Ye; Mingshan Cheng; Michael Brehm; Dale Greiner; Leonard Shultz; James Keck, PhD; | Immunotherapy Toxicities | Checkpoint blockade; Cytokine; Immune toxicity |
| P717 | Involvement of IL17 in a case of fatal neuroendocrine toxicity associated with dual immune checkpoint blockade | Luca Mazzarella, MD PhD; Silvia Giugliano; Paolo D'Amico; Carmen Belli; Bruno Duso; Giuseppe Curigliano, MD, PhD; Maria Rescigno, MD, PhD; Luca Mazzarella, MD PhD; | Immunotherapy Toxicities | Checkpoint blockade; Cytokine; Dendritic cell; Immune toxicity |
| P718 | A case of dual-mechanism hematologic immune-related adverse event in a patient with metastatic melanoma treated with combined nivolumab and ipilimumab | Daniel J. Olson, MD; Melissa Tjota, MD, PhD; Padma Rajagopal, MD; Girish Venkataraman, MD; Jason J. Luke, MD, FACP; Thomas F. Gajewski, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune toxicity |
| P719 | CD8+ Tcell integrin α4β7expression: a potential predictor of severity and steroid sensitivity in checkpoint inhibitor induced colitis | Anna C. Olsson-Brown, MBChB (Hons), BSc (Hons); Joseph Sacco, MSc, MBChB, MRCP, Ph; Sandra CP. Cachinho; Carol Jolly; Vanessa Fontana; Rosemary Lord; Mark Coles; Munir Pirmohamed; | Immunotherapy Toxicities | Immune toxicity; Inflammation; Solid tumors; T cell |
| P720 | The use of in vitro assays to reduce the risk of unwanted immunogenicity | Amin Osmani; Thibault Jonckheere; Sofie Pattijn; Mayuko Oh; Thibaut Janss; | Immunotherapy Toxicities | Dendritic cell; Immune suppression; Immune tolerance; Immune toxicity; Monocyte/Macrophage; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell |
| P721 | Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis | Hamzah Abu-Sbeih, MD; Lauren N. Herrera; Tenglong Tang, MD; Mehmet Altan; Anne-Maria P. Chaftari; Pablo C. Okhuysen; Robert Jenq, MD; Yinghong Wang, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune toxicity; Inflammation; Microbiome |
| P722 | Opportunistic Infection Outcomes in Patients Receiving Corticosteroids for Immune Checkpoint Inhibitor Toxicity | Michael R. Cook, MD; Michael B. Atkins, MD; | Immunotherapy Toxicities | Checkpoint blockade; Immune suppression; Immune toxicity |
| P723 | Interleukin-6 blockade to de-couple CTLA-4 blockade colitis from anti-tumor efficacy | Yared Hailemichael, PhD; Daniel H. Johnson, MD; Wai C. Foo; Kenneth R. Hess, BS, MS, PhD; Cara Haymaker, PhD; Chantal M. Saberian, MD; Salah E. Bentebibel; Elizabeth Burton; Yinghong Wang, MD, PhD; Scott Woodman; Patrick Hwu, MD; Adi Diab, MD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Chemokine; Cytokine; Immune toxicity; Inflammation; Monocyte/Macrophage; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs) |
| P724 | Analysis of healthcare provider management of immune-related adverse events and concordance with NCCN Guidelines® | Megan Cartwright, PhD; Krista Marcello, BA; Jillian L. Scavone, PhD; Kevin L. Obholz, PhD; Timothy A. Quill, PhD; John A. Thompson; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune toxicity |
| P725 | Clinical features of immune checkpoint inhibitor-related adrenal insufficiency: a retrospective analysis | Qinwen Zhou, MD; Sandip P. Patel, MD; Qinwen Zhou, MD; Vala Hamidi; Qinwen Zhou, MD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors |
| P728 | Inference of immunotherapy response-predictive biomarkers in lung adenocarcinoma from hematoxylin and eosin (H&E) stained images | Kimary Kulig, PhD, MPH; Cory Batenchuk, PhD; Peter Cimermancic; Huang-Wei Chang, PhD; Eunhee S. Yi, MD; Vanessa A. Velez; Hardik L. Patel; Ali Behrooz; Kamilla Tekiela; Robert Findlater; Cory Batenchuk, PhD; | Machine Learning, Artificial Intelligence, and Computational Modeling | Biomarkers; Checkpoint blockade; Tumor microenvironment |
| P731 | Identification and Validation of Shared Neoantigens for Cancer Immunotherapy | Jennifer Busby, PhD; Melissa Rotunno; Tyler Murphy; William Brinton; Michael Zhong; Lina Kim; Abu Jalloh; Amanda Costa; Michael Fray; Aaron Yang; Meghan Hart; Matthew Davis; Rita Zhou; Elizabeth Maloney; Alexis Mantila; Karin Jooss, PhD; Aleksandra Nowicka; Christine D. Palmer, PhD; James Sun; Roman Yelensky, PhD; Jennifer Busby, PhD; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Neoantigens; Proteomics |
| P744 | Physical fitness influences the composition of human T cell populations | Michael P. Gustafson, PhD; Courtney M. Wheatley-Guy, PhD; Svetlana Bornschlegl; Allan B. Dietz, PhD; Dennis A. Gastineau, MD; Emmanuel Katsanis, MD; Richard J. Simpson, PhD; Bruce D. Johnson, PhD; | Microbiome and other environmental factors | Immune monitoring; Immune suppression; T cell |
| P745 | Tumor cell metabolism as a barrier to immunotherapy in melanoma | Ashley Menk, MS; Greg M. Delgoffe, PhD; Yana G. Najjar, MD; Ashley Menk, MS; John M. Kirkwood, MD; | Microbiome and other environmental factors | Adoptive immunotherapy; Checkpoint blockade; Metabolism; Tumor microenvironment |
| P746 | Global metabolomics of advanced gastric cancer patients identifies signatures associated with response and clinical benefit from nivolumab | Carrie B. Brachmann, PhD; Daniel Cooper; Kari Wong; Ethan Grant; Daniel V. Catenacci, MD; David Cunningham; Jean-Philippe Metges; Eric Van Cutsem, MD, PhD; Zev Wainberg, MD; Dung Thai; Pankaj Bhargava; Emon Elboudwarej; Ondrej Podlaha; Wadud Khan; Jennifer A. Wargo, MD, MMSc; Manish Shah, MD; | Microbiome and other environmental factors | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Metabolism; Microbiome; Solid tumors |
| P747 | Leveraging the Second Genome platform to develop microbiome-derived cancer immunotherapies | Dhwani Haria; Jayamary D. Ravichandar; Lynn Yamamoto; Cheryl-Emiliane Chow; Bernat Raja; Joanna Dreux; Kareem Graham; Kathryn Iverson; Shoko Iwai; Sunit Jain; Yuliya Katlinskaya; Sabina Lau; Jina Lee; Michelle Lin; Paul Loriaux; Nicole Narayan; Erica Rutherford; Connor Skennerton; Thomas Weinmaier; Michi Wilcoxon; Yonggan Wu; Todd DeSantis; Toshihiko Takeuchi; Karim Dabbagh; Helena Kiefel, PhD; | Microbiome and other environmental factors | Microbiome; Solid tumors; Tumor microenvironment |
| P748 | A rationally-designed consortium of human gut commensals induces IFNg+ CD8+ T cells and enhances tumor immunity | Amanda Prince, PhD; Johnny Lightcap; Amit Reddy; Sachin K. Deshmukh; Steve McClellan; Bruce L. Roberts, PhD; Rose Szabady; Arthur E. Frankel; | Microbiome and other environmental factors | Checkpoint blockade; Dendritic cell; Microbiome; T cell; Tumor infiltrating lymphocytes (TILs) |
| P749 | Investigation of immune-microbiota interaction in lung cancer using genetically engineered mouse models | Chengcheng Jin, PhD; Tyler Jacks, PhD; Georgia Lagoudas; | Microbiome and other environmental factors | Cytokine; Granulocyte; Immune contexture; Inflammation; Myeloid cells; Microbiome; Solid tumors; Tumor microenvironment |
| P750 | Predicting response to anti-PD1 therapy from metagenomic sequencing data with machine learning | Jan Majta, MSc; Krzysztof Odrzywolek; Agata Szymanek; Monika Majchrzak-Gorecka; Szymon Wojciechowski; Zuzanna Karwowska; Kaja Milanowska; | Microbiome and other environmental factors | Bioinformatics; Checkpoint blockade; Microbiome |
| P751 | A targeted next generation sequencing assay to analyze and characterize the gut microbiome for health research | Anna McGeachy, PhD; David Merrill; Shrutii Sarda; Birgit Drews; Wing Lee; Heesun Shin; Janice Au-Young; Rajesh K. Gottimukkala, MS; Aren Ewing; Fiona Hyland; | Microbiome and other environmental factors | Autoimmunity; Bioinformatics; Biomarkers; Carcinogenesis; Checkpoint blockade; Immune monitoring; Inflammation; Metabolism; Microbiome |
| P752 | Antitumor activity of neoantigen cancer vaccine delivered by DNA electroporation is driven by the microbiota | Lucia Lione; Erika Salvatori; Antonella Conforti; Gennaro Ciliberto; Luigi Aurisicchio; Fabio Palombo, PhD | Microbiome and other environmental factors | Microbiome; Neoantigens; T cell |
| P753 | Trial in progress: A phase I study of live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours | John D. Weinberg, MD; Jonathan Krell, PhD, MRCP, MBChB, BSc; | Microbiome and other environmental factors | Clinical study; Clinical trial; Cytokine; Microbiome; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P754 | Using advanced imaging techniques to study the interactions among malignant cells, immune system, and microbiota in lung adenocarcinoma | Chen Zhao, MD; Weizhe Li; Chengcheng Jin, PhD; Tyler Jacks; Ronald N. Germain, MD, PhD; | Microbiome and other environmental factors | Solid tumors; Tumor microenvironment |
| P755 | Microbiome spatial patterns as markers of cancer immune therapy response | Bokai Zhu, BS; Yunhao Bai, BS; Sizun Jiang, PhD; Xavier Rovira-Clave; Justin Sonnenburg; Garry Nolan; | Microbiome and other environmental factors | Immune monitoring; Microbiome |
| P756 | HER2-targeting TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR- dependent manner. | Shelley E. Ackerman, PhD; Joseph C. Gonzalez; Cecelia I. Pearson; Shelley E. Ackerman, PhD; Justin A. Kenkel; Po Y. Ho; Angela Luo; Murray N. Nguyen; Jason C. Paik, MD PhD; Arthur Lee; Richard P. Laura; Hai Li; Cindy Kreder; Karla A. Henning; Steve J. Chapin; Bruce H. Devens; Brian S. Safina; David Y. Jackson; Edgar Engleman; David Dornan, PhD; Michael N. Alonso; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; TLR; Tumor antigens |
| P757 | Novel SIRP antibodies with differentiated characteristics for targeting innate immunity in cancer | Gabriela Andrejeva, PhD; Benjamin J. Capoccia, PhD; Michael J. Donio, MS; Ronald R. Hiebsch, BS; Robyn J. Puro, PhD; Myriam N. Bouchlaka, PhD; Daniel S. Pereira, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Monocyte/Macrophage; Targeted therapy |
| P758 | COBRA: A novel conditionally active bispecific antibody that regresses established solid tumors in mice | Anand Panchal; Andisheh Bagheri, MS; Maia Vinogradova; Tim Chen; Russell Wall; Stéphanie Levon; Pui Seto; Jessica Krakow; Brian Hillier; Ying Zhu; Danielle Dettling; Jeremiah Degenhardt; Aakash Datt; Eilene Kwok; Lucy Quach; Patricia A. Culp; Chad May; Bob DuBridge; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P759 | DZD2269, a novel A2AR antagonist capable of overcoming high adenosine induced immunosuppression | Yu Bai, M.Sc; Xin Zhang; Jie Zheng; Yingchun Wang; Lingli Zhang; Yu Bai, M.Sc; Yu Bai, M.Sc; Zhenfan Yang; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Chemotherapy; Cytokine; Immune suppression; Radiotherapy; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P760 | Local modulation of T cell PD-1 using self-delivering RNAi as a potential immunotherapeutic | John A. Barrett, PhD; James Cardia; Melissa Maxwell; Mani D. Kadiyala, M.S>; Dingxue Yan, PhD; Winnie Tam; Simon P. Fricker, PhD; Gerrit Dispersyn, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P761 | Tumor-targeted bacterial nanocells carrying a super-cytotoxic drug elicit an anti-tumor immune response, long-term survival, prolonged tumor remission, and resistance to tumor re-challenge | Himanshu Brahmbhatt, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Chemokine; Cytokine; Monocyte/Macrophage; NK/NK T cell; T cell; Targeted therapy; Tumor microenvironment |
| P762 | Antibodies to ILT3 (LILRB4) abrogate myeloid immunosuppression and combine with PD1 blockade to enable T cell activation and function. | Philip E. Brandish, PhD; Jeanne Baker; Alan Byford; MIchael Caniga; Craig Chappell; Holly Cherwinski; Daniel J. Cua; Laurence Fayadat-dilman; Brian Hall; Barbara Joyce-Shaikh, BS.; Veronica Juan; Carl Mieczkowski; Anthony Palmieri; Yujie Qu, MD; Latika Singh; Peter Stiivers; Jie Zhang-Hoover; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Dendritic cell; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor evasion |
| P763 | Target Engagement and PK/PD quantification in humanized tumor model for anti-ILT3 mAb discovery | Alan J. Byford, MSc.; Yujie Qu, MD; Xiaoyan Du; Daping Zhang; Yvonne Yannoni; Laurence Fayadat-dilman; Brian Hall; Jeanne Baker; Michael Meehl; Scott Pruitt, MD, PhD; Lily Moy; Philip Brandish; Jie Zhang-Hoover; | Novel Single-Agent Immunotherapies | Biomarkers; Myeloid cells; Tumor infiltrating lymphocytes (TILs) |
| P764 | Directly targeting FOXP3 with AZD8701, a first-in-class high affinity antisense oligonucleotide to relieve immunosuppression in cancer. | Larissa S. Carnevalli, PhD; Alexey Revenko; Charles So. Sinclair; Alison Peter; Molly A. Taylor; Anisha Solanki, PhD; Melissa Chapman; James Yates; Helen K. Angell, BSc PhD; Frederick Goldberg; Robert MacLeod; Larissa S. Carnevalli, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor evasion; Tumor microenvironment |
| P765 | First in class antibody targeting Galectin-9 promotes anti-tumor response against pancreatic and other solid cancers | Linxiao Chen, PhD; Wei Wang, MD; Akiko Koide, PhD; Adrian Seifert, MD; Lena Seifert; Aleksandra Filipovic, MD, PhD; George Miller; Shohei Koide, PhD; Linxiao Chen, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P766 | The distinct binding footprints of bispecific T cell receptors (TCR) and TCR-mimic antibodies underpin their altered pHLA selectivity | David K. Cole; Rory Crean; Johanne Pentier; Ben de Wet; Angharad Lloyd; Bent K. Jakobsen, PhD; Christopher Holland; | Novel Single-Agent Immunotherapies | Antibody; Immune toxicity; T cell; Targeted therapy; Tumor antigens |
| P767 | Single-Cell Cytometry with the Genesis System - A scalable solution for high-parameter epitope detection | Jon Bell, BS, MS; Yad Deol, PhD, MS; Shaun Connor, BS, MBA; Tyler Burns, PhD; | Novel Single-Agent Immunotherapies | Antibody; B cell; Biomarkers; Immune monitoring; Myeloid cells; NK/NK T cell; T cell; Targeted therapy |
| P768 | Antagonism of Signaling through the Vasoactive Intestinal Peptide Receptor as a Novel Immunotherapy in Preclinical Models of Melanoma. | Rohan K. Dhamsania, BS; Sruthi Ravindranathan, PhD; Shuhua Wang, MD; Rebecca A. Pankove, MS; David Francis; Susan N. Thomas, PhD, BS; Brian Pollack; Edmund K. Waller, MD, PhD, FACP; | Novel Single-Agent Immunotherapies | Adoptive immunotherapy; Checkpoint blockade; Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P769 | Inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8+ T cells, NK cells, and CD103+ dendritic cells in the mouse syngeneic MC38-OVA tumor model | Aatman S. Doshi, MS; Susan Cantin; Michael Secinaro; Yanjun Wang; Laura Prickett; Sharon Tentarelli; Scott Mlynarski; Eric Gangl; M. Raymond V. Finlay; Wenlin Shao, PhD; Alwin Schuller; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Cytokine; Dendritic cell; Immune suppression; Myeloid cells; Metabolism; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P770 | A novel class of multi-specific antibodies targeting NKp30 on innate immune cells | Monia Draghi, PhD; Allison Nelson; Amanda Oliphant; Alan Leung; Jay Vekeria; Zach Frye; Claire Chottin; Sara Haserlat; Rachel Rennard; Caitlin Goshert; Rachel McCrory; Lucy Liu; Kenneth Rogers; Francois Villinger; Piotr Bobrowicz; Michael Schmidt; Jennifer Watkins-Yoon; | Novel Single-Agent Immunotherapies | NK/NK T cell |
| P771 | An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T cells (Tregs) | Kwong Y. Tsang, PhD; Massimo Fantini, PhD; Justin M. David; M Maria Morelli, MD; Christina M. Annunzata, MD; Philip M. Arlen, MD; | Novel Single-Agent Immunotherapies | Antibody; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Targeted therapy; Tumor antigens |
| P772 | Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and oncogenes expressed on the tumor | Michael Khodadoust, MD PhD; Youn H. Kim, MD; Michael Yang; Heather Torrey, PhD; Lisa Tran; Denise L. Faustman, MD, PhD; | Novel Single-Agent Immunotherapies | Antibody; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell; Tumor microenvironment |
| P773 | ONCR-177, an oncolytic HSV designed to safely and potently activate systemic anti-tumor immunity | Sonia Feau, Ph.D; Melissa Hayes; Brian Haines; Agnieska Denslow; Jacqueline Gursha; Daniel Wambua; Shreeya Khatiwada; Lingxin Kong; Jacob Spinale; Prajna Behera; Peter Grzesik; Jennifer s. Lee; Terry Farkaly; Edward m. Kennedy; Lorena Lerner; Christophe Queva; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Chemokine; Costimulation; Cytokine; Dendritic cell; Immune adjuvant; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P774 | Intratumoral depletion of regulatory T cells using CD25 targeted photoimmunotherapy elicits anti-cancer immune activity and synergizes with PD1 checkpoint blockade in immunocompetent mouse models | Michelle A. Hsu; Stephanie M. Okamura; Daniele M. Bergeron; Estela Solis; Dany Gitnick; Roger Heim; Jerry Fong, PhD; Jerry Fong, PhD; Miguel Garcia-Guzman; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P775 | Crosslink-Independent CD137 Agonism is Associated with Liver Inflammation | Miguel Gaspar, PhD; John Pravin; Leonor LR. Rodrigues, MSc; Alexander Koers, PhD; Mihriban Tuna, PhD; Neil Brewis, PhD; | Novel Single-Agent Immunotherapies | Antibody; Costimulation; Immune adjuvant; Immune toxicity; Inflammation; Regulatory T cell (Treg cell); T cell |
| P776 | Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity | Laurent Gauthier, PhD; Ariane Morel, PhD; Nadia Anceriz; Benjamin Rossi; Audrey Blanchard-Alvarez; Gwendoline Grondin; Sylvia Trichard; Cédric Cesari; Melody Sapet; Frédéric Bosco; Hélène Rispaud-Blanc; Franceline Guillot; Stéphanie Cornen; Alain Roussel; Béatrice Amigues; Guillaume Habif; Flavien Caraguel; Sandrine Arrufat; Romain Remark, PhD; François Romagné; Yannis Morel, PhD; Eric Vivier; | Novel Single-Agent Immunotherapies | Antibody; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P777 | Engineered monomeric JAG1 and multimeric DLL1 Notch ligand constructs enhance antitumor immunity by reducing exhaustion of T-effector memory cells | Uttam Laksmi Mounika Goruganthu, M Tech; Anil Shanker, PhD; David P. Carbone, MD, PhD; Elena Tchekneva, MD; Anneliese Antonucci; Michael Koenig; Longzhu Piao; Anwari Akhter, PhD; Parvathi Ranganathan; Nicholas Long; Thomas Magliery; Jason Evans; Rajeswara Arasada; Pierre P. Massion, MD; Mikhail M. Dikov, PhD; Roman V. Uzhachenko, PhD MD; Portia Thomas; Asel K. Biktasova, MD, PhD; Duafalia Dudimah; Maria Teresa P. De Aquino, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Dendritic cell; Regulatory T cell (Treg cell); Solid tumors; Tumor evasion |
| P778 | ATRC-101: A First-in-Class Engineered Fully Human Monoclonal Antibody that Targets a Tumor-Restricted Ribonucleoprotein Complex | Norman M. Greenberg, PhD; Jeffrey DeFalco, PhD; Daniel Emerling, PhD; Amy Manning-Bog, PhD; Gilson Baia, PhD; Shaun M. Lippow, PhD; Alexander Scholz, PhD; Yanhong Zhu, MD; Guy Cavet, PhD; Wayne Volkmuth, PhD; Ish Dhawan, PhD; Jonathan Benjamin, MD, PhD; William Robinson, MD PhD; Tito A. Serafini, PhD; Norman M. Greenberg, PhD; | Novel Single-Agent Immunotherapies | Antibody; B cell; Bioinformatics; Checkpoint blockade; Targeted therapy; Tumor antigens |
| P779 | HER2/PD-L1/CD3/HSA tetra-specific antibody mediates cytolytic synapse-restricted PD-L1 blockade and potent depletion of HER2+ tumors | Tea Gunde, PhD; Alexandre Simonin; David Urech; Stefan Warmuth; Christian Hess; Matthias Brock; Eva Oswald; Julia Zeberer; Dania Diem; Dana Mahler; Diego Morenzoni; Simone Muntwiler; Benjamin Küttner; Robin Heiz; Naomi Flückiger; Sebastian Meyer; Timothy Egan; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Solid tumors; Targeted therapy |
| P780 | Selection and in vitro characterization of ABBV-368, a novel anti-OX40 agonist antibody | Fiona Harding, PhD; Marcia Stickler; Margo Werner; Jennifer Tran; Nicole Belmar, BS; Archana Thakur; Enrico DiGiammarino; David Powers; Fiona Harding, PhD; | Novel Single-Agent Immunotherapies | Antibody; Costimulation; T cell |
| P781 | A new approach used to characterise off target peptide repertoires for T cell receptors that target the cancer testis antigen NY-ESO-1-HLA-A*02:01 | Stephen Harper; Charlotte H. Coles, PhD; Rachel M. Mulvaney; Sunir Malla, PhD; Andrew Walker, PhD; Kathrine J. Smith; Angharad Lloyd; Jane Harper; Zoe Donnelan; Andrew Knox; Andrea R. Stacey; Joseph Dukes; Emma Baston; Suzanne Griffin; | Novel Single-Agent Immunotherapies | T cell; Tumor antigens |
| P782 | A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism | Kristen Hurov, PhD; Punit Upadhyaya; Marianna Kleyman; Jessica Kublin; Tom L. Stephen; Jun Ma; Elizabeth M. Repash; Julia Kristensson; Sophie Watcham; Liuhong Chen; Sailaja Battula, PhD; Johanna lahdenranta; Kevin McDonnell, PhD; Nicholas Keen; | Novel Single-Agent Immunotherapies | Costimulation; Cytokine; Myeloid cells; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P783 | DuoBody®-CD3x5T4 shows potent preclinical anti-tumor activity in vitro and in vivo in a range of cancer indications | Kristel Kemper, PhD; Ellis Gielen; Laura Smits-de Vries; Sandra Verploegen; Mischa Houtkamp; Saskia Burm; Edward van den Brink; Rik Rademaker; Dennis Verzijl; Patrick Engelberts; Bart E.C.G. de Goeij; David Satijn; A. Kate Sasser; Esther Breij, PhD; | Novel Single-Agent Immunotherapies | Antibody; Biomarkers; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P784 | SBT6050, a HER2-directed TLR8 agonist antibody conjugate, designed to overcome primary resistance to and synergize with checkpoint inhibition in HER2-expressing tumors | Kara Moyes; Jamie Brevik; Damion Winship; Ty Brender; Heather Metz; Yvette Latchman, PhD; Monica Childs; Michael Comeau; Jenny R. Chang; Sean W. Smith; Hengyu Xu; Ben Setter; Ray Carrillo; Li-Qun Fan; Phil Tan; Robert E. DuBose; Peter Baum; Valerie Odegard, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Dendritic cell; Myeloid cells; Solid tumors; T cell; Targeted therapy; TLR; Tumor antigens; Tumor microenvironment |
| P785 | Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure compared to recombinant IL-12 | Katherine Kirwin; Chang Ling Sia; Sonya Haupt; Ke Xu; Kevin Dooley; Su Chul Jang, PhD; Bryan Choi; Adam Boutin; Christine McCoy; Scott Estes; Kyriakos Economides; Sriram Sathyanarayanan; Nuruddeen Lewis, PhD; | Novel Single-Agent Immunotherapies | Cytokine; Immune adjuvant; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P786 | Network meta-analysis (NMA) and matching-adjusted indirect comparison (MAIC) of pembrolizumab versus atezolizumab for second-line (2L) locally advanced/metastatic urothelial carcinoma (mUC) | Dave Gelb; Yichen Zhong, PhD; Rodolfo Fleury Perini; James Luke Godwin; Yizhen Lai; Stella Arndorfer; Maria Lorenzi, MSc; Haojie Li; Dave Gelb; | Novel Single-Agent Immunotherapies | Checkpoint blockade |
| P787 | Novel humanized CD3ε mouse model for evaluation of bi-specific T-cell engager antibodies | Xiaofei Zhou; Quinn Li; Dirui Li; Rui Huang; Yuelei Shen; | Novel Single-Agent Immunotherapies | Adoptive immunotherapy; Antibody; T cell |
| P788 | Development of ADG116, a novel antagonist anti-CTLA-4 human antibody for cancer immunotherapy | Guizhong Liu, PhD; Felix Fangyong Du; Kristine She; Peter Luo; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Costimulation; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs) |
| P789 | Vaccination of high-risk neuroblastoma patients with anti-id antibody ganglidiomab to maintain protective immunity after passive immunotherapy with anti-GD2 antibody ch14.18/CHO | Hans Loibner, PhD; Holger N. Lode, MD, PhD; Nikolai Siebert, PhD; Sascha Troschke-Meurer, BS; Oliver Mutschlechner; Holger N. Lode, MD, PhD; | Novel Single-Agent Immunotherapies | Antibody; Immune adjuvant; Pediatric tumors; Tumor antigens; Vaccine |
| P790 | The anti-tumor activity of an anti-CD39 antibody (ES002) in a multiple myeloma model is dependent on NK cells | Yangsheng Qiu; Hongtao Lu, PhD; Qinglin Du, PhD; Meiling Sun; Rui Gao, PhD; Huimin Kong; Roumei Xing; Yufei Shi; Mengying Xu; Zhihao Wu, PhD; Hongtao Lu, PhD; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Checkpoint blockade; Dendritic cell; Immune suppression; Myeloid cells; NK/NK T cell; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P791 | Anti-tumor activity of a small molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1) | Andy MacKinnon, PhD; Deepthi Bhupathi, MS; Jason Chen; Rosalyn Dang; Tony Huang; Weiqun Li, PhD; Yong Ma; Natalija Sotirovska, MS; Sandra Spurlock; Susanne Steggerda, PhD; Winter Zhang; Francesco Parlati, PhD; | Novel Single-Agent Immunotherapies | Immune suppression; Myeloid cells; Metabolism; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P792 | A GUCY2C-CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors | Divya Mathur, PhD; Adam Root; Bozena Bugaj-Gaweda; Xingzhi Tan; Wei Fang; Stephanie Bisulco; Jonathon Golas; Jessica Kearney; Erik Upeslacis; Johnny Yao; Edward Rosfjord; Chad Stevens; Lindsay King; Jatin Narula; Kerry Kelleher; Cynthia Rohde; Lioudmila Tchistiakova; Anhco Nguyen; Puja Sapra, PhD; | Novel Single-Agent Immunotherapies | Angiogenesis; Antibody; Biomarkers; Checkpoint blockade; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P793 | ALPN-202, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, Utilizes Multiple Mechanisms to Elicit Potent Anti-Tumor Immunity Superior to Checkpoint Blockade Alone | Mark F. Maurer, BS; Chelsea J. Gudgeon, BS; Katherine E. Lewis, PhD; Sherri Mudri, BS; Stacey R. Dillon, PhD; Martin Wolfson, BS; Steven D. Levin, PhD; Kristine M. Swiderek, PhD; Stanford Peng, MD, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Checkpoint blockade; Coinhibition; Costimulation; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs) |
| P794 | A novel fully synthetic dual targeted EphA2/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism | Sailaja Battula, PhD; Punit Upadhyaya; Marianna Kleyman; Jessica Kublin; Eric Haines, PhD; Jun Ma; Elizabeth M. Repash; Tom L. Stephen; Julia Kristensson; Liuhong Chen; Kristen E. Hurov; Johanna lahdenranta; Kevin McDonnell, PhD; Nicholas Keen; | Novel Single-Agent Immunotherapies | Costimulation; Cytokine; Myeloid cells; NK/NK T cell; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P795 | Anti-MUC1 monoclonal antibodies derived from the first non-viral prophylactic cancer vaccine clinical trial can target cancer cells and facilitate their immune-mediated elimination | Michelle L. McKeague, PhD; Jason Lohmueller, PhD; Eric Ricci; William Lu; Olivera J. Finn, PhD; | Novel Single-Agent Immunotherapies | Antibody; NK/NK T cell; Vaccine |
| P797 | Novel dual A2A/A2B receptor antagonist reverses adenosine-mediated immune suppression - in vitro and in vivo characterization. | Michal Galezowski; Paulina Wegrzyn; Aneta Bobowska; Katarzyna Dziedzic; Magdalena Bonkowska; Karolina Grycuk; Joanna Szeremeta-Spisak; Marcin Nowogródzki; Grzegorz Satala; Alicja Obara; Iwona Lozinska-Raj; Przemyslaw Wyrebek; Marcelina Dudek; Anita Janiga; Jacek Reus; Marek Wronowski; Magdalena Zastawna; Grzegorz Statkiewicz; Maciej Rogacki; Mateusz Swirski; Jakub Woyciechowski; Kinga Michalik; Agnieszka Adamus; Karolina Wiatrowska; Natalia Literska; Aniela Golas; Olga Haberkiewicz; Luigi Stasi; Peter Littlewood; Krzysztof Brzózka; Mateusz Nowak; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Immune suppression; Inflammation; Metabolism; Tumor evasion; Tumor microenvironment |
| P798 | Think Globally Act Locally: Biodistribution of BETA-PRIME, a Replication-Competent Type 5 Adenovirus Enhanced with a Trap for the Immunosuppressive Cytokine, TGF-Beta | Christopher Larson, MD PhD; Bryan Oronsky, MD PhD; Tony Reid, MD PhD; | Novel Single-Agent Immunotherapies | Immune adjuvant; Immune suppression; Regulatory T cell (Treg cell); T cell |
| P799 | Innate leukocyte chemoattractant chemerin is an intrinsic tumor suppressor in prostate cancer | Zhongping Xu, PhD; Woo Jae Shin, BA; Kevin Kim; Brian Zabel, PhD; Russell Pachynski, MD; | Novel Single-Agent Immunotherapies | Chemokine; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P800 | Development of PY314, a monoclonal antibody that selectively depletes tumor-associated macrophages, for the treatment of solid tumors | Mikhail Binnewies; Joshua L. Pollack; Venkataraman Sriram, PhD; Erick Lu; Nadine Jahchan; Xiaoyan Du; Aritra Pal; Evan Greger; Kevin Baker; Michel Streuli, PhD; Len Reyno; Venkataraman Sriram; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment; Tumor stroma |
| P801 | Development of the first in class immunotherapy targeting immuno-suppressive δ1 containing γδ T cells for the treatment of pancreatic ductal adenocarcinoma and other solid tumors | Tanya Panchenko, PhD; Wei Wang; Eric Denbaum; Takamitsu Hattori; Akiko Koide, PhD; Aleksandra Filipovic, MD, PhD; George Miller; Tanya Panchenko, PhD; Shohei Koide; | Novel Single-Agent Immunotherapies | Antibody; Immune suppression; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P802 | Single cell Immuno- and Cancer Marker Profiling of Non-Small Cell Lung Cancer Tissue: Checkpoint Marker Expression on CD103+, CD4+ T-cells Correlates with Circulating Tumor Enumeration | Kaylan Handique, PhD; Bruce Patterson, BS, MD; Lianne McLean, BA; Bruce Patterson, MD; Will Chow, PhD; Priya Gogoi, PhD; Vishal Sharma, PhD; | Novel Single-Agent Immunotherapies | Adoptive immunotherapy; B cell; Biomarkers; Gene expression; Immune monitoring; NK/NK T cell; Proteomics; T cell; T cell lineages; Targeted therapy |
| P803 | CUE-101, a novel HPV16 E7:pMHC:IL-2:Fc fusion protein, enhances tumor antigen specific T cell activation for the treatment of HPV16-driven malignancies | Steven N. Quayle, PhD; Natasha Girgis, PhD; Dharma Raj Thapa; Zohra Merazga, M.S.; Miguel Moreta; Sandrine Hulot, PhD; Alyssa Nelson, BS.; Lauren Kraemer, BS.; Dominic Beal, PhD; Mark Haydock, BS.; Luke Witt, BS.; Jessica Ryabin, BS.; Jonathan Soriano, MSc; Emily Spaulding, PhD; John F. Ross, PhD; Rodolfo Chaparro, PhD; Ronald Seidel, PhD; Anish Suri, PhD; Saso Cemerski; Kenneth J. Pienta, MD; Mary C. Simcox, PhD; | Novel Single-Agent Immunotherapies | Costimulation; Cytokine; T cell; Vaccine |
| P804 | In vivo efficacy of a PD-L1 targeted Engineered Toxin Body (ETB) comprised of direct cytotoxicity and T-cell mediated tumor targeting | Brigitte Brieschke, BS; Sara LeMar; Joseph D. Dekker, PhD; Garrett Cornelison; Asis Sarkar; Garrett L. Robinson; Jay Zhao, PhD; Aimee Iberg, PhD; Jack P. Higgins, PhD; Hilario J. Ramos, PhD; Erin K. Willert, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Solid tumors; T cell; Targeted therapy |
| P805 | SRF388, a first-in-class, fully human monoclonal antibody targeting IL 27, blocks the immunoregulatory effects of IL-27 in immune cells and demonstrates preclinical in vivo antitumor activity | Matthew P. Rausch, PhD; Jing Hua; Devapregasan Moodley; Kerry F. White; Katherine H. Walsh; Christine E. Miller; Jamie Strand; Pamela Holland, PhD; Vito J. Palombella, PhD; Jonathan A. Hill, PhD; | Novel Single-Agent Immunotherapies | Antibody; Cytokine; Immune suppression; T cell |
| P806 | Structural implications for GITR agonism in immunotherapies | Hamsell M. Alvarez, PhD; Bryan M. Rogers, MSc; Sarah Chan; Lance Bigelow; Samuel Cichanowicz; Marc Lake; Russell Judge; Ramesh Iyer; Kenton Longenecker; | Novel Single-Agent Immunotherapies | Antibody; Costimulation; Immune adjuvant; T cell |
| P807 | Characterization of anti-tumor immune responses and Effects on Survival of Neoadjuvant Oncolytic Virotherapy in spontaneous Osteosarcoma | Aish Sathyanarayan; Kelly Makielski, DVM, MS, DACVIM; Aishwarya Sathyanarayan, PhD; Shruthi Naik, PhD; Jaime F. Modiano, VMD, PhD; Stephen J. Russell, MD, PhD; Michael Henson, DVM, PhD; Kathleen Stuebner; Flaviu Alexandru Tabaran; Gerard O; Andrea Eckert; Donna Groschen; Lauren Mills, PhD; Milcah Scott, BS; Aaron L. Sarver, PhD; Michael A. Farrar; Ingrid Cornax, PhD; | Novel Single-Agent Immunotherapies | Cytokine; Immune monitoring; Solid tumors |
| P809 | Preclinical Development of a Novel, Allogeneic, OX40L-Secreting, Therapeutic Cancer Vaccine for use in Combination with a gp96-Secreting Vaccine for Solid Tumors | Matthew M. Seavey, PhD; Jason Rose, MS; Patrick Dillon, PhD; Jayalakshmi Miriyala, MS; Vikas Tahiliani, PhD; Jeff Hutchins, PhD; | Novel Single-Agent Immunotherapies | Immune adjuvant; Tumor antigens; Vaccine |
| P810 | An engineered bi-function fusion protein (CD86-Fc-NKG2a) to reverse NK cell tolerance of malignant cells | Casey W. Shuptrine, PhD; Taylor H. Schreiber, MD, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Costimulation; Immune tolerance; NK/NK T cell; Tumor evasion; Tumor microenvironment |
| P811 | Utilizing novel oncolytic vaccinia virus for selective expression of immunotherapeutic payloads in metastatic tumors | Adrian Pelin; Mike Huh, PhD; Matthew Tang, PhD; Fabrice Le Boeuf, PhD; Brian Keller; Jessie Duong; Katherine Clark-Knowles, PhD; Victoria A. Jennings, PhD; Julia Petryk; Alan A. Melcher; Mathieu Crupi, PhD; Ragunath Singaravelu, PhD; Larissa Pikor, PhD; Caroline Breitbach, PhD; Steven H. Bernstein, MD; Michael Burgess, MD, PhD; John Bell, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Chemokine; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P812 | Development of PY159, a monoclonal antibody that repolarizes tumor-associated inhibitory myeloid cells, for the treatment of solid tumors | Michel Streuli, PhD; Linda Liang; Chris Chan; Michel Streuli, PhD; Venkataraman Sriram, PhD; Erick Lu; Joshua L. Pollack; Mikhail Binnewies; Xiaoyan Du; Aritra Pal; Vladi Juric; Evan Greger; Kevin Baker; Len Reyno; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Granulocyte; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor evasion; Tumor microenvironment |
| P813 | TAS0313, a novel cocktail vaccine of multivalent HLA-A2-, A24- and A3 superfamily-restricted epitopes, demonstrates a synergistic antitumor effect with anti-PD-1 antibody | Yuki Tanaka, MS; Hiroshi Wada, MS; Risa Goto; Toshihiro Osada; Keisuke Yamamura; Satoshi Fukaya; Kazuhisa Minamiguchi; Koichi Ikizawa; Teruhiro Utsugi; | Novel Single-Agent Immunotherapies | Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P814 | Antibody-interferon-gamma fusion protein for the treatment of B-cell lymphomas | Alex Vasuthasawat; Reiko Yamada King; Kham R. Trinh; Neiki Rokni; Sherie L. Morrison, PhD; John M. Timmerman, MD | Novel Single-Agent Immunotherapies | Antibody; Cytokine; Leukemia/Lymphoma; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P815 | Targeting multiple immune checkpoint proteins with novel small molecule inhibitors of Sec61-dependent cotranslational translocation | Jennifer A. Whang, PhD; Janet L. Anderl; Andrea Fan; Christopher J. Kirk; Eric Lowe; Dustin McMinn; Beatriz Millare; Meera Rao; Jack Taunton, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; T cell; Tumor microenvironment |
| P816 | DRP-104 Induces Durable Responses In Vivo by Inhibiting Tumor Glutamine Addiction, Remodeling the Tumor Microenvironment and Stimulating Both the Innate & Adaptive Immune Systems | Yumi Yokoyama, PhD; Michael Nedelcovych, PhD; Robert Wild, PhD; | Novel Single-Agent Immunotherapies | Cytokine; Monocyte/Macrophage; Metabolism; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P817 | Potent ERAP1 inhibitors modify the immunopeptidome and generate novel neoantigens | Jamie Ware; Kris Clark; Carmen Tong; Jason Shiers; Elisa Lori; Emma Reeves; Henry Leonard; Alihussein Remtulla; Nicola Ternette; Edd James, PhD; Martin Quibell; Lesley Young, PhD; Peter I. Joyce; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Neoantigens; NK/NK T cell; T cell |
| P818 | EGFR Exon-20 Insertion-based Neoantigen Stimulated Effective T-cell Immunity against Non-Small Cell Lung Cancer | Jinpu Yu; Dandan Liu; | Novel Single-Agent Immunotherapies | Neoantigens; Tumor antigens |
| P819 | Regulation of isatuximab-mediated antibody-dependent cellular cytotoxicity of multiple myeloma cells: Rationale for combining isatuximab with anti-PD-1 / anti-TGFβ to enhance anti-myeloma activity | Anlai Wang; Zhili Song; Guang Yang; Rita M. Greco; Joachim Theilhaber; Elvis Shehu; Beatriz Ospina; Fangxian Sun; Yu-Tzu Tai; Kenneth C. Anderson, MD; Chen Zhu; Marielle Chiron, PhD; Francisco J. Adrián; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; NK/NK T cell; Targeted therapy |
| P820 | Analysis of synergy between early-incorporation immunotherapy and extracranial radiotherapy in stage IV non-small cell lung cancer | Corbin D. Jacobs, MD; Parth A. Chodavadia, BS; Frances Wang, MS; Joseph K. Salama, MD; Christopher R. Kelsey, MD; Jeffrey M. Clarke, MD; Neal E. Ready, MD, PhD; Jordan A. Torok, MD; | Other | Radiotherapy |
| P821 | Induction of anti-tumor immune responses in ovarian cancer with c-MET inhibitor Capmatinib | Maureen Drakes, PhD; Swati Mehrotra, MD; Ronald Potkul, MD; M.Sharon Stack, PhD; Patrick J. Stiff, MD; | Other | Immune suppression; Solid tumors; T cell; Targeted therapy |
| P822 | Evidence that a germline genetic variant impairs a robust anti-tumor immune response in a substrain of C57BL/6 mice | Jessica L. Fessler, BS; Vyara Matson, PhD; Thomas F. Gajewski, MD, PhD; | Other | Genetic polymorphism; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P823 | The Cancer Moonshot Immuno-Oncology Translational Network | Alan D. Hutson, PhD; Song Liu; Martin Morgan; Kunle Odunsi, MD, PhD; | Other | Adoptive immunotherapy; Biomarkers; CAR T cells; Gene expression; Immune suppression; Neoantigens; T cell; Tumor antigens |
| P824 | Development of anti-Globo H Bispecific Antibody for Breast Cancer Therapy | Yow-Sien Lin, PhD; Jei-Hwa Yu; Chia-Cheng Wu; | Other | Antibody; Cytokine; Tumor antigens |
| P825 | Increased and co-localized CD4+FOXP3+ and CD8+ T cells is a strong independent prognostic indicator in gastric cancer | Minyu Wang; Yu-Kuan Huang; Joe Kong; Yu Sun; Daniela Tantalo; Han Xian Aw Yeang; Le Ying; Feng Yan; Dakang Xu; Heloise Halse; Natasha di Costanzo; Ian Gordon; Catherine Mitchell; Laura K. Mackay; Rita Busuttil; Paul J. Neeson, PhD; Alex Boussioutas; | Other | Checkpoint blockade; Gene expression; Immune contexture; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P826 | Preliminary results of a Phase 2 study of INCMGA00012 in patients with squamous carcinoma of the anal canal (SCAC) who have progressed following platinum-based chemotherapy (NCT03597295) | Sheela Rao; Jaume Capdevila; Duncan Gilbert; Stefano Kim; Laetitia Dahan; Talal Kayyal; Marwan Fakih, MD; Anne Demols; Mark Cornfeld, MD, MPH; Chuan Tian, PhD; Melissa Catlett; Jean-Philippe Spano; | Other | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P827 | Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers | Rachel E. Sanborn, MD; Nashat Y. Gabrail, MD; Mark O'Hara, MD; Nina Bhardwaj, MD, PhD; Michael S. Gordon, MD; Ralph J. Hauke, MD; Rodolfo E. Bordoni, MD; Danny Khalil, MD PhD; Tracey Rawls; Laura Vitale, BS; Richard Gedrich; Thomas Hawthorne; Tibor Keler, PhD; Eirc Forsberg, BS; Lawrence Thomas, PhD; Michael Yellin, MD; | Other | Antibody; Antigen presenting cells; Clinical study; Costimulation; Dendritic cell; Immune monitoring |
| P828 | Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR–anti-CD3 directed against gp100, in patients with advanced melanoma | Alexander N. Shoushtari, MD; Mark R. Middleton; Neil M. Stevens; Thomas J. Evans; Jeffrey R. Infante; Mario Sznol, MD; Alan Anthoney; Avinash Gupta; Victoria Woodcock; Tina Wiseman; Cheryl McAlpine, MSN; Chris Cohen; Omid Hamid, MD; | Other | Biomarkers; Chemokine; Clinical study; Clinical trial; Cytokine; Solid tumors; T cell; Targeted therapy |
| P829 | The pattern of expression of hMENA isoforms impacts tumor immune microenvironment of early node-negative non-small cell lung cancer | Sheila Spada, PhD; Francesca Di Modugno, PhD; Anna Di Carlo; Isabella Sperduti; Enzo Gallo; Mariangela Panetta; Belinda Palermo; Francesca De Nicola; Lorenzo D'Ambrosio; Barbara Antoniani; Paola Trono; Francesco Facciolo; Paolo Visca; Paola Nistico', MD; | Other | B cell; Dendritic cell; Immune contexture; Immunoscore; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P830 | Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonist-based adjuvants | Jason D. Marshall, PhD; Athina Zacharia, PhD; | Other | Immune adjuvant; Immune monitoring |
| P833 | Timing of IL-2 treatment delivery after transplantation of B16 melanoma in a murine model differentially influences tumour growth | Brendon J. Coventry, MD PhD; Suzanne Edwards, BSc; Brendon J. Coventry, MD PhD; | Timing of Immunotherapy administration | Cytokine; Immune monitoring; Immune suppression; Immune tolerance |
| P836 | Immunopathological properties of the fibroblastic niche for cancer stem cells and the niche-targeted immunotherapy | Toshihiko Torigoe, MD, PhD; Yoshihiko Hirohashi, MD, PhD; Toshihiko Torigoe, MD, PhD; | Tumor and Stromal Cell Biology | Stem cell/cancer-initiating cell; Solid tumors; Tumor antigens; Tumor microenvironment; Tumor stroma |
| P838 | Disrupting hypoxic tumor niches to sensitize pancreatic cancer to immunotherapy | Arthur J. Liu, BS; Michael A. Curran, PhD; | Tumor and Stromal Cell Biology | Angiogenesis; Immune suppression; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P839 | DNA demethylating agent sensitizes lung cancer cells to immune attack of γδ T cells | Rueyhung R. Weng, PhD; Chien-Ting Lin; Hsuan-Hsuan Lu; Chong-Jen Yu; Hsing-Chen Tsai; | Tumor and Stromal Cell Biology | Chemotherapy; Proteomics; Solid tumors; T cell; Tumor antigens |
| P840 | Characterization of syngeneic tumor models and their microenvironment for immunotherapeutic approaches | Marco Carretta, PhD; Marie Louise Thorseth; Dennis A. Agardy; Silvia Redondo Garcia; Anne Mette Hvid Larsen, M.Sc; Dorota E. Kuczek, MSc; Daniel H. Madsen; | Tumor and Stromal Cell Biology | Solid tumors; Tumor microenvironment |
| P850 | Metabolically reprogram MDSCs by targeting Pim kinases to overcome resistance to PD-1 blockade immunotherapy | Gang Xin; Yao Chen; Paytsar Topchyan; Aimin Jiang, PhD; Yiliang Chen; Roy Silverstein; Weiguo Cui; Gang Xin; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Metabolism; Solid tumors; Tumor microenvironment |
Late-Breaking | ||||
| P851 | Identifying potential predictive biomarkers from plasma exosomes and adoptive T cells that differentiate short and long-term metastatic nasopharyngeal cancer survivors treated with chemotherapy and virus-specific T cells | Timothy Shuen, Who-Whong WANG, PhD, Han Chong Toh, MBBChir, Janice Lim, Cherlyn Tan, Jennie Kosasih, Rachael Cheong | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Biomarkers; Gene expression; Solid tumors; T cell |
| P852 | Transcriptomic analysis of dysfunctional CD8+ TILs in melanoma identifies bile acid and MTOR pathways as novel potential immunotherapy targets | Cheryl Cameron, PhD, Brian Richardson, Jackelyn Golden, Lukas Pfannensttiel, Michael Cartwright, Yousef Moustafa, Samjhana Thapaliya, Gustavo Roversi, Yee Peng Phoon, Mark Cameron, Brian Gastman, MD, Cheryl Cameron, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Immune tolerance; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P853 | Single Cell transcriptome analysis identifies unique features in circulating CD8+ T cells that can predict immunotherapy response in melanoma patients | Chuan Li, Yee Peng Phoon, Keaton Karlinsey, Ye Tian, Samjhana Thapaliya, Lili Qu, Mark Cameron, Cheryl Cameron, PhD, Antoine Menoret, Pauline Funchain, MD, Jung-Min Song, RN, CNS, C. Marcela Diaz-Montero, Annabelle Rodriguez, Christopher Bonin, Anthony Vella, Beiyan Zhou, Brian Gastman, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Immune tolerance; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P855 | High-resolution maps of heterogeneous antigen expression in glioblastoma and implications for immunotherapy | Michael Barish, PhD, Lihong Weng, Dina Awabdeh, MD, Blake Brewster, Massimo D'Apuzzo, Yubo Zhai, Alfonso Brito, Brenda Chang, Annie Sarkissian, Renate Starr, MS, Wen-Chung Chang, Brenda Aguilar, BS, Araceli Naranjo, Suzette Blanchard, Russell Rockne, PhD, Behnam Badie, MD, Vanessa Jonsson, PhD, Stephen Forman, MD, Christine Brown, PhD , Michael Barish, PhD | Combination Immunotherapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Targeted therapy; Tumor antigens |
| P856 | AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: Results of a Phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients | Timothy Yap, MD PhD , Daniel Araujo, Debra Wood, MD, Jean-François Denis, PhD, Tina Gruosso, PhD, Gilles Tremblay, PhD, Maureen O'Connor-McCourt, Ria Ghosh, Sandra Sinclair, Paul Nadler, MD, Lilian Siu, MD, Nehal Lakhani, MD, PhD | Clinical Trial Completed | Biomarkers; Clinical study; Clinical trial; Solid tumors; Tumor microenvironment; Tumor stroma |
| P857 | ONM-500 - A Novel STING-activating therapeutic nanovaccine platform for cancer immunotherapy | Jason Miller, PhD, Min Luo, Hua Wang, Zhaohui Wang, Xinliang Ding, PhD, Ashley Campbell, Jonathan Almazan, Zhijian Chen, Jinming Gao, Tian Zhao | Immune-stimulants and immune modulators | Antigen presenting cells; Immune adjuvant; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P858 | An Open-Label, Multi-center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with Cemiplimab in Subjects with Newly-Diagnosed Glioblastoma (GBM) | Jeffrey Skolnik, MD , David Reardon, MD, Steven Brem, MD, Arati Desai, Stephen Bagley, Sylvia Kurz, Macarena de la Fuente, Seema Nagpal, Mary Welch, Brian Sacchetta, Sarah Bartra, Amy-Lee Bredlau, Israel Lowy, MD, PhD, Kimberly Kraynyak, BS PhD, Matthew Morrow, Trevor McMullan, Jean Boyer, PhD | Clinical Trial In Progress | Adoptive immunotherapy; Checkpoint blockade; Clinical study; Clinical trial; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P859 | Association of immunopharmacodynamic responses of Imprime PGG plus Pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy | Nadine Ottoson, BS, Nandita Bose, PhD , Anissa Chan, PhD, Xiaohong Qiu, BS, Ben Harrison, MS, Richard Walsh, BS, Paulette Mattson, BFA, Michele Gargano, MS, Joanna Cox, MD, Michael Chisamore, PhD, Mark Uhlik, PhD, Jeremy Graff, PhD | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Monocyte/Macrophage; Myeloid cells; Solid tumors |
| P864 | Combination of fecal microbiota transplantation from healthy donors with anti-PD1 immunotherapy in treatment-naïve advanced or metastatic melanoma patients | Saman Maleki, PhD , John Lenehan, Jeremy Burton, Michael Silverman, Seema Nair Parvathy, Mikal El-Hajjar, Mithunah Krishnamoorthy | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Microbiome; T cell |
| P865 | Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies - independent review committee data update | Amod Sarnaik, MD, Nikhil Khushalani, MD, Jason Chesney, MD, Harriet Kluger, MD, Brendan Curti, MD, Karl Lewis, MD, Theresa Medina, MD, Sajeve Thomas, Anna Pavlick, MD, MBA, Eric Whitman, MD, FACS, Salvador Algarra, Pippa Corrie, PhD, BMBCh, FRCP0, Omid Hamid, MD, Jose Lutzky, MD, FACP, Judit Olah, MD, PhD, Jeffrey Weber, MD, PhD, James Larkin, MD, Wen Shi, Kelly DiTrapani, RN, BSN, Harry Qin, PhD, Mariam Mirgoli, Renee Wu, Toshimi Takamura, BS, Maria Fardis, PhD, MBA, John Kirkwood, MD | Clinical Trial In Progress | Adoptive immunotherapy; Clinical trial; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
© 2019 Society for Immunotherapy of Cancer (SITC). All rights reserved. SITC Meeting Code of Conduct.
